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Introduction to the Thesis  
In 1986, French researchers succeeded in the development and upscaling of a semi-
synthetic process using the readily available inactive precursor, 10-deacetylbaccatin III 
isolated from the needles of the European yew tree Taxus Baccata, to produce the second 
taxane (the first being paclitaxel), docetaxel (Taxotere®). Docetaxel was initially approved 
for the treatment of patients with locally advanced or metastatic breast cancer. Now, 
approximately 10 years later, approval also includes the treatment of patients with non-small-
cell lung cancer, androgen-independent prostate cancer and advanced gastric cancer, making 
this anticancer drug one of the most widely active agents currently available. 
 
An important limitation associated with docetaxel chemotherapy, the recommended 
treatment being a 1-hour intravenous infusion once every 3 weeks (‘3-weekly’), is the 
substantial and, more importantly, highly unpredictable interindividual variability in toxicity 
and efficacy. Moreover, a large population pharmacokinetic-pharmacodynamic (PK-PD) 
analysis demonstrated that variability in toxicity is strongly associated with wide 
interindividual variability in docetaxel pharmacokinetics 1. Against this background it was the 
aim of the work described in this thesis to assess whether purposeful modulation of docetaxel 
pharmacokinetics could help to improve docetaxel-based treatment and to lay the foundation 
for the development of future improved (individualized) dosing strategies. 
 
Although the majority of research aimed to improve the risk-benefit ratio for 
docetaxel treatment has focused on the pharmacokinetics of docetaxel since the drug’s early 
clinical development, several other pharmacological strategies, including optimizing route 
and schedule of administration, reversing drug resistance, and the development of structurally 
related second-generation taxanes and alternative, solvent-free formulations, have also been 
investigated in an attempt to overcome the limitations associated with 3-weekly docetaxel 
treatment. These strategies are reviewed in Chapters 2, 3 and 4. 
 
Hepatic cytochrome P450 (CYP) isozyme 3A activity, responsible for the extensive 
metabolism of docetaxel to several pharmacologically inactive metabolites 2, has been 
identified as the strongest predictor of docetaxel clearance, accounting for the majority of the 
interpatient pharmacokinetic differences 3. Indeed, wide variation has been observed in 
phenotypic CYP3A activity and this has been attributed to a combination of factors including 
variations in both basal content and catalytic activity of total CYP3A, disease-related 
differences 4, drugs inducing or repressing transcription, and possibly genetic and ethnic 
differences 5-8. Moreover, CYP3A activity can be readily induced or inhibited by 
concomitantly administered drugs, food constituents and complementary and alternative 
medicine, thus rendering docetaxel subject to a host of enzyme-mediated pharmacokinetic 
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drug-interactions. The influence of medicinal cannabis (variety Bedrocan®) on the 
pharmacokinetics of docetaxel was investigated in Chapter 9 as we anticipated an increased 
use of medicinal cannabis in combination with anticancer drugs following the introduction, 
September 2003 in The Netherlands, of this standardized, legal product, with reported 
beneficial effects for cancer patients 9-12. 
 
Recently attempts have been made to individualize docetaxel dosing through CYP3A 
phenotyping and genotyping strategies 13-16. Despite the availability of phenotypic probes, all 
current phenotyping techniques are associated with practical disadvantages, and attempts to 
individualize docetaxel dosing through CYP3A genotyping strategies have, to date, yielded 
controversial results, in part due to underpowered studies. Thus presently, interindividual 
variability in CYP3A activity is not taken into account when dosing docetaxel. An alternative 
approach to optimize docetaxel dosing strategy is to temporarily eliminate the source of 
interindividual variability in CYP3A metabolic activity, i.e. to purposefully inhibit CYP3A 
temporarily. Theoretically, inhibiting CYP3A using a potent CYP3A-inhibitor such as 
ketoconazole 17, could provide a tool to reduce the substantial interindividual variability in 
docetaxel pharmacokinetics, thereby leading to a uniform pharmacokinetic profile and thus 
ultimately to a more predictable toxicity profile, while maintaining cytotoxic efficacy. 
Furthermore, this approach also has the potential to achieve a considerable reduction in drug 
costs (anticancer drug expenditure accounts for up to approximately 30 % of overall hospital 
drug costs) since a markedly reduced docetaxel dose is necessarily administered, due to 
ketoconazole-induced prolonged systemic docetaxel exposure. To investigate this strategy, 
intended modulation of docetaxel pharmacokinetics through oral ketoconazole administration 
was first evaluated using the standard antifungal ketoconazole dose 18 as described in 
Chapter 5. Evaluation of this strategy was continued in Chapter 6 with a higher 
ketoconazole dose as interindividual variability in docetaxel pharmacokinetics was not 
reduced upon standard-dose ketoconazole, possibly due to wide interindividual variability in 
ketoconazole systemic exposure. In addition, high-dose ketoconazole in combination with 
docetaxel is currently under investigation for the treatment of patients with androgen-
independent prostate cancer 19, allowing us to evaluate the undesirable clinical consequences 
of this drug-interaction. 
 
Following extensive CYP3A-mediated metabolism, the administered docetaxel dose 
is primarily excreted into the faeces via the biliary route 20. Indeed, only less than 10 % of the 
administered dose is excreted unchanged into the faeces and total urinary excretion urinary 
accounts for less than 5 % 21,22. Temporarily inhibiting CYP3A activity therefore not only 
affects the plasma pharmacokinetic profile of docetaxel, but also influences the faecal and 
urinary excretion of the drug. Moreover, ketoconazole, besides being a potent CYP3A 
inhibitor, is also a modest inhibitor of the ATP-binding cassette membrane-localized 
Chapter 1 
 12
transporter, ABCB1 23,24, for which docetaxel is also a substrate 25,26, and which plays a 
prominent role in the faecal elimination of docetaxel 27. Collection of both urinary and faecal 
samples of the patients treated with standard- and high-dose ketoconazole in combination 
with docetaxel (Chapters 5 and 6) allowed us to assess purposeful ketoconazole-induced 
modulation of docetaxel faecal and urinary disposition and subsequently total excretion (i.e. 
mass balance) using [3H]-docetaxel. Such an evaluation, described in Chapter 8, can 
contribute to a better overall understanding of the mechanistic aspects involved in docetaxel 
metabolism and elimination. 
 
Ideally assessing a mass balance is undertaken by administering a non-toxic tracer 
amount of radiolabelled drug to a patient, allowing one to quantify the drug in biological 
samples (e.g. faeces, urine) at concentrations below the lower limit of quantification for 
routinely used analytical techniques. However, most radiolabelled biological samples, 
including faeces, require extensive sample preparation to reduce quenching interference 
before quantification of radioactivity is possible. Clearly, a more rapid and simple method 
has important advantages. Chapter 7 describes the development and validation of a rapid and 
simple combustion method to quantify [3H]-docetaxel excreted in human faeces and urine. 
The validated method was successfully applied in cancer patients administered docetaxel and 
a tracer amount of [3H]-docetaxel as described in Chapter 8. 
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Abstract 
The anticancer agent docetaxel is approved for the treatment of patients with locally 
advanced or metastatic breast cancer, non-small-cell lung cancer (NSCLC) and for the 
treatment of androgen-independent prostate cancer patients. At the recommended dose of 60 
mg/m2 to 100 mg/m2 given once every 3 weeks, severe neutropenia is the dose-limiting 
toxicity and a major concern, especially when treating patients at high-risk for myelotoxic 
complications. A less toxic schedule, involving weekly docetaxel administration was 
developed for patients with a poor performance status, multiple comorbidities, poor 
haematological reserves, or those who were heavily pretreated and/or elderly or for patients 
for whom palliation is the focus of treatment. Recent randomized trials allow a comparison of 
efficacy and toxicity between weekly and 3-weekly treatments. Efficacy appears to be similar 
for the two schedules regardless of the disease, while weekly docetaxel is significantly less 
myelotoxic. However, this benefit comes at the cost of cumulative increases in 
hyperlacrimation, skin- and nail-toxicity and negatively affects quality of life. Currently, 3-
weekly docetaxel remains the standard schedule for treatment, whereas the weekly schedule 
offers a possibility for treatment individualization for those patients where the risk of 
myelosuppression is considered unacceptable.  
 
Introduction 
The anticancer drug docetaxel (Taxotere®) is a semi-synthetic taxane, with antitumour 
activity against a broad range of human malignancies. It is approved for the treatment of 
patients with locally advanced or metastatic breast cancer or non-small-cell lung cancer 
(NSCLC) and more recently for the treatment of androgen-independent metastatic prostate 
cancer. The docetaxel dose recommended for treating cancer patients ranges from 60 mg/m2 
to 100 mg/m2 given as a 1-hour infusion once every 3 weeks (hereafter referred to as ‘3-
weekly’). Severe myelosuppression is common and a concern. Neutropenia occurs in 
virtually all patients regardless of dose and, treated with 100 mg/m2 docetaxel, a substantial 
number of patients require a dose reduction to control grade 4 neutropenia lasting 1 week or 
longer. Management of neutropenic infection requires patient hospitalization and treatment 
with intravenous antibiotics. The other major side-effect is neuropathy that is related to 
cumulative dose and which can potentially limit the number of cycles that can be given. In 
general, non-haematological toxicities are rarely severe and mostly manageable. 
In view of the myelosuppression, there are specific patient groups who are expected 
not to tolerate the full-dose 3-weekly regimen. In general, this applies to patients with a poor 
performance status, patients with multiple comorbidities, patients with poor haematological 
reserves, whether or not due to heavy pretreatment, and elderly patients. Indeed, treatment 
recommendations for the heterogeneous group of elderly patients are inconsistent or lacking 
3-weekly Docetaxel vs weekly Docetaxel 
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as the elderly are largely underrepresented in clinical trials coupled to a general reluctance to 
administer chemotherapy to this group 1,2. In addition, prolonging survival without excessive 
treatment-related toxicity is a major challenge in the management of patients where treatment 
focus is not curative. For these reasons, soon after the introduction of docetaxel in 1996, 
clinical trials were initiated investigating alternative docetaxel schedules with infusions given 
once every week (hereafter referred to as ‘weekly’). This was in spite of the fact that during 
the initial development of docetaxel, studies with a day-1 and day-8 schedule every 3 weeks 
were not pursued due to excessive toxicity 3. The primary goal of the new set of studies was 
to reduce severe haematological toxicity while preserving dose intensity. Although, some 
investigators even hoped to increase dose intensity and achieve a higher cumulative dose. In 
the end, the recommended phase II dose for weekly docetaxel was established at 36 
mg/m2/week based on a schedule of 6 consecutive weekly administrations followed by a 2-
week rest interval 4. This dose is equivalent to a (planned) dose intensity of 27 mg/m2/week 
and comparable to the (planned) dose intensity for the recommended 3-weekly doses, 75 
mg/m2 and 100 mg/m2 (25 mg/m2/week and 33 mg/m2/week, respectively) 5. The landmark 
phase I trial demonstrated that the toxicity profile of weekly docetaxel was significantly 
altered and that dose-limiting toxicities were fatigue/asthenia, while overall 
myelosuppression was mild and severe haematological toxicity uncommon. This new side-
effect profile suggested a potential for better tolerance. Since then, numerous clinical trials 
have further investigated the activity of weekly administrations of docetaxel, both as single 
agent and, given its favourable toxicity profile, in combination with other (myelosuppressive) 
cytotoxic drugs, new biological agents and radiotherapy. 
This review aims to discuss the efficacy and toxicity of weekly docetaxel and to 
compare these features to the 3-weekly regimen when used to treat patients with metastatic 
breast cancer, NSCLC and hormone refractory prostate cancer. 
 
Efficacy of docetaxel treatment 
3-weekly docetaxel – metastatic breast cancer, NSCLC, hormone refractory prostate cancer 
Treatment of patients with locally advanced or metastatic breast cancer after failure of 
prior chemotherapy was the first indication for which docetaxel was granted approval 6,7, 
followed by approval for the treatment of locally advanced or metastatic NSCLC patients 
after failure of prior platinum-based chemotherapy 8,9, and treatment of chemotherapy-naïve 
NSCLC patients in combination with cisplatin 10,11. In addition, based upon a recent 
randomized phase III trial it was concluded that first-line treatment with single agent 
docetaxel could be a reasonable option for patients who do not tolerate cisplatin 12. After 
early phase II trials demonstrated activity of single agent docetaxel in the treatment of 
patients with hormone refractory prostate cancer 13,14, approval was recently also granted for 
this indication based on a large phase III trial 15. An overview of the efficacy of 3-weekly 
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docetaxel in the treatment of patients with metastatic breast cancer, NSCLC and hormone 
refractory prostate cancer is provided in Table 1. 
 
Weekly docetaxel – metastatic breast cancer 
Several phase II clinical trials have assessed the activity of weekly docetaxel in 
patients with metastatic breast cancer, the majority of which had been pretreated with 
chemotherapy (Table 2) 16-22. Unfortunately, only one trial was designed to directly compare 
safety and activity of weekly and 3-weekly treatment in a randomized phase II setting 21. Two 
non-randomized trials specifically targeted the elderly and/or frail population 17,22. The 
pivotal trials for the 3-weekly schedule in metastatic breast cancer patients had reported an 
overall response rate (ORR) of 47.8 % and 30 %, for patients previously treated with 
alkylating agent-containing or anthracycline-containing chemotherapy, respectively (Table 1) 
6,7. As summarized in Table 2, the activity of weekly schedules seems to be in the same 
range. Although not powered to detect a difference, the randomized phase II study also 
suggests similar activity 21. The limitations of phase II trial designs are expressed in the fact 
that ORRs and time to progression (TTP) in the indicated studies range from 25 % to 41 %, 
and from 4 months to 9 months, respectively. Apart from differences in prognostic factors, 
part of the observed variation could be explained by selection bias. In that sense, the 
randomized phase II study 21 provides the most reliable information. 
 
Weekly docetaxel – NSCLC 
A number of phase II clinical trials have assessed weekly docetaxel in the treatment of 
patients with advanced NSCLC, both as first-line treatment, in combination with cisplatin, 
and as single agent second-line treatment (Table 3) 23-28. Importantly, several randomized 
(phase II/III) trials are ongoing and definitive results are awaited 29-32. 
Two recent clinical trials evaluated weekly docetaxel in combination with cisplatin 
25,26. The trial performed by Ohe and colleagues 25 specifically targeted elderly patients (≥ 75 
years), who however, all had a good performance status (0-1). These two studies yielded 
activity in the same range as for 3-weekly docetaxel followed by cisplatin 75 mg/m2 (Table 1) 
10. The results of randomized studies are again eagerly awaited. The importance of such phase 
III evaluations is further stressed by the fact that seemingly achieved activity is less than 
expected in chemotherapy-naïve elderly patients or (young) patients who were poor 
candidates for first-line combination therapy (Table 3) 23. 
Lilenbaum and colleagues 24 evaluated second-line treatment with single agent 
docetaxel in a small (N = 30) group of patients, where 1 in 3 had a poor performance status (≥ 
2). Importantly, it should be noted that all patients with a poor performance status progressed, 
underlining the 2003 treatment guidelines, which recommend that second-line treatment with 
docetaxel be confined to patients with adequate performance status 11, as well as the possible 
influence of selection bias on outcome parameters. 
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Most recently, two small randomized clinical trials comparing weekly and 3-weekly second-
line treatment have been completed 27,28. Gridelli and colleagues 27 focused on quality of life 
(QoL) issues and found no overall statistically significant differences in the assessed items. 
Disappointingly, both studies showed low response rates regardless of schedule and even 
opposite differences in 1-year survival rate (Table 3), again suggesting that larger trials will 
be needed to completely eradicate selection bias. 
 
Weekly docetaxel – hormone refractory prostate cancer  
Phase II clinical trials had demonstrated that weekly or 3-weekly docetaxel had single 
agent activity in hormone refractory prostate cancer patients (Tables 1 and 4) 13,14,33-36. For 
this reason, a large phase III study was performed comparing weekly docetaxel-prednisone to 
3-weekly docetaxel-prednisone and to mitoxantrone-prednisone 15. In assessing the outcome 
one has to take into account that prostate cancer patients are frequently elderly and frail, and 
that treatment is often intended to be palliative. In the randomized phase III study there was 
no significant difference between weekly and 3-weekly efficacy and the percentage of 
patients who had an improvement in QoL was also similar in both docetaxel groups. 
Although based on phase II studies 34,36 age does not seem to affect treatment outcome (Table 
4). In addition, a retrospective analysis of the pooled individual patient data from two trials 
33,34 also showed no difference between older and younger patients with respect to efficacy 
endpoints 37. Most importantly in this respect, survival benefit in the randomized phase III 
study was similar for patients younger than 65 years vs those 65 years or older 15.  
 
Docetaxel Toxicity 
The toxicity profile of docetaxel when given once every 3 weeks is well known. The 
dose is limited by dose-dependent, mostly short-lasting neutropenia, relatively frequently 
complicated by fever. Other side-effects include nausea, vomiting, stomatitis and diarrhoea. 
Docetaxel induces a peculiar type of skin- and nail-toxicity, peripheral oedema as well as 
frequent hypersensitivity reactions. All of these latter side-effects can be largely 
circumvented or diminished by adding a short prophylactic corticosteroid schedule 6-10,12-15. 
Finally, the drug induces neuropathy related to cumulative dose rather than the cycle dose. 
The toxicity profile of weekly docetaxel is significantly altered compared to 3-weekly 
treatment. Overall, acute toxicities are uncommon. However, chronic toxicities, which 
develop and increase with successive weekly dosing (i.e. related to cumulative dose) are 
(more) prominent. Although the randomized trials comparing weekly and 3-weekly docetaxel 
treatment were performed in three different patient categories, taken together they provide a 
relevant overview of the toxicities related to both schedules (Table 5). 
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Haematological toxicity: As expected, weekly docetaxel is associated with mild 
haematological toxicity; severe neutropenia ranged from 2 % to 16 % for weekly docetaxel 
and febrile neutropenia was either absent or low (≤ 5 %) (Table 5). Only one non-randomized 
trial reported a higher incidence (22 %) of severe neutropenia which was attributed to 
baseline abnormalities in haematology parameters 22. In the randomized trials, incidences of 
grade 3 to 4 neutropenia for 3-weekly treatment ranged from 19 % to 48 %, which is 
relatively low compared to previously reported values even though all patients had received 
some form of prior chemotherapy. Severe anaemia and thrombocytopenia are uncommon 
regardless of schedule. In two non-randomized trials higher incidences of severe anaemia 
(range, 13 - 17 %) were also reported, possibly explained by the fact that more than one third 
of all patients had a poor baseline performance status 23,24. 
Non-haematological toxicity:  Severe fatigue and asthenia were the most common 
complaints after weekly treatment. These side-effects usually occur at the end of the 
consecutive treatment weeks (6 weeks) and were partly reversible during the 2-week rest 
interval. In general, incidences range between 5 % and 20 %, which is actually not higher 
than observed after 3-weekly treatment. Higher incidences (33 %) were only incidentally 
observed (in patients with a poor performance status) 24. Indeed, studies from Tannock and 
Gridelli 15,27 observed no difference in the incidence of fatigue/asthenia between the two 
schedules. In contrast, Tabernero and Gervais 21,28 have both reported that fatigue/asthenia 
were more common with the weekly regimen. Recommendations for management of severe 
fatigue include a dose reduction or a shorter schedule, for instance 2 or 3 consecutive weekly 
infusions, followed by a 1-week rest interval. However, it is advisable to exercise caution as 
it is unknown how these schedule changes will affect activity. 
Weekly docetaxel is associated with an unexpected increase in the incidence of 
excessive tearing (incidences up to 52 % have been reported) 16. Hyperlacrimation, due to 
canalicular/nasolacrimal duct stenosis, possibly a result of docetaxel secretion in tears 38, was 
initially classified as an unexpected and merely bothersome side-effect. However, currently it 
is recognized to be a complaint which, although mild (rarely classified ≥ grade 3), can be 
particularly persistent, leading to significant problems with reading, driving, and other daily 
activities requiring adequate visual function. Indeed, this recently underestimated side-effect 
has a substantial negative impact on a patient’s QoL. Esmaeli and colleagues 39 specifically 
reported on the severity and management of excessive tearing in patients who received 
weekly (N = 71) or 3-weekly docetaxel (N = 72). After a median cumulative dose of 1080 mg 
(range, 168 – 2116 mg), corresponding to a median of 24 weeks (range, 11 – 48 weeks) after 
initiation of weekly treatment, a surgical intervention (temporary silicone intubation, 
dacryocystorhinostomy (DCR) with placement of a temporary silicone tube or a permanent 
Pyrex tube) was required in more than 40 % of patients’ eyes, and successfully relieved 
symptoms. Indeed, in 21 patients with complaints in both eyes who received no surgical 
treatment, either due to patient refusal or because of other comorbidity, complaints were still 
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persistent 6 months after docetaxel discontinuation. Only 28 % of the patients had mild 
complaints and they were treated with topical steroids. In contrast, in the majority of patients 
given 3-weekly docetaxel complaints were adequately managed with topical treatment and 
only 3 patients required surgical intervention. Recommendations for the management of this 
common side-effect include a baseline ophthalmologic examination followed by regular 
monitoring so that early diagnosis is possible and appropriate treatment can be initiated 39,40. 
Silicone intubation has been recommended as the safest approach in symptomatic patients if 
weekly treatment is to be continued 39. 
In addition, cumulative nail toxicity can lead to severe discomfort, limitation of 
function and treatment discontinuation after repetitive dosing 18,22. Although the incidence of 
low grade nail toxicity was not different for weekly or 3-weekly docetaxel in metastatic 
breast cancer patients, nail changes substantially affected the QoL in the weekly treatment 
arm and were the major reason for withdrawal, followed by excessive tearing, asthenia and 
infection 21. Similarly, in the prostate cancer phase III trial 15, major reasons for withdrawal 
also included fatigue and nail changes. It should be noted that, in acknowledgement of the 
severe impact on a patient’s QoL, the recent version of the Common Toxicity Criteria of the 
National Cancer Institute (CTC-NCI, version 3.0) includes grade 3 nail changes (interfering 
with daily life, severe adverse event), whereas version 2.0 only included rating up to grade 2 
(partial/complete loss of nail(s), pain in nail beds). Most trials published to date, and certainly 
most of the larger randomized trials where accrual started several years ago, have used 
version 2.0 CTC-NCI for toxicity rating. It is likely that the reported severity of nail disorders 
is underestimated due to the lack of a more specific rating. 
In general, in the randomized trials dose reductions were less often required after 
weekly treatment. Yet, in 3 out of 4 randomized trials, treatment discontinuations were more 
common after weekly treatment (Table 5). It is conceivable that persistent cumulative 
toxicities eventually lead to treatment discontinuation. 
 
Prophylaxis schedules  
Prophylaxis of cumulative fluid retention and hypersensitivity reactions is 
recommended when patients are treated with docetaxel. The most commonly used 
premedication schedule for 3-weekly treatment is dexamethasone 8 mg administered orally 
twice daily for 3 days, starting 1 day prior to treatment (range, 40 - 48 mg/3 weeks; dose 
intensity range, 13 - 16 mg/week). Although steroid premedication remains mandatory 41, at 
this point there is no universally recommended prophylactic regimen for weekly docetaxel. In 
most cases, an abbreviated course of 3 oral administrations of dexamethasone 8 mg given 
every 12 hours starting 12 hours prior to docetaxel infusion is chosen (24 mg/week; dose 
intensity 18 mg/week). This schedule adequately controls fluid retention and hypersensitivity 
reactions. It has been advised to monitor (elderly) patients more closely for signs of toxicity 
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after repetitive corticosteroid dosing. However, the incidence of corticosteroid-related 
complications (e.g. hyperglycaemia, peptic/duodenal ulcers) is low 34. Indeed, dexamethasone 
dose intensity with weekly docetaxel is only marginally higher. Incidentally used schedules 
include (methyl)-prednisone containing regimens or a single dose of 8 mg dexamethasone 1 
hour prior to infusion 15,18,19,22,28,36. 
 
Conclusion 
Since the landmark phase I trial 4, numerous clinical trials have evaluated weekly 
docetaxel treatment. However, due to considerably different patient populations enrolled in 
the various trials and the limited numbers, comparisons of weekly vs 3-weekly efficacy have 
been difficult. Hence, recommendations when or when not to consider weekly treatment were 
lacking. Recently, final results of the first comparative trials have become available. These 
randomized trials demonstrate, for the three approved indications, that the efficacy of weekly 
docetaxel is comparable to 3-weekly treatment, with the addition that activity in NSCLC is 
disappointingly low for both schedules. The toxicity profile of weekly docetaxel does 
however distinguish this schedule from the standard 3-weekly regimen. Acute toxicities, in 
particular myelosuppression, are, as expected, mild and never dose-limiting. However, 
cumulative side-effects were much more prominent and require increased awareness and 
early recognition for adequate management. The most common and dose-limiting toxicity is 
fatigue/asthenia. Other chronic toxicities include alopecia, excessive tearing and nail 
disorders. Despite the fact that the latter two side-effects are usually of low grade they were 
persistent and had a substantial negative impact on a patient’s QoL, which has previously 
largely been underestimated. As of yet, there has not been any health economics assessment 
of the differences between the two schedules.  
Given the similar efficacy observed for the two schedules and the above remarks on 
toxicity, it is reasonable to conclude that, at this point, 3-weekly docetaxel should still be 
considered the standard and most convenient schedule, and that treatment with weekly 
docetaxel should only be considered as an alternative for specific patient populations who are 
unlikely to tolerate the standard 3-weekly treatment. For patients with a poor performance 
status, multiple comorbidities, a history of extensive pretreatment and severe toxicity, 
decreased haematological reserves and elderly patients at high risk for myelotoxic 
complications, weekly docetaxel offers an additional treatment option. The place of elderly 
patients in this list deserves a more detailed discussion. Elderly patients form a heterogeneous 
group and therefore the interpretation of clinical trial results and subsequent implementation 
of treatment recommendations is especially difficult. Chronologic age itself is not a contra-
indication for full-dose chemotherapy. However, ageing, a highly individual process, is 
frequently associated with a high prevalence of comorbidity, poor performance status and 
with a decline in functional reserves of organ systems, especially bone marrow. A patient’s 
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physiologic age, determined through a comprehensive geriatric assessment has therefore been 
suggested to better predict the increased risk of chemotherapy induced (haematological) 
toxicity. In general, largely due to poor haematological reserves, elderly patients are 
considered to be more susceptible to drug-induced myelosuppression yet, if otherwise fit, not 
at an increased risk for other toxicities 42-45. In our opinion, a decision to administer weekly or 
3-weekly docetaxel to an elderly person should take into account all these aspects and result 
in a treatment tailored to the individual’s tolerance. As increased exposure to docetaxel is a 
strong predictor of haematological toxicity regardless of schedule 46,47, altered 
pharmacokinetics have also been suggested to play a role. However, there are no differences 
in docetaxel pharmacokinetics between elderly and non-elderly patients 45,48 or for that 
matter, between the 3-weekly and weekly schedule 49. Interestingly, in these trials, the 
majority of baseline patient characteristics did not differ between the age groups, however, 
elderly patients had statistically significant, albeit only slightly lower serum alpha–1 acid 
glycoprotein (AAG) levels (P = 0.018 and P = 0.04). Docetaxel is extensively bound to AAG 
and this protein is one of the main determinants of the fraction of unbound, 
pharmacologically active drug. Docetaxel-induced haematological toxicity is significantly 
better correlated with systemic exposure to unbound drug than with exposure to total drug 50. 
Although unbound docetaxel pharmacokinetics have not been extensively investigated in 
elderly patients, it is possible that besides the increased susceptibility for myelosuppression 
due to a functional decline in haematological reserves, decreased AAG levels result in a 
higher exposure to the unbound fraction of docetaxel and contribute to the increased 
myelosuppression. 
Several aspects of weekly docetaxel administration still remain to be further 
elucidated. The optimal duration of subsequent administrations, the timing of rest episodes 
and the optimal number of courses have not yet been established. Furthermore, it is unknown 
how frail patients selected for weekly treatment perceive more frequent visits to the hospital 
and the burden of travelling. The negative impact on QoL as reported is a particular concern 
in this respect. Finally, as indicated, there is as yet no comparative cost-effectiveness analysis 
including direct and indirect costs. For 3-weekly treatment the indirect costs associated with 
the management of adverse effects can significantly increase (up to 20 %) the total cost of 
docetaxel treatment 51. 
For the time being, 3-weekly docetaxel remains the first schedule to be considered. 
However, there is no single schedule for any drug that offers an optimal balance between 
efficacy and toxicity in all patients. Instead, dose, schedule and overall toxicity should be 
considered against an individual’s characteristics, including performance status, comorbidity, 
haematological reserves and prior treatment. As an individualized treatment, the weekly 
schedule of docetaxel appears to be an acceptable alternative. 
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Abstract 
Since the introduction of docetaxel, research has focused on various approaches to 
overcome treatment limitations and to improve outcome. This review discusses the 
pharmacological attempts at treatment optimization, which include reducing interindividual 
pharmacokinetic and pharmacodynamic variability, optimizing schedule and route of 
administration, reversing drug resistance, and the development of structurally related second-
generation taxanes. 
 
Introduction 
The anticancer drug docetaxel (Taxotere®) is approved for the treatment of patients 
with locally advanced or metastatic breast or non-small-cell lung cancer (NSCLC) and 
androgen-independent metastatic prostate cancer. The recommended dose ranges from 60 
mg/m2 to 100 mg/m2 given as a 1-hour intravenous infusion once every 3 weeks. An 
important limitation associated with docetaxel use is the unpredictable interindividual 
variability in efficacy and toxicity. Since its clinical introduction, attempts to improve 
docetaxel treatment have covered various areas: reducing the interindividual pharmacokinetic 
(PK) and pharmacodynamic (PD) variability, optimizing schedule, route of administration 
and drug formulation, and reversing drug resistance. This review will discuss 
pharmacological strategies aimed to overcome the limitations of docetaxel therapy. 
 
Alternative Schedules  
When treated at a dose of 100 mg/m2 once every 3 weeks, grade 4 neutropenia and 
febrile neutropenia occur in 75 %, respectively 11 %, of patients; a dose of 75 mg/m2 only 
moderately reduces this incidence (http://www/taxotere.com). For patients with a poor 
performance status (PS), multiple comorbidities, decreased haematological reserves, a history 
of extensive pretreatment and severe toxicity, elderly patients and for patients for whom 
treatment is palliative, a less toxic schedule seemed desirable. Therefore, a schedule 
involving weekly administration was developed. Numerous trials have evaluated this 
schedule; however, due to considerably different study populations and small sample sizes, 
comparisons of weekly vs 3-weekly efficacy were difficult. Recent randomized trials 
although demonstrate, for the approved indications, that the efficacy of weekly docetaxel is 
comparable to 3-weekly treatment 1, the toxicity profiles are, however, distinctly different. 
With weekly docetaxel, acute toxicities, in particular myelosuppression, are mild and never 
dose-limiting. In contrast, cumulative side-effects are much more prominent. The most 
common and dose-limiting toxicity is fatigue/asthenia. These side-effects can only be 
managed by reducing the dose or by shortening the schedule, to 2 to 3 consecutive weekly 
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infusions, followed by a 1-week rest interval. Other cumulative toxicities include alopecia, 
excessive tearing and nail disorders. Although the latter two side-effects are usually mild, 
they are persistent, can lead to treatment discontinuation and have a substantial negative 
impact on a patient’s quality of life. Given the similar efficacy observed for the two schedules 
and the remarks on toxicity, it is reasonable to conclude that, at this point, 3-weekly docetaxel 
is still the standard and most convenient schedule. Treatment with weekly docetaxel should 
only be considered as an alternative for specific patient populations. 
 
Pharmacokinetic Optimization  
The pharmacokinetics (PK) of total docetaxel are linear and independent of schedule. 
Nonetheless, there is large interpatient variability in exposure (AUC) and drug clearance 2-6. 
In a large population PK/PD analysis variability in efficacy and toxicity was associated with 
variability in PK 3; a 50 % decrease in docetaxel clearance increased the odds of developing 
grade 4 neutropenia and febrile neutropenia 4.3-fold and 3.0-fold, respectively. Subsequent 
studies have therefore focused on identifying factors, which most affect PK variability. 
Ultimately, reducing interpatient exposure variability should improve the risk-benefit ratio of 
docetaxel therapy. 
Initially, the main predictors of total docetaxel clearance (variability) were body 
surface area (BSA), alpha-1 acid glycoprotein (AAG), hepatic function (elevated alkaline 
phosphatase (ALKPH) and transaminases levels) and age 7. More recently, (hepatic) 
cytochrome P450 (CYP) isozyme 3A4 activity was also included 2. The relevance of all these 
predictors to docetaxel dose optimization has been further (re-)evaluated. 
Normalization of clearance for BSA reduces interindividual variability marginally (< 
2 %), thus questioning the clinical relevance of BSA-based dosing 5. Clearance was, 
however, significantly higher by 33 % (P = 0.0029) for patients with BSA values > 2.00 m2 
compared to values < 1.71 m2. Flat-dosing, possibly differentiating for extremes of BSA (> 
2.00 m2), may be easier and just as precise and should be investigated prospectively. 
In general, the unbound (i.e. free) fraction of any drug is pharmacologically active. In 
serum, docetaxel is extensively bound to albumin, lipoproteins and AAG; indeed the latter is 
the main determinant of docetaxel serum binding variability. Furthermore, AAG levels in 
cancer patients vary at least 4-fold 3,6,8. High AAG levels have been associated with a 
decrease in the unbound fraction of docetaxel in vitro, and with reduced total docetaxel 
clearance 7,8 and lower response rate in man 3. Yet, dosing recommendations based on 
individual AAG levels are not available. The formulation vehicle polysorbate 80, although 
rapidly degraded by serum esterases, also influences docetaxel protein binding, increasing the 
unbound drug fraction by on average 16 % to 24 % at peak polysorbate 80 concentrations 6,8. 
Furthermore, higher polysorbate 80 exposure resulted in lower unbound docetaxel clearance. 
Most importantly, haematological toxicity is highly correlated with systemic exposure to 
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unbound docetaxel 6. Thus, measuring unbound docetaxel concentrations should be 
considered in future PK/PD studies. 
Mild hepatic impairment (total bilirubin < 1.5 x ULN, transaminases ≥ 1.5 to ≤ 3.5 x 
ULN concurrent with ALKPH ≥ 2.5 to ≤ 5 x ULN) decreases total docetaxel clearance by 27 
% 3, and moderate (total bilirubin ≥ 1.5 to < 3.0 x ULN with any transaminase and ALKPH 
elevations) to severe impairment (total bilirubin ≥ 3.0 x ULN with any transaminase and 
ALKPH elevations) does so by 50 %. This should obviously have consequences, yet one is 
only warned that docetaxel should generally not be given to patients with total bilirubin > 
ULN, or with transaminases > 1.5 x ULN concomitant with ALKPH > 2.5 x ULN 
(http://www.taxotere.com). Dose adjustments therefore are left to the discretion of the 
physician, while they seem required. 
Elderly age (≥ 65 years) does not alter total docetaxel PK 4. Interestingly, the elderly 
patients’ serum AAG levels were significantly (P ≤ 0.04), albeit only slightly lower. 
Decreased AAG levels contribute to higher exposure to unbound docetaxel resulting in more 
myelosuppression 6. Jointly with the increased susceptibility for myelosuppression due to a 
functional decline in haematological reserves at ageing, this could be a concern. Yet, toxicity 
did not occur more frequently in the elderly. Thus, age-related dose recommendations should 
predominantly be based on individual PS and comorbidity. 
Docetaxel is primarily metabolized by (hepatic and intestinal) CYP3A, in particular 
by isoforms CYP3A4 and CYP3A5, the latter of which has a 10-fold lower affinity for 
docetaxel. Docetaxel metabolites are substantially less active than the parent drug; hence, 
CYP3A-mediated metabolism is the major route of inactivation. CYP3A activity in adults, 
and in patients treated with docetaxel, varies largely between individuals. This is believed to 
depend on environmental (CYP3A modulation), physiological (hepatic impairment) and 
genetic (CYP3A polymorphism) factors. Pretreatment CYP3A phenotyping has been 
suggested as a tool to individualize docetaxel dosing 9-12. At present, the midazolam 
hydroxylation test and the erythromycin breath test (ERMBT) are the most widely applied 
phenotyping strategies, albeit that both have their limitations. The ERMBT did not 
consistently correlate with results from other CYP3A phenotypic probes 13 and may have 
limited value for CYP3A-phenotyping of docetaxel patients as erythromycin is preferentially 
metabolized by CYP3A4, whereas docetaxel is metabolized by CYP3A4 and CYP3A5. Yet, 
when compared to other variables (ALKPH, alanine aminotransferase and AAG), the 
ERMBT was the best single predictor of docetaxel clearance 2 and probe specificity issues are 
relevant only in individuals expressing significant CYP3A5 levels, which is rarely the case in 
Caucasians. In contrast, African-Americans have much higher CYP3A5 expression and in 
these patients midazolam, metabolized by both CYP3A4 and CYP3A5, may be more 
suitable. Clinical trials correlating phenotyping results to docetaxel PK demonstrate that 
midazolam, erythromycin and dexamethasone are predictors of docetaxel clearance 2,9,11. As 
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dexamethasone is routinely used as premedication, it may be more attractive as a probe drug 
than midazolam or erythromycin. Recently, individualized dosing based on the 24-hour 
urinary metabolite of exogenous cortisol as phenotypic CYP3A probe was evaluated 12. 
Individualized phenotypic dosing significantly reduced the interindividual PK variability 
compared to BSA-based dosing. Further larger studies, preferably comparing phenotyping 
strategies, are required to assess which probe is the best predictor of CYP3A activity. 
Nonetheless, phenotyping techniques have practical disadvantages (i.e. 24-hour urine 
collection, radioisotope administration) that may limit their applicability in common 
oncology practice. 
The involvement of CYP3A in docetaxel elimination renders the drug potentially 
subject to a host of enzyme-mediated PK drug-interactions with conventional drugs, 
complementary and alternative medicine and food constituents that interfere with CYP3A 
function or expression. Docetaxel has a narrow therapeutic window. Therefore, the risk of a 
PK interaction resulting in under- or overexposure, thereby modifying treatment outcome, is 
high. For several coadministered cytotoxic agents, PK interactions with docetaxel are known 
and have led to dose or schedule recommendations. Interestingly, for the potent CYP3A 
inhibitor ketoconazole interaction data are inconsistent. Both trials observed large 
interindividual variability in reduction of docetaxel clearance 14,15. Yet, in one this was highly 
significant 14 whereas in the other, although docetaxel clearance decreased 2 to 4-fold in 25 % 
of the patients, thus increasing the risk for severe neutropenia, it was not 15. Efforts to reduce 
the interindividual PK variability through inhibition of CYP3A by ketoconazole have not 
been successful. No clinically relevant PK interaction has been observed between 
dexamethasone, a possible CYP3A inducer, and docetaxel 2,11. Thus, there is no reason to 
abandon routine dexamethasone premedication. Clearly, the degree to which a PK interaction 
is clinically relevant, and requires an intervention, depends upon the CYP3A-inducing or -
inhibiting properties of the coadministered agent. Since specific dose adjustment 
recommendations are not available, concomitant administration of potent CYP3A-modulating 
comedication should generally be avoided. 
Docetaxel is also a substrate for the ATP-binding cassette transmembrane transporter 
protein ABCB1 (P-glycoprotein (P-gp); MDR-1). ABCB1 is expressed in tumours and in 
normal tissues including the blood-brain-barrier (BBB), biliary tract and intestinal epithelium. 
Although ABCB1 plays a (major) role in the intestinal absorption and biliary excretion of 
orally administered substrates, its influence on the plasma PK of intravenously administered 
drugs, including docetaxel, is minimal to absent 16. ABCB1 inhibition does, however, 
significantly influence the faecal disposition of docetaxel, reducing the amount of excreted 
unchanged drug (approximately 18-fold) without affecting plasma PK 16, indicating that the 
effects of ABCB1 modulation on docetaxel PK cannot be evaluated when analysing only 
plasma. 
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Monitoring plasma levels and PK-guided dose adjustments is referred to as 
therapeutic drug monitoring (TDM). At present, the use of TDM in oncology is limited. A 
prerequisite for TDM is that intraindividual PK variability is less than interindividual PK 
variability, which is the case for docetaxel. For reasons of patient convenience and 
practicality, validated limited sampling strategies (LDS), requiring only 2 to 4 samples to 
characterize an individual PK profile 3,7, should be used. LDS used in combination with a 
population PK model and Bayesian analysis, allows individual PK parameters to be estimated 
with adequate precision, while sampling and dosing times remain flexible. TDM could 
become an interesting strategy to docetaxel dose individualization provided a target 
concentration or exposure profile can be defined. It should be noted, however, that obtaining 
2 to 4 samples from outpatients requires adequate planning and a good collaboration between 
pharmacy, outpatient clinic and the prescribing oncologist to assure that the sampling can be 
completed within the service hours of an oncology day unit. 
 
Reversal of Drug Resistance  
The most extensively studied mechanism of acquired or intrinsic resistance to taxanes 
is the overexpression of ABCB1. Numerous (pre)clinical investigations have evaluated 
coadministration of ABCB1 modulators (e.g. verapamil, cyclosporin A, valspodar), aiming to 
restore or enhance sensitivity to chemotherapy. However, the results were largely 
disappointing. To overcome the limitations of these first- and second-generation modulators 
(unacceptable toxicity and unpredictable PK interactions), highly specific and potent third-
generation ABCB1 modulators, lacking interference with the plasma PK of cytotoxics, were 
developed. 
In phase I trials, oral and intravenous R101933 (laniquidar) administered in 
combination with docetaxel, inhibited ABCB1 both in an ex vivo assay and in vivo (indicated 
by intestinal P-gp inhibition), and docetaxel plasma PK was not altered 16,17. However, phase 
II studies were negative. Similar disappointing efficacy results were obtained in clinical trials 
of XR9576 (tariquidar) and docetaxel, and at present, there are no plans for further clinical 
development (http://www.qltinc.com). A phase I trial of docetaxel in combination with the 
orally administered agent LY335979 (zosuquidar) showed no PK interaction 18. The limited 
cerebrospinal fluid penetration of docetaxel is also assumed to be due to ABCB1-mediated 
drug efflux and restricts treatment of brain tumours with docetaxel. Preclinical investigations 
with GF120918 (elacridar) suggested increased docetaxel brain concentrations without effect 
on plasma PK 19, but a phase I trial reported increased systemic exposure to docetaxel and 
reduced clearance 20. This interaction will likely limit further clinical development. 
Docetaxel is also a substrate of CYP1B1, a cytochrome isozyme not detected in 
human liver but (over)expressed in various tumours. In vitro docetaxel cytotoxicity in cells 
transfected with human CYP1B1 was decreased 21, but CYP1B1-mediated docetaxel 
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metabolism was not affected 22. Meanwhile, the ability of CYP1B1 inhibitors to increase the 
cytotoxic effect of docetaxel has recently been demonstrated in vitro. Clinical studies have 
not yet been performed and the functional role of intratumoural CYP1B1(-mediated 
resistance) on docetaxel cytotoxicity remains to be elucidated. 
Clearly the ultimate (multi)drug resistance reversal agent is not (yet) available. 
Moreover, one should realize that modulating one resistance mechanism will not yield 
important antitumour benefit, given the large number of resistance mechanisms in human 
tumour tissue. 
 
Alternative Routes of Administration - Oral administration 
In vitro increasing the duration of taxane exposure above a threshold level is more 
important than achieving high peak concentrations. Clinically, the duration of exposure to 
plasma levels greater than 0.080 µg/mL indeed predicted response 3. Oral docetaxel treatment 
would be a patient-convenient way to achieve long-term drug exposure. However, 
development of a suitable oral formulation has been impeded by low (< 10 %) and highly 
variable oral bioavailability, due to the discussed extensive CYP3A-mediated first-pass 
metabolism and, to a lesser degree, to affinity for outward-directed transport by ABCB1 in 
the gastrointestinal tract. Modulating these elimination routes has therefore been a focus of 
research. 
In wild-type mice, exposure to orally administered docetaxel was 6-fold lower 
compared to Abcb1a/1b knock-out mice 23. More importantly, the relative bioavailability 
increased from 4 % to 183 % by coadministration of the potent CYP3A (and poor ABCB1) 
inhibitor ritonavir, increasing systemic exposure 50-fold. Subsequently, a small PK study, in 
which patients were given oral docetaxel (75 mg/m2) with or without the ABCB1- and 
CYP3A inhibitor cyclosporin A (CsA), confirmed the observation 24. In the presence of CsA, 
systemic exposure increased approximately 7-fold (from 0.37 mg.h/L ± 0.33 mg.h/L to 2.71 
mg.h/L ± 1.81 mg.h/L). When given 100 mg/m2 docetaxel intravenously (without CsA) the 
resulting systemic exposure was 4.27 mg.h/L ± 2.26 mg.h/L. Adjusted for the difference in 
dose, exposure following oral administration with concomitant CsA does not greatly differ 
from exposure after intravenous administration without CsA. The investigators performed a 
phase II trial with weekly oral docetaxel (100 mg) in combination with CsA 25. Interpatient 
PK variability, haematological toxicity and antitumour activity seem to be in the same range 
as for intravenous docetaxel. Oral docetaxel (100 mg) was also combined with OC144-093, a 
potent and selective oral ABCB1 inhibitor, and compared to 100 mg intravenous docetaxel 26. 
The relative oral bioavailability of docetaxel was 26 % ± 8 %, lower than previously 
observed after CsA coadministration, and systemic exposure after intravenous docetaxel was 
3-fold higher compared to the oral application, despite the ABCB1 modulation. Thus 
indicating that CYP3A-mediated (first-pass) metabolism is the crucial process involved in the 
Chapter 3 
 40
poor oral bioavailability of docetaxel. Notwithstanding the fact that the oral bioavailability of 
docetaxel can be increased through pharmacologic modulation, the development of second-
generation oral taxanes, is likely to prevail.  
 
Second Generation Docetaxel-based Taxanes  
Lately, structure activity relationship studies have focused on identifying novel 
structurally related docetaxel analogues with increased cytotoxicity in resistant tumours, 
increased penetration across the BBB, decreased toxicity, oral bioavailability and higher 
water solubility, the latter facilitating drug formulation. Chemical modification of the core 
structure of docetaxel has resulted in docetaxel-based second-generation taxanes, which are 
in different phases of clinical development (Table 1). 
Docetaxel is synthesized from 10-deacetylbaccatin III, a non-cytotoxic precursor 
derived from the European yew tree. Research initially focused on modifications of this 
compound and yielded XRP9881 (RPR109881A) and XRP6258 (RPR116258A or TXD258). 
Both agents have comparable mechanism of action to docetaxel, and in tumour models 
sensitive to docetaxel, cytotoxic activity was similar to docetaxel 
(http://www.AventisOncology.com). Importantly, in vitro these agents are characterized by 
potent growth inhibitory activity in moderately and highly docetaxel-resistant cell lines, most 
probably based upon a substantially lower affinity for ABCB1. Furthermore, glioblastoma 
models proved to be sensitive to these agents, suggesting penetration of the BBB. Phase I 
trials and early phase II studies with XRP9881 in metastatic breast cancer patients suggest 
adequate activity 27. A differentiating feature of XRP6258 is its antitumour activity following 
oral administration, yet initial development is as intravenous administration. Both agents 
demonstrate marked interpatient variability in drug clearance, similar to docetaxel. Short-
lasting and manageable neutropenia, fatigue and diarrhoea are the dose-limiting toxicities. 
Several cytotoxic analogues derived from 14-β-hydroxy-10-deacetylbaccatin III, a 
natural compound closely related to the core structure of docetaxel, have been evaluated. The 
most interesting is ortataxel (IDN5109, BAY59-8862). Ortataxel has adequate oral 
bioavailability and can modulate the function of various ABC transporter proteins, including 
ABCB1, MRP and BCRP 28. The drug is not active in renal cancer patients, and phase II 
studies in taxane-resistant metastatic breast cancer and NCSLC patients are ongoing. MAC-
321 or TL00139 exhibits a similar mechanism of cytotoxic activity as docetaxel 29, is highly 
effective both orally and intravenously administered and currently under investigation 
involving both administration routes. DJ-927 is a novel semi-synthetic taxane with high water 
solubility, lack of neurotoxicity, good oral bioavailability and superior antitumour activity 
compared to docetaxel in in vitro and in vivo models 30. Preliminary results of a phase I trial 
of orally administered DJ-927 suggest that the agent may have favourable toxicological and 
pharmacological properties. 
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Conclusion 
Continued research has offered us new and complementary insights on various 
aspects of docetaxel treatment, and yet, dose and schedule are still based on initial 
recommendations. Although this may sound disappointing, important steps forward have 
been made (Table 2) and research is ongoing. Besides the discussed areas of treatment 
optimization, future investigations will focus on further development of preclinically 
promising alternative formulations, on pharmacogenomic-based treatment optimization and 
on pharmacogenetic-based dose individualization strategies. However, given the large, 
ethnically diverse population studies required, introduction of the latter two strategies is not 
expected in the foreseeable future. On shorter term, it is likely that TDM will be explored as 
it provides a potential tool for rapidly achievable treatment optimization. 
 
Table 2. Investigated areas of improvement of docetaxel-based chemotherapy  
Area of improvement Outcome  
Weekly schedules Alternative for patients at high risk for myelotoxic 
complications 
Pharmacokinetics  Interindividual variability can be decreased by phenotypic 
individualized dosing 
 Most predictive phenotyping probe controversial 
Practical disadvantages of phenotyping in oncology practice 
Therapeutic drug monitoring requires investigation 
Reversal of resistance ABCB1-modulating agents insufficiently reverse (multi)drug 
resistance due to multiple resistance mechanisms 
Oral administration Oral administration feasible upon pharmacologic modulation 
Second-generation oral taxanes likely to prevail 
Second-generation taxanes In clinical phase I/II development; also oral drugs 
Alternative formulations  Alternative formulations in preclinical phase 
Introduction not foreseen in near future 
Pharmacogenomics and 
Pharmacogenetics  
Sufficiently powered trials necessary to determine clinical 
relevance 
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Abstract 
The anticancer drug docetaxel (Taxotere®) is formulated in the non-ionic surfactant 
polysorbate 80 (Tween®80). Early in the clinical development of docetaxel it became clear 
that docetaxel administration is associated with the occurrence of unpredictable (acute) 
hypersensitivity reactions and cumulative fluid retention. These side-effects have been 
attributed, in part, to the presence of polysorbate 80 and have consequently initiated research 
focused on the development of a less toxic, better-tolerated polysorbate 80-free formulation 
of docetaxel. More recently, there is increasing interest in developing a (polysorbate 80-free) 
docetaxel formulation that selectively targets malignant tissue, thereby increasing efficacy 
while decreasing the occurrence of side-effects related to wide and non-specific body 
distribution. 
This review aims to discuss the preclinical and clinical results of pharmaceutical 
strategies (i.e. PEGylated (immuno)liposomal docetaxel, docetaxel-fibrinogen-coated olive 
oil droplets, docetaxel encapsulated nanoparticle-aptamer bioconjugates, submicronic 
dispersion formulation) to develop an alternative, solvent-free, delivery form for docetaxel 
characterized by increased efficacy and decreased toxicity. 
 
Introduction 
The anticancer drug docetaxel (Taxotere®, Sanofi-Aventis) demonstrates significant 
antitumour activity against various human malignancies and is approved for the treatment of 
patients with locally advanced or metastatic breast cancer, non-small-cell lung cancer, 
hormone refractory prostate cancer and advanced gastric cancer 1. Docetaxel (Figure 1) is a 
semi-synthetic drug prepared by chemical modification of 10-deacetylbacattin III, an inactive 
precursor compound isolated from the needles of the European yew tree, Taxus Baccata. Due 
to its poor water solubility (3 µg/mL) docetaxel is dissolved in the non-ionic surfactant 
polysorbate 80 (Tween®80), the major component of which is polyoxyethylene-20-sorbitan 
monooleate (Figure 2), structurally similar to polyethyleneglycols. In early phase I clinical 
trials, docetaxel was supplied as a sterile solution containing 15 mg/mL docetaxel in 50 % 
polysorbate 80 and 50 % ethanol 2-6. In order to decrease the amount of polysorbate 80 and 
ethanol administered to patients, this formulation was optimized and a new formulation was 
used in the phase II and III clinical trials, and subsequently marketed. The currently approved 
formulation contains 40 mg/mL docetaxel and 1040 mg/mL polysorbate 80 (i.e. 26 mg 
polysorbate 80 per mg docetaxel) and requires further dilution with 13 % ethanol prior to 
addition to the intravenous infusion solution. 
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Figure 1. Chemical structure of docetaxel. 
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Figure 2. Chemical structure of the primary constituent of polysorbate 80: polyoxyethylene-20-
sorbitan monooleate.  
 
Early in the clinical development of docetaxel it became clear that docetaxel 
administration is associated with the occurrence of unpredictable (acute) hypersensitivity 
reactions, widely ranging in incidence (range, 5 - 60 %) and severity (from mild pruritus to 
systemic anaphylaxis). In addition, fluid retention resulting in weight gain, peripheral 
oedema, and occasionally pleural or pericardial effusions, was reported with an incidence 
increasing above 50 % at cumulative docetaxel doses of ≥ 400 mg/m2 7-9. The occurrence of 
hypersensitivity reactions has, in part, been attributed to intrinsic toxic effects of polysorbate 
80, more specifically to oxidation products and oleic acid present in polysorbate 80, which 
are known to cause histamine release 10,11. The role of histamine in the aetiology of 
polysorbate 80-induced hypersensitivity reactions is further supported by the fact that these 
side-effects are effectively ameliorated by premedication with corticosteroids and 
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antihistamines 12,13. However, more recently, the allergenic origin of these hypersensitivity 
reactions has been opposed and a pathogenetic mechanism, involving the release of 
vasoactive substances, has been suggested 14. The occurrence of cumulative fluid retention 
may, in part, be explained by the fact that the formulation vehicle has been shown to increase 
membrane permeability 15. This finding is in line with reports of increased filtration of fluid 
to the interstitial space following a decrease in plasma colloid osmotic pressure, which occurs 
upon multiple docetaxel courses 16,17. Moreover, the fact that corticosteroids significantly 
reduce and delay the onset of fluid retention, allowing for a higher cumulative dose to be 
administered 13, may also indicate an effect of vessel wall permeability. Although of minor 
importance, it should be noted that the beneficial effects of prophylactic corticosteroid 
administration may come at the cost of treatment-related morbidity (e.g. hyperglycaemia, 
peptic/duodenal ulcers). Finally, polysorbate 80 has been shown to increase plasma viscosity 
and produce changes in erythrocyte morphology, effects which have been suggested to 
contribute to mechanisms related to docetaxel-mediated cardiovascular side-effects 18. 
The drawbacks associated with the presence of polysorbate 80 in the formulation of 
docetaxel initially initiated research focused on developing a formulation that enhances the 
solubilization of docetaxel while avoiding the use of polysorbate 80, thus resulting in a less 
toxic, better-tolerated polysorbate 80-free formulation. More recently, there is increasing 
interest in developing more advanced (solvent-free) formulations, which provide selective 
tumour delivery. Examples include targeted (immuno)liposomes and nanoparticles, which 
profoundly modify both the pharmacokinetics (PK) and pharmacodynamics (PD) of 
docetaxel, thereby increasing efficacy while decreasing the occurrence of side-effects related 
to wide and non-specific body distribution (e.g. neurotoxicity, musculo-skeletal toxicity, 
neutropenia). 
This review aims to discuss the preclinical and clinical results of pharmaceutical 
strategies to develop an alternative, solvent-free delivery form for docetaxel. Related 
strategies, including the development of novel, structurally related docetaxel analogues, 
although also aimed at optimizing the risk-benefit ratio (i.e. balance between treatment-
related toxicity and efficacy) for docetaxel treatment, have been discussed previously 
elsewhere 19. 
 
Prerequisites for a polysorbate 80-free formulation  
A polysorbate 80-free docetaxel formulation is only desirable if polysorbate 80 does 
not substantially contribute to docetaxel’s antitumour efficacy. Several reports have 
suggested that polysorbate 80 possesses intrinsic tumour activity in vitro and in animals 
models 20,21, possibly attributable to oleic acid, rapidly cleaved from polysorbate 80 upon 
serum carboxylesterase-mediated hydrolysis 22, and known to interfere with malignant cell 
proliferation 23. However, the exact contribution of polysorbate 80 and/or oleic acid to 
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clinically observed antitumour efficacy has not (yet) been clarified. Furthermore, due to its 
extremely low volume of distribution 24,25, delivery of polysorbate 80 outside the central 
compartment to the tumour is believed to be insignificant, consequently excluding any 
substantial contribution to cytotoxicity. In addition, docetaxel is a well known substrate for 
the transmembrane transporter ABCB1 (P-glycoprotein; MDR-1) 26. ABCB1, which is 
expressed in tumours and normal tissues, acts as a drug/xenobiotic-efflux pump 27 and its 
overexpression is implicated in the occurrence of (multi)drug resistance (MDR). Polysorbate 
80-mediated inhibition of ABCB1 has been observed in vitro 28,29, although not confirmed in 
vivo 30. Moreover, to date, clinical investigations evaluating docetaxel administration in 
combination with ABCB1 inhibitors (e.g. laniquidar, tariquidar, zosuquidar, elacridar) 19, in 
the hope of restoring or enhancing chemosensitivity, have been disappointing and have not 
(yet) yielded an adequate MDR-reversal agent. Furthermore, although ABCB1 plays a 
(major) role in the faecal disposition of docetaxel 31, its influence on docetaxel plasma PK is 
minimal to absent 32. Overall, it is unlikely that a polysorbate 80-free docetaxel formulation 
will significantly affect docetaxel’s cytotoxic properties. 
Recent in vitro and in vivo data have demonstrated that low doses of docetaxel 33,34 
and clinically achievable concentrations of polysorbate 80 35 both exhibit antiangiogenic 
properties. However, clinically relevant concentrations of polysorbate 80 (i.e. concentrations 
achieved at the end of docetaxel infusion) nullify docetaxel-mediated inhibition of 
angiogenesis 35, suggesting that a polysorbate 80-free docetaxel formulation may potentially 
have a positive effect on the antiangiogenic capacity of docetaxel. 
In vitro studies have demonstrated that docetaxel is extensively bound to albumin and 
alpha-1 acid glycoprotein (AAG) and that the latter is the main determinant of variability in 
docetaxel serum binding 36. Lately, the influence of polysorbate 80 on the PK of total and 
unbound docetaxel (the latter being the pharmacologically active fraction) has been 
extensively investigated 37. At clinically relevant concentrations, polysorbate 80 significantly 
increased the fraction of unbound docetaxel in vitro, a finding that was confirmed in vivo. In 
addition, Baker et al. demonstrated that there is a significant relationship between systemic 
exposure to polysorbate 80 and the clearance rate of unbound docetaxel; higher polysorbate 
80 exposure is associated with reduced clearance of unbound docetaxel, consequently 
resulting in increased unbound drug exposure 25. Moreover, exposure to unbound docetaxel 
was more closely related to drug-induced severe haematological toxicity than total docetaxel 
exposure. The exact mechanistic basis for the decreased protein binding of docetaxel in the 
presence of polysorbate 80 is unknown, yet is presumably the result of micellar complexes 
formed by polysorbate 80 with serum proteins (albumin and AAG) 38, thus leading to 
saturable protein binding of docetaxel 36 and/or the result of displacement of protein-bound 
docetaxel by rapidly generated polysorbate 80 degradation products (e.g. oleic acid) 39. 
Overall, it is clear that the degree of docetaxel plasma binding and consequently the fraction 
of, and exposure to unbound drug is, in part, influenced by the formulation vehicle. A 
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polysorbate 80-free formulation, may thus, through a decrease in the fraction of unbound 
drug, reduce the incidence and severity of unpredictable neutropenia, thereby improving the 
risk-benefit ratio for docetaxel treatment. One could argue that such a formulation might 
compromise drug efficacy due to decreased concentration of the pharmacologically active 
drug fraction in plasma and, more importantly, at the tumour site. However, to date, 
population PK/PD studies have identified systemic docetaxel exposure as a significant 
predictor of (haematological) toxicity, yet the correlation between any measure of docetaxel 
exposure (i.e. total clearance, total systemic exposure, peak plasma-level, duration of plasma-
levels greater than a certain value) and antitumour response is much less clear 9. Furthermore, 
data on intratumoural docetaxel PK are lacking and an improvement in the risk-benefit ratio, 
through a decrease in toxicity, may outweigh a decrease, to a yet unknown degree, in 
antitumour efficacy. 
In conclusion, based on the biological and pharmacological properties of polysorbate 
80, it seems unlikely that a polysorbate 80-free docetaxel formulation will compromise 
docetaxel antitumour efficacy. 
 
Alternative formulations – Preclinical data 
Avoiding the use of polysorbate 80 while at the same time developing a drug 
formulation that targets malignant tissue, has received substantial interest recently and has led 
to several alternative, solvent-free docetaxel formulations with varying potential to 
selectively deliver docetaxel to the tumour, thereby potentially enhancing efficacy while 
decreasing the occurrence of undesirable side-effects. One approach to avoid polysorbate 80 
administration and selectively target the tumour is the use of fibrinogen microspheres as 
delivery vehicle, as previously investigated for other anticancer drugs 40,41. Local fibrin(ogen) 
deposition occurs within the stroma of the majority of solid tumours and is associated with 
tumour angiogenesis, growth and metastatic potential 42. In addition, thrombin-mediated 
accumulation and retention of intravenously administered fibrinogen-coated olive oil 
droplets, at fibrin(ogen)-rich sites, has been demonstrated 43. These features initiated the 
preparation of murine-fibrinogen-coated micronized olive oil droplets loaded with docetaxel 
44 and subsequently, evaluation of this formulation’s antitumour activity upon intraperitoneal 
(i.p.) administration to mice bearing a fibrin(ogen)-rich ascites tumour 45. Upon i.p. treatment 
with the docetaxel-fibrinogen-coated olive oil droplet formulation (docetaxel dose ∼ 20 
mg/kg; mean olive oil droplet size ∼ 12 µm), median survival increased approximately 2-fold 
compared to treatment with docetaxel solubilized in polysorbate 80. A preliminary toxicity 
assessment based on the change in weight of healthy, tumour-free mice 15 days following i.p. 
injection of either normal saline, docetaxel solubilized in polysorbate 80 or docetaxel-loaded-
fibrinogen-coated olive oil droplets demonstrated no significant differences. The association 
of docetaxel with tumour cells was monitored by administering tumour-bearing mice either 
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docetaxel solubilized in polysorbate 80 or docetaxel-loaded-fibrinogen-coated olive oil 
droplets, both spiked with [3H]-docetaxel. Docetaxel association with tumour cells, measured 
by liquid scintillation counting 48 hours after treatment, was at least 10-fold increased upon 
i.p. administration of docetaxel-loaded olive oil droplets compared to docetaxel solubilized in 
polysorbate 80. These findings suggest potential to improve the therapeutic efficacy of 
docetaxel treatment. However, several issues require to be further addressed, including the 
feasibility of intravenous administration, which requires smaller droplet size, the influence of 
anticoagulants or fibrinolytic agents, which may potentially reduce the therapeutic efficacy of 
the fibrinogen-coated olive oil formulation and toxicity aspects related to the observed 
significant antibody response (i.e. droplet-induced production of antifibrinogen antibodies), 
of which the long-term effects on effectiveness are yet unclear. 
Recently, research has increasingly focused on nanotechnological devices for the 
development of (biomarker)-targeted delivery systems for multiple therapeutic agents 46. 
Nanotechnology is a multidisciplinary field, which covers a diverse array of devices derived 
from engineering, biology, physics and chemistry. These nanotechnology devices 
(nanotherapeutics) include nanovectors aimed at improving the tumour-targeting efficacy of 
anticancer drugs 47. An injectable drug-delivery nanovector is defined as a hollow or solid 
structure with a diameter in the 1 - 1000 nm range. It can be filled with anticancer drugs and 
targeting moieties can be attached to its surface resulting in specific and differential uptake 
by the targeted cells, in order to deliver a constant dose of chemotherapy over an extended 
period of time. Probably the most well known, simplest and earliest examples of nanovectors 
applied in cancer treatment are liposomes, which are a hollow type of nanovector, whereas 
nanoparticles are considered solid nanovectors. Liposomes are spherical particles (vesicles) 
consisting of one or more lipid bilayer membranes, which encapsulate an internal space 
where notably hydrophilic agents can be entrapped; the lipid bilayer membrane of the 
liposome may serve as a reservoir for hydrophobic drugs. PEGylated liposomes (STEALTH® 
[sterically-stabilized] liposomes) differ from conventional liposomes by a polymer 
(polyethylene glycol, PEG) surface coating. These modified liposomes are characterized by 
reduced uptake by the reticulo-endothelial system, favourable PK (long circulating time, slow 
clearance rate, small volume of distribution), reduced accumulation in healthy tissues and, 
most importantly, by increased, preferential tumour uptake due to their ability to extravasate 
through the hyperpermeable tumour vasculature, a tumour-targeting mechanism known as 
enhanced permeation and retention 48,49. These distinct features make PEGylated liposomes 
an attractive drug carrier. Indeed, for anticancer drugs, the advantages of PEGylated 
liposomes are best illustrated by PEGylated liposomal doxorubicin (Caelyx®, Doxil®, 
Myocet®). The wish to circumvent the use of polysorbate 80 and to improve the therapeutic 
index for docetaxel-based therapy through specific tumour targeting has led to the successful 
preparation of PEGylated liposomal docetaxel 50 without compromising cytotoxicity. Indeed, 
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in vitro cytotoxic activity of the PEGylated docetaxel formulation was almost equipotent to 
the non-liposomal docetaxel formulation. PK profiles for docetaxel solubilized in polysorbate 
80 and docetaxel encapsulated in the PEGylated liposomes, assessed after a single 
intravenous bolus dose to mice, were both best described by a two-compartment model. 
However, the PK parameters differed significantly; docetaxel terminal half-life was increased 
nearly 13-fold upon liposomal encapsulation and clearance and volume of distribution were 
decreased more than 100-fold and 6-fold, respectively, compared to docetaxel solubilized in 
polysorbate 80. Further increase of the docetaxel concentration inside the PEGylated 
liposomes (currently 0.7 ± 0.2 mg/mL) is required before clinical trials can be initiated to 
determine if the improved PK features result in selective and efficient tumour uptake and 
reduced toxicity. Interestingly, in rats and mice 51,52, the PK of a second dose of PEGylated 
liposomes (devoid of encapsulated drug) was dramatically altered compared to the first dose 
in a time-interval dependant manner. The most prominent difference was a major increase in 
clearance, hence the observation is referred to as the ‘accelerated blood clearance’(ABC)-
phenomenon. Initially, the ABC-effect was suggested to be caused by a considerable increase 
in hepatic accumulation, possibly involving certain serum factor(s) secreted into the blood 
after the first dose of PEGylated liposomes. Most recently, evaluations have demonstrated 
that IgM is the major serum protein, which selectively binds to PEGylated liposomes upon 
repeated injection, and that these IgM-bound PEGylated liposomes can then activate the 
complement system 53, thus leading to accelerated clearance and enhanced hepatic uptake. 
Theoretically, the ABC-phenomenon can potentially compromise therapeutic efficacy and the 
strongly increased drug uptake in the liver may cause severe undesirable liver toxicity. 
Moreover, repeated administration of PEGylated liposomes may lead to the occurrence of 
unexpected immune reactions. However, in clinical practice the occurrence of immune 
reactions after repeated doses of PEGylated liposomal doxorubicin is rare (1 - 5 %), 
suggesting that the observed ABC-phenomenon for PEGylated docetaxel may have only a 
minor impact. Nevertheless, future research in the design and clinical use of PEGylated 
liposomal docetaxel, should determine the implications of these findings. 
Covalent attachment of targeting ligands, such as monoclonal antibodies specific for 
antigens expressed on the surface of cancer cells, is another modification of the conventional 
liposome with the aim to improve selective tumour delivery. Docetaxel has been shown to 
enhance tumour response upon irradiation 54, however, clinical application of this 
radiosensitizing potential is limited due to side-effects associated with the drug’s poor tumour 
selectivity. To increase tumour delivery and to evaluate the radiosensitizing properties of 
docetaxel, human colon adenocarcinoma cell lines expressing carcinoembryonic antigen 
(CEA), were treated with irradiation and PEGylated docetaxel ‘immunoliposomes’, i.e. 
immunoliposomes prepared by coupling monoclonal antibodies against CEA to the PEG-
coating of the lipid membrane 55. Specifically, cells were incubated (2 h, 37 °C) with 
different concentrations of immunoliposomal docetaxel or liposomal docetaxel (range, 1 – 
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1000 nmol/L docetaxel) after which the cells were washed and further incubated (24 - 48 h, 
37 °C). Non-incubated cells received a series of test radiation doses ranging from 0 Gy to 8 
Gy to determine the degree of radiotoxicity; radiotoxicity was most pronounced at a dose of 2 
Gy. Consequently, this radiation dose was used to irradiate the cells incubated with 
immunoliposomal- and liposomal docetaxel. Cytotoxicity, assessed using the colourimetric 
MTT assay, was induced by immunoliposomal docetaxel in a dose and time-dependant 
manner. Similar evaluation of the cytotoxic efficacy of the multimodality treatment 
demonstrated that the effects of immunoliposomal docetaxel were potentiated upon radiation 
compared to liposomal docetaxel with irradiation or only irradiation (P < 0.05). Furthermore, 
flow cytometric analysis demonstrated that upon treatment with immunoliposomal docetaxel 
combined with irradiation, apoptosis was significantly increased compared to the 
multimodality treatment for liposomal docetaxel. Further research should determine if this 
specific immunoliposomal docetaxel formulation offers potential to improve local 
radiotherapy in the treatment of colon cancer. 
As mentioned, an expanding number of nanovectors are currently under development 
for novel, optimized drug-delivery modalities 46,47,56. Approaches include molecular targeting 
of nanovectors through conjugation of active recognition moieties to the surface of the 
nanovector (an approach characterized by potential advantages above conventional antibody-
targeted therapy), intracellular targeting of nanoparticles by folate, dendritic polymers as 
multifunctional nanodevices, silicon and silica materials as materials for injectable 
nanovectors, metal-(e.g. gold) based nanovectors and polymer-based nanovectors of which 
the latter seem to be the most promising for clinical translation. Most recently, docetaxel-
encapsulated nanoparticles formulated with biocompatible and biodegradable poly(D,L-
lactic-co-glycolic acid)-block PEG-copolymer and surface functionalized with A10 2’-
fluoropyrimidine aptamers (i.e. RNA oligonucleotides; nucleic acid ligands) 57 that bind to 
the extracellular domain of the transmembrane prostate-specific membrane antigen (PSMA), 
a well characterized antigen expressed with high specificity on the surface of prostate cancer 
cells, have been successfully developed in vitro (Figure 3) and their cytotoxicity evaluated 
using a xenograft nude mouse prostate cancer model 58. Due to the surface functionalization 
with the specific PSMA aptamers, these docetaxel-encapsulated nanoparticle-aptamer 
bioconjugates (Doc-Np-Apt) exert significantly enhanced cellular cytotoxicity in vitro 
resulting from targeted delivery and enhanced cell-specific uptake compared to non-targeted 
docetaxel-encapsulated nanoparticles (lacking the PSMA aptamer). A single intratumoural 
injection of Doc-Np-Apt (40 mg/kg) in vivo was significantly more efficacious regarding 
tumour size reduction and survival time compared to an equivalent dose of non-targeted 
docetaxel-encapsulated nanoparticles. The enhanced efficacy was attributed to delayed 
clearance from the target site due to preferential binding to the PSMA proteins, leading to 
internalization and subsequent intracellular drug release. Mean body weight loss at nadir was 
significantly decreased (2-fold) for Doc-Np-Apt compared to non-targeted docetaxel-
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encapsulated nanoparticles, suggesting reduced treatment toxicity. Furthermore, there was no 
evidence of persistent haematological toxicity. Several aspects of this approach have the 
potential to facilitate translation into clinical practice, including the fact the poly(D,L-lactic-
co-glycolic acid) is a component the FDA has approved for clinical use, and the fact that the 
targeting molecules (aptamers) are small, relatively stable, non-immunogenic and easy to 
produce on a large scale. However, before clinical application is possible several aspects, 
including potential sensitization reactions, biological/biophysical barriers impeding targeted 
delivery, and the tailoring of dosing and administration schedules remain to be examined. 
 
 
 
 
 
 
Figure 3. Schematic representation of the coupling of amine-functionalized A10 PSMA aptamers to a 
docetaxel-encapsulated, PEGylated nanoparticle by carbodiimide chemistry, thus resulting in a 
docetaxel-encapsulated-PEGylated-poly(D,L-lactic-co-glycolic-acid)-nanoparticle-aptamer-
bioconjugate. 
Abbreviations: PEG, polyethyleneglycol; COOH, carboxylic acid; PLGA, poly(D,L-lactic-co-glycolic 
acid); NH2-aptamer, amine-functionalized A10 prostate specific membrane antigen aptamer; EDC, 1-
ethyl-3-(3-dimethylaminopropyl)-carbodiimide; NHS, N-hydroxysuccinimide.  
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Alternative formulations – Clinical data  
Clinical studies evaluating the efficacy and safety profile of a polysorbate 80-free 
docetaxel formulation are limited to two phase I studies 59,60. Both trials evaluated a 
polysorbate 80-free submicronic dispersion formulation (Sanofi-Aventis) administered once 
every three weeks, as a 1-hour intravenous infusion without corticosteroid or antihistamine 
premedication. In patients with advanced solid tumours (N = 41), the maximum tolerated 
dose (MTD) was 145 mg/m2 (without granulocyte colony-stimulating factor support), setting 
the recommended dose level at 130 mg/m2, which is significantly higher than 100 mg/m2, the 
highest recommended single agent dose (http://www.taxotere.com). Despite the lack of 
premedication, no hypersensitivity reactions were observed and fluid retention occurred in 49 
% of the patients at a relatively high median cumulative dose (575 mg/m2), yet was severe in 
less than 5 % of the cases. Dose-limiting toxicities (DLT) did not differ from those seen with 
the current formulation of docetaxel (severe neutropenia and febrile neutropenia), nor did the 
spectrum of haematological and non-haematological toxicities. Interestingly, a retrospective 
analysis concluded that at equimolar doses the solvent-free formulation appeared to result in 
a lower incidence and severity of infections, mucositis, diarrhoea and neuropathy, the latter 
finding supporting the notion that polysorbate 80, capable of producing vesicular 
degeneration 61, contributes, in part, to the predominantly mild sensory neuropathy observed 
in a high proportion of patients treated with docetaxel. The overall response rate (ORR) 
among thirty one breast cancer patients who had received a dose ≥ 100 mg/m2 was 48.4 % 
(95 % confidence interval (CI), 30.2 – 66.9 %), which is comparable to the results of the 
pivotal trial leading to the approval of docetaxel for locally advanced or metastatic breast 
cancer (ORR 47.8 %; 95 % CI, 40.1 – 55.5 %) 62. A PK evaluation revealed that clearance 
was independent of dose and similar to previously observed values 9. The polysorbate 80-free 
formulation was also administered in combination with doxorubicin as first-line 
chemotherapy to patients with metastatic breast cancer (N = 38). In this study, antitumour 
activity was observed at all dose levels and the MTD was reached at 100 mg/m2 polysorbate 
80-free docetaxel and 60 mg/m2 doxorubicin. Febrile neutropenia was again the DLT. The 
recommended dose for phase II evaluation was set at 85 mg/m2 polysorbate 80-free docetaxel 
and 60 mg/m2 doxorubicin, which is higher than the doses applied in a randomized phase III 
study evaluating docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) treatment for the same 
indication 63. In order to continue the development of this well tolerated and active 
formulation the manufacturing process was modified to allow for large-scale (i.e. industrial) 
production. However, this upscaling process led to some slight modifications of the 
formulation’s physico-chemical properties, which may have been the cause of toxicities 
(oedema, hand and foot skin reactions) observed at lower doses and in earlier cycles 
compared to the initial solvent-free formulation. Although these toxicities were not severe 
enough to be classified as DLTs, they did often lead to treatment withdrawal and were the 
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reason to discontinue further clinical development of this polysorbate 80-free formulation 
(personal communication Sanofi-Aventis). 
 
Discussion 
Pharmaceutical excipients have an essential role in drug formulations. However, in 
contrast to earlier views, these excipients, including the non-ionic surfactant polysorbate 80 
used to solubilize the hydrophobic anticancer drug docetaxel, are not inert vehicles, but are 
able to affect drug disposition and toxicity patterns 61. Consequently, acknowledging that a 
less toxic (i.e. polysorbate 80-free) formulation of docetaxel is desirable, recent research has 
focused on developing alternative (solvent-free) drug delivery forms while continuing to 
maximize the drug’s antitumour efficacy through preferential uptake of the drug at the site of 
action, the tumour. This pharmaceutical strategy has lead to several alternative drug 
formulations including fibrinogen-coated olive oil droplets loaded with docetaxel, PEGylated 
docetaxel liposomes, docetaxel immunoliposomes, and docetaxel-encapsulated nanoparticle-
aptamer bioconjugates, all currently in different preclinical stages of development and with 
different advantages and disadvantages (Table 1). Whether the observed advantages 
(improved PK, selective tumour uptake, increased survival) over the current docetaxel 
formulation translate to clinical benefits remains to be seen. Potential drawbacks, which 
require to be overcome include the ABC-effect observed with PEGylated liposomes, the 
occurrence of (unexpected) immune reactions, also seen with docetaxel-fibrinogen-coated 
olive oil droplets and, most importantly, overcoming the pharmaceutical challenge of 
achieving encapsulation of a therapeutically meaningful amount of drug in the liposomes 64. 
It would seem that the use of monoclonal antibodies or the more recently introduced aptamers 
(DNA or RNA oligonucleotides) as targeting ligand has much potential given the increasing 
number of well defined biomarkers (e.g. antigens) expressed on the cancer cell surface. 
Which of these two targeting approaches proves to be the more suitable remains to be 
examined. Initial problems related to specificity, purity, immunogenicity, relatively long 
development times and batch-to-batch variability upon large-scale biological production of 
(monoclonal) antibodies, although largely overcome, could still complicate their general 
application. On the other hand, aptamer synthesis does not rely on biological systems and is 
an entirely chemical process, which can easily be scaled up. Indeed, aptamer drug-targeting 
could potentially provide an adequate alternative to antibody-based drug-targeting 
techniques. Moreover, although the aptamer-based targeting approach is considered highly 
promising, it is expected that the greatest gain in optimizing therapeutic selectivity will be 
achieved by synergistic combinations of different nanotechnological targeting strategies.
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Currently, only one polysorbate 80-free docetaxel formulation has been evaluated 
clinically in two phase I trials. Although this formulation demonstrated uncompromised 
cytotoxic activity, the occurrence of toxicities leading to treatment withdrawal resulted in the 
discontinuation of further clinical development of this solvent-free docetaxel formulation. 
To date, attempts to improve taxane-based treatment have largely focused on, and 
have been most successful for paclitaxel 65,66, the first taxane to be introduced (FDA approval 
1992). Indeed, most recently paclitaxel nanoparticles conjugated to albumin molecules 
(Abraxane®, Abraxis Oncology; FDA approval 2005), the latter enhancing the transport of 
the nanoprticles across the vascular endothelium, demonstrated an improved therapeutic 
index compared to paclitaxel (Taxol®) in the treatment of patients with metastatic breast 
cancer 67. Several reasons may explain why the majority of research has focused on 
improvement of the paclitaxel drug formulation and include the earlier introduction and thus 
larger body of clinical experience, and the fact that a greater improvement may be made for 
current paclitaxel-based treatment with less effort, as the formulation vehicle Cremophor EL 
used to solubilize paclitaxel presents more PK and PD drawbacks 61 than polysorbate 80. 
However, docetaxel is also a highly suitable candidate to concentrate on, given its superiority 
above paclitaxel in overall survival in patients with metastatic breast cancer 68, linear PK 69, 
single enzyme-mediated metabolism 70,71 and the existing extensive knowledge on PK/PD 
relationships 9. The success of Abraxane® suggests that developing merely a solvent-free 
formulation is not enough therapeutic improvement to warrant extensive clinical evaluation. 
The combination of a solvent-free docetaxel formulation with tumour targeting characteristics 
ultimately shows the most promise of future therapeutic gain for this highly active drug. 
In conclusion, preclinical research aimed at optimizing the risk-benefit ratio for 
docetaxel-based therapy through development of a less toxic, solvent-free (polysorbate 80-
free) formulation with tumour targeting properties is ongoing and encouraging. However, it is 
unlikely that an alternative formulation will be available for clinical use in the near future. 
Although this may sound disappointing it is clear that one is convinced of the need to 
optimize the risk-benefit ratio for docetaxel treatment and any advances which can be made 
in this area, however modest they may be, are worth further research. 
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Abstract 
Objective: In vitro studies indicate that the anticancer drug docetaxel is primarily 
eliminated by cytochrome P450 (CYP) 3A4-mediated metabolism. Coadministration of drugs 
that modulate the activity of CYP3A4 is, therefore, likely to have undesirable clinical 
consequences. We investigated the effects of the potent CYP3A4 inhibitor ketoconazole on 
the pharmacokinetics of docetaxel in cancer patients. 
Methods: Seven patients were treated in a randomized cross-over design with 
docetaxel (100 mg/m2) followed 3 weeks later by docetaxel (10 mg/m2) given in combination 
with orally administered ketoconazole (200 mg once daily for 3 days), or the reverse 
sequence. Plasma concentration-time data were analysed using noncompartmental analysis. 
Results: Ketoconazole coadministration resulted in a 49 % decrease in clearance of 
docetaxel (P = 0.018). The mean (± SD) clearance values were 35.0 L/h ± 11.8 L/h (95 % 
confidence interval, 24.1 – 45.9 L/h) for docetaxel alone and 18.2 L/h ± 9.68 L/h (95 % 
confidence interval, 9.22 – 27.1 L/h) in the presence of ketoconazole, respectively. The 
docetaxel clearance ratio in the presence and absence of ketoconazole was weakly related to 
the area under the plasma concentration-time curve of ketoconazole (R2 = 0.529; P = 0.064). 
Conclusion: Inhibition of CYP3A4 by ketoconazole in vivo results in docetaxel 
clearance values that were previously shown to be associated with a several-fold increase in 
the odds for febrile neutropenia at standard docetaxel doses. Caution should be taken and 
substantial dose reductions are required if docetaxel has to be administered together with 
potent inhibitors of CYP3A4.  
 
Introduction  
Drug-interactions are a major cause of morbidity and mortality in modern clinical 
practice 1. Many anticancer drugs have a narrow therapeutic index and are administered to 
cancer patients who are also taking numerous concomitant medications 2. An understanding 
of the implications of interactions is, therefore, particularly important in anticancer therapy. 
The human cytochrome P450 (CYP) 3A subfamily, which is involved in the metabolism of 
more than 50 % of currently prescribed drugs, plays a dominant role in many clinically 
relevant drug-interactions 3. In adults, CYP3A activity represents the combined activities of 
the isoforms CYP3A4, CYP3A5, and CYP3A7 4. In the majority of humans, however, 
CYP3A activity in the intestine and liver is predominantly reflected by CYP3A4 activity. 
Significant interindividual variability in the pharmacokinetics of CYP3A substrates has been 
observed both in vitro and in vivo. These differences are thought to be related to variations in 
both basal content and catalytic activity of total CYP3A 4. Disease-related differences, drugs 
inducing or repressing transcription, and possibly inherited and ethnic differences are also 
factors contributing to CYP3A phenotype 5. 
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The anticancer drug docetaxel is extensively metabolized by CYP3A 6,7. The major 
metabolites and less than 10 % of the parent drug are excreted into the faeces, whereas total 
urinary excretion is also less than 10 % 8. The metabolites demonstrate substantially reduced 
cytotoxic activity as compared with the parent drug, making biotransformation by CYP3A a 
major route of inactivation 9. Furthermore, total CYP3A activity has been identified as a 
strong predictor of docetaxel clearance and most likely accounts to a large extent for the 
observed interindividual variability in drug clearance and area under the plasma 
concentration-time curve 10-12. Although the fact that docetaxel is predominantly metabolized 
by CYP3A makes the agent subject to a host of enzyme-mediated drug-interactions, data on 
potential interactions are lacking in humans. The aim of this trial was to assess the effect of 
CYP3A inhibition on the pharmacokinetics of docetaxel in cancer patients, by the use of the 
model inhibitor ketoconazole 13.  
 
Methods  
Patient selection 
Eligible patients had a histologically or cytologically confirmed diagnosis of cancer 
for which docetaxel has proven efficacy or for which no other treatment option was available. 
Additional eligibility criteria included the following: (1) a life expectancy of at least 12 
weeks; (2) a World Health Organization performance status of 1 or less; (3) no 
chemotherapy, hormonal therapy, radiotherapy, or major surgery within 4 weeks prior to 
treatment; (4) age more than 18 years; (5) adequate contraception for women of child-bearing 
potential; and (6) adequate bone marrow function (absolute neutrophil count > 1.5 × 109/L; 
platelet count > 100 × 109/L), renal function (serum creatinine level ≤ 1.5 × the upper limit of 
normal), and hepatic function (serum bilirubin ≤ 1 × the upper limit of normal, alanine 
aminotransferase and aspartate aminotransferase levels < 2.5 × the upper limit of normal, and 
alkaline phosphatase level ≤ 5 × the upper limit of normal in the presence of only bone 
metastases and in the absence of any liver disorders). Simultaneous use of any medication, 
dietary supplements, or other compounds known to inhibit or induce CYP3A was not 
allowed. The study protocol was approved by the Erasmus Medical Center Ethical Review 
Board, and all patients provided written informed consent before study entry. 
 
Study design 
Treatment consisted of two courses of docetaxel (Taxotere®; Aventis Pharma, 
Hoevelaken, The Netherlands), administered 3 weeks apart. Docetaxel was diluted in 250 mL 
of 0.9 % (wt/vol) sodium chloride solution and delivered as a 1-hour intravenous infusion. 
One course was given at a docetaxel dose of 100 mg/m2, and the other was given at a dose of 
10 mg/m2 in combination with three 200 mg doses of orally administered ketoconazole 
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(Nizoral®; Janssen Pharmaceutical, Beerse, Belgium). Previously, it was shown that the area 
under the plasma concentration-time curve of docetaxel is dose-proportional over a large dose 
range (5 mg/m2 to 145 mg/m2) in the tested 3-week regimen with the drug administered as a 
1-hour intravenous infusion, indicating a linear pharmacokinetic behaviour (reviewed by 
Clarke and Rivory 8). Therefore, values for clearance of docetaxel between the treatment 
courses with and without ketoconazole coadministration were compared directly without any 
correction. 
The first ketoconazole dose was administered 1 hour before the docetaxel infusion 
was started, and the second and third doses were given 24 and 48 hours later. The 
ketoconazole dose and schedule were based on previously published data 14. We 
hypothesized that CYP3A inhibition would prolong the exposure to docetaxel, and that a 
significant dose reduction was required to prevent unacceptable toxicity in the combination 
cycle. The decision to administer docetaxel at a dose of 10 mg/m2 (in combination with 
ketoconazole) was based on the mild toxicity profile seen at this dose level in a previous 
Phase I study with single agent docetaxel 15, and the hypothesis that transient inhibition of 
CYP3A-mediated metabolism of docetaxel would result in associated exposure levels not 
exceeding those observed at the recommended single agent dose for docetaxel in this 
regimen, while being maintained above the therapeutic threshold level. The allocation 
sequence of the courses for each patient was determined at study entry by use of a restricted-
block randomization procedure. Premedication consisted of dexamethasone (8 mg oral dose) 
given twice daily for 3 consecutive days, starting on the evening before docetaxel infusion. 
Side-effects were scored according to the National Cancer Institute common toxicity criteria 
(version 2.0) 16. Patients benefiting from docetaxel treatment were offered continuation of 
treatment beyond cycle two at standard doses outside of the study protocol. 
 
Sample size calculation 
The mean clearance for docetaxel used in the sample size calculation was 23.99 
L/h/m2, estimated from a group of 56 cancer patients that had sampling for pharmacokinetics 
on at least 2 occasions (Sparreboom A, unpublished data, 2002). In this group of patients, the 
standard deviation (SD) of the expected differences of the 2 measurements was estimated to 
be 4.89 L/h/m2. It was assumed that the interval between treatments was an adequate washout 
period, with no carryover or period effect. The trial was designed to detect an effect size of 
6.00/4.89, where 6.00 is 25 % of the mean docetaxel clearance. On the basis of a pair-wise 
(2-sided) analysis, this results in a sample size of (at least) 6 for the prospective evaluation, 
with a significance level of 0.05 (5 %) and power of 0.7 (70 %). The statistical analysis was 
performed in the SISA-Binomial program (D. G. Uitenbroek, Hilversum, The Netherlands, 
1997) 17. 
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Pharmacokinetic analysis   
Blood samples were collected in glass tubes containing lithium heparin as 
anticoagulant and immediately centrifuged (4000 g at 4 ºC for 10 minutes) to separate 
plasma, which was stored at –80 ºC until analysis. Samples were taken at the following time 
points: immediately before infusion, at 30 minutes after the start of infusion, immediately 
before the end of infusion, and at 10, 20, 30 minutes, and 1, 1.5, 2, 4, 8.5, 24, 32, 56, 64, and 
72 hours after the end of infusion. Determination of docetaxel and ketoconazole 
concentrations in plasma was performed by high-performance liquid chromatography with 
tandem mass spectrometric and ultraviolet detection, respectively, according to published 
procedures 18,19. This assay for docetaxel has a lower limit of quantitation of 0.0004 µg/mL 
(0.5 nmol/L), which is sufficiently sensitive to allow quantitation of docetaxel in samples 
(within the collection time period tested) obtained from patients treated with low drug doses. 
Determination of the fraction of unbound docetaxel was performed by use of equilibrium 
dialysis with a tritiated docetaxel tracer (Moravek Biochemicals, Brea, CA, USA) 20.  
Pharmacokinetic parameters for docetaxel and ketoconazole were calculated by non-
compartmental analysis as implemented in the software package WinNonlin version 4.0 
(Pharsight, CA, USA). For docetaxel, the parameters of interest included the peak plasma 
concentration (Cmax), area under the plasma concentration-time curve extrapolated to infinity 
(AUC), clearance (defined as dose divided by AUC), and volume of distribution at steady 
state (Vss), as well as the half-life of the terminal phase. The latter parameter was calculated 
as ln(2)/k, in which k is the rate constant of the terminal phase estimated from log-linear 
regression analysis of the final 3 to 5 sampling time points. For ketoconazole, the parameters 
of interest included Cmax, time to Cmax, and AUC over the first dosing interval. 
 
Statistical considerations 
Pharmacokinetic data are presented as mean values ± SD with 95 % confidence 
intervals (CIs), unless stated otherwise. The effect of ketoconazole coadministration on the 
pharmacokinetic parameters of docetaxel was evaluated statistically by use of a 
nonparametric, 2-sided, Wilcoxon signed rank test for paired observations. The relationship 
between the exposure to ketoconazole and reduction of docetaxel clearance was evaluated by 
a least-squares linear regression analysis. The cut-off for statistical significance was set at P < 
0.05. All statistical calculations were performed using NCSS 2001 (Number Cruncher 
Statistical System, Kaysville, UT, USA). 
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Results 
Patients and toxicity profiles 
To determine the influence of ketoconazole coadministration on the pharmacokinetics 
of docetaxel, a total of 7 patients entered the study (Table 1). All patients completed the study 
within the scheduled time. Uncomplicated grade 4 neutropenia was observed in 3 patients and 
grade 3 leukocytopenia was observed in another 2 patients during the single agent cycle with 
docetaxel. During the combination course with ketoconazole administration, only minimal 
toxicity was noted. 
 
Table 1. Baseline patient characteristics 1 
Characteristic No. of patients  Median Range 
Age (years)  40 36 - 59 
Sex    
              Male 4   
              Female 3   
Body-surface area (m2)  1.8  1.6 – 2.1 
WHO performance   1 0 – 1 
              0 3   
              1 4   
Tumour type    
Head and neck 2   
Cervix 1    
Sarcoma 1   
Melanoma 1   
ACUP 1   
Rectum  1   
Chemistry    
ASAT (U/L)  24 17 – 79 
ALAT (U/L)  18 6 – 30 
Alk Phos (U/L)  73 62 – 241 
Total bilirubin (µmol/L)  6 4 – 11 
WBC (x 109/L)  8.4 6.7 – 12.9 
ANC (x 109/L)  7.1 2.6 – 15.1 
 
Abbreviations: WHO, World Health Organization; ACUP, adenocarcinoma of unknown primary; 
ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; Alk Phos, alkaline phosphatase; 
WBC, white blood cell count; ANC, absolute neutrophil count. 1The upper limit of institutional 
normal for the pretherapy clinical chemistry parameters are as follows: ASAT, < 93 U/L for men and 
< 78 U/L for women, ALAT, < 103 U/L for men and < 78 U/L for women; Alk Phos, ≤ 600 U/L; total 
bilirubin, < 16 µmol/L.  
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Ketoconazole analysis 
The median peak concentration and AUC for ketoconazole over the first dosing 
interval were 1.90 µg/mL (range, 0.886 – 7.37 µg/mL) and 7.80 µg·h/mL (range, 2.73 – 44.8 
µg·h/mL), respectively; these are similar to previous findings. The mean time to peak 
concentration on day 1 was observed at 2.24 hours (range, 1.50 – 3.47 hours), suggesting that 
high concentrations of ketoconazole were present during and immediately after the 
administration of docetaxel. Although ketoconazole is generally well absorbed, large 
interindividual and intraindividual pharmacokinetic variation after the same oral dose has 
been reported. This is partly a result of differences in gastric acidity, because an increased pH 
in the stomach decreases the extent of ketoconazole absorption. A large interindividual 
variation in peak concentration and AUC was also observed in the current population; for 1 
patient this could be explained by administered comedication (see below). 
 
Docetaxel analysis 
The observed plasma concentrations of docetaxel for both treatments are shown in 
Figure 1. When ketoconazole was coadministered, the fractional change for clearance was 
0.51 (95 % CI, 0.36 – 0.65; range, 0.26 – 0.68), indicating that, overall, clearance was 
reduced by 49 % (P = 0.018) (Table 2). However, large interindividual variability was seen in 
the reduction in clearance, which reached a maximum value of 74 %. The fractional change 
in docetaxel clearance was weakly correlated with the corresponding AUC of ketoconazole 
(Figure 2), as determined by a linear regression analysis (R2 = 0.529; P = 0.064). A similar 
relationship was not observed with the time to peak concentration of ketoconazole (R2 = 
0.047; P = 0.639), suggesting that the rate of absorption was unrelated to variability in effect. 
For 1 patient, the fractional change was only 0.68, which was attributable to a very low 
exposure to ketoconazole resulting from concomitant administration of ranitidine, which is 
known to alter the gastrointestinal absorption of ketoconazole 21. 
It may seem paradoxical that although docetaxel clearance is inhibited by 
ketoconazole, the terminal half-life for docetaxel was found to be slightly shorter in the 
presence of ketoconazole (Table 2). However, the elimination half-life also depends on 
intercompartmental rate constants. When these processes take place at a higher rate, the 
elimination half-life, which characterizes the decline in plasma concentration from the site of 
measurement, will decrease. 
Docetaxel in plasma was approximately 94 % bound in all patients (mean, 94.2 % ± 
1.45 %; range, 88.8 – 96.7 %), which is consistent with previous estimates 20. The fraction 
unbound docetaxel was not significantly different in courses with and without ketoconazole 
(5.74 % ± 1.96 % vs 5.81 % ± 1.45 %; P = 0.74), indicating that protein binding of docetaxel 
is not significantly affected by ketoconazole. 
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Figure 1. Observed plasma concentrations of docetaxel in the absence (closed circles, solid lines; 
dose, 100 mg/m2) and presence of ketoconazole coadministration (open circles, dashed lines; dose, 10 
mg/m2; data normalized to 100 mg/m2). 
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Figure 2. Relationship between ketoconazole area under the curve (AUC, µg·h/mL) and the fractional 
change in docetaxel clearance (CL), defined as the ratio of CL in the presence and absence of 
ketoconazole coadministration. The change is described by the following equation: (0.623 ± 0.0660) 
– (0.0077 ± 0.0033) × (ketoconazole AUC in µg·h/mL); R2 = 0.529; P = 0.064). 
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Discussion 
This study shows that the clearance of docetaxel is significantly reduced by 49 % on 
coadministration with ketoconazole, albeit with large interindividual variability. This degree 
of variability was shown to be related to interindividual differences in the systemic exposure 
to ketoconazole, with low AUC values leading to only minimal inhibitory effects. 
The main toxic side-effect associated with docetaxel treatment is a short-lasting 
neutropenia that reaches grade 3 to 4 in approximately 90 % of patients 
(http://www.taxotere.com). Bruno et al. 22 have reported previously that the AUC of 
docetaxel is a significant predictor of severe neutropenia; a 50 % decrease in clearance 
corresponds to a 4.3-fold increase in the odds for grade 4 neutropenia and in a 3.0-fold 
increase in the odds for febrile neutropenia. In this study, the maximum decrease in clearance 
observed was 74 %, which translates into a 6.5-fold increase in the odds for grade 4 
neutropenia, and in a 4.5-fold increase in the odds for febrile neutropenia. This could have 
had clinical consequences had docetaxel been administered in combination with ketoconazole 
at the full recommended dose. Calculation of the predicted AUC in combination with 
ketoconazole (i.e. the AUC normalized to a 100 mg/m2 dose) for this same patient resulted in 
a relative increase in exposure of approximately 290 %, further supporting the potential for a 
substantially increased risk of severe toxicity. The current findings are inconsistent with 
previously published data that suggest that ketoconazole does not consistently affect 
docetaxel pharmacokinetics 23, even though much higher doses of ketoconazole were 
administered. In that study, however, plasma concentrations of ketoconazole were not 
reported, making a direct comparison impossible. 
As mentioned previously, human adult CYP3A activity reflects the heterogeneous 
expression of CYP3A4, CYP3A5, and CYP3A7, although the level of hepatic CYP3A4 
seems to be the major determinant in the metabolism of docetaxel 24. However, the 
polymorphic distribution of CYP3A5 indicates that metabolically active CYP3A5 is 
expressed in approximately 30 % of Caucasians and in 50 % to 73 % of African Americans 
25,26. In these individuals, CYP3A5 expression accounts for at least 50 % of the total CYP3A 
content, and likely contributes substantially to the metabolic clearance of many CYP3A 
substrates. However, CYP3A5 is less susceptible to inhibition by ketoconazole as 
demonstrated by increased inhibition constant values 27. Furthermore, the percentage of 
inhibition by ketoconazole is inversely related to the fractional percentage of CYP3A5 in 
total CYP3A 27. The presence of variable expression ratios of CYP3A4/CYP3A5 in other 
ethnic populations may therefore result in a different drug-interaction between docetaxel and 
ketoconazole. 
In conclusion, coadministration of the potent CYP3A4 inhibitor ketoconazole leads to 
a 49 % decrease in docetaxel clearance and, as such, to an increased risk for severe 
neutropenia. The extent to which docetaxel clearance is reduced depends on the exposure to 
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ketoconazole, as expressed by AUC. Further research is required to ascertain whether this 
measurement of ketoconazole exposure can be used a priori to identify patients potentially at 
risk for a clinically relevant interaction when being treated with ketoconazole and docetaxel, 
a strategy that is currently being pursued in the treatment of androgen-independent prostate 
cancer 28,29. Most importantly, with concomitant use of docetaxel and ketoconazole, or other 
potent CYP3A4 substrates or inhibitors, potentially dangerous interactions are likely. Hence, 
caution should be taken and substantial dose reductions are necessary if these drugs need to 
be administered together. 
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Abstract  
Objective: The pharmacokinetics (PK) of docetaxel are characterized by large 
interindividual variability in systemic drug exposure (AUC) and drug clearance. The PK 
variability is thought to be largely related to differences in the catalytic function of CYP3A, 
involved in docetaxel metabolism and elimination. As variability in efficacy and toxicity is 
associated with variability in docetaxel AUC and clearance, reducing interindividual PK 
variability may help improve the risk-benefit ratio of docetaxel therapy. We investigated if 
high-dose ketoconazole, a potent CYP3A inhibitor, could result in a uniform reduction of 
docetaxel clearance and reduce the interindividual variability in docetaxel AUC and 
clearance. 
Methods: Seven patients were treated in a randomized cross-over design with 
intravenous docetaxel (100 mg/m2) followed 3 weeks later by docetaxel (15 mg/m2) given in 
combination with orally administered ketoconazole (400 mg 3 times daily, up to 47 hours 
after docetaxel infusion) or vice versa. Docetaxel plasma concentration-time data were 
described by a three-compartment PK model. Ketoconazole plasma concentration-time data 
were described by a one-compartment PK model. 
Results: Docetaxel clearance was reduced by 50 % (P = 0.018) from 32.8 L/h ± 13.7 
L/h to 16.5 L/h ± 8.15 L/h upon ketoconazole coadministration, albeit with large 
interindividual variability (fractional change in clearance, range 0.31 – 0.66). In the presence 
of ketoconazole, interindividual variability in docetaxel clearance and AUC, expressed as 
coefficient of variation, was increased from 41.6 % to 49.5 % and from 28.0 % to 35.1 %, 
respectively, and not, as we had hypothesized, reduced. 
Conclusion: Inhibition of CYP3A by concomitant high-dose ketoconazole 
administration does not result in a uniform reduction of docetaxel clearance and does not 
reduce the interindividual variability in docetaxel AUC or clearance. This approach is 
unsuitable as method to achieve a uniform docetaxel PK profile. 
 
Introduction 
Since the introduction of docetaxel (Taxotere®) the metabolism, elimination pathways 
and clinical pharmacokinetics (PK) of this anticancer drug have been subject of thorough 
investigation. After intravenous (i.v.) administration, the drug is extensively metabolized to 
four pharmacologically inactive metabolites 1 by hepatic and intestinal cytochrome P450 
(CYP) isozymes 3A 2-4, the catalytic activity of which is represented by two major isoforms, 
CYP3A4 and CYP3A5. CYP3A4 is regarded as the most active enzyme, possesses the 
highest affinity for docetaxel 4 and is predominant in Caucasians individuals 5-7. Docetaxel is 
also a substrate for the ATP-binding cassette transmembrane protein ABCB1 (P-
glycoprotein; MDR-1), which is known to act as a (drug/xenobiotic-)efflux pump 8. 
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Docetaxel plasma PK, although linear and independent of dose and schedule 9,10, is 
characterized by large interpatient variability notably in the PK parameters systemic drug 
exposure (expressed as area under the plasma concentration-time curve, AUC) and drug 
clearance. Indeed, for these two parameters typical values for interpatient variability 
(expressed as coefficient of variation) range between 30 % to 45 % 11-16. Bruno et al. 14 
reported that docetaxel AUC is a significant predictor of time to progression and that 
docetaxel clearance is a strong and independent predictor of severe neutropenia and febrile 
neutropenia. Theoretically, reducing the interindividual variability in AUC and clearance 
could aid in optimizing the risk-benefit ratio for docetaxel therapy. A potential approach to 
reduce the interindividual variability in docetaxel PK parameters is by eliminating the source 
(i.e. cause) of variability. Phenotypic expression of CYP3A activity has been identified as a 
strong predictor of docetaxel clearance 11,17-19 and observed variation in (intrinsic) CYP3A 
catalytic activity has been suggested to account to a large extent for the significant 
interindividual variability in docetaxel PK 2. Moreover, the involvement of CYP3A, the 
activity of which can be readily induced or inhibited, in docetaxel elimination, renders the 
drug subject to a host of enzyme-mediated PK drug-interactions. 
We recently conducted a randomized cross-over trial to evaluate the effect of 
concomitant orally administered standard-dose ketoconazole, a potent CYP3A inhibitor 20, on 
the plasma PK of docetaxel in cancer patients 12. The reduction of docetaxel clearance was 
highly significant (average decrease 49 %, P = 0.018). However, we observed wide 
interindividual variability in the decrease of docetaxel clearance (range, 32 – 74 % reduction) 
as also previously reported by others 21. Moreover, the decrease in docetaxel clearance was 
weakly correlated with corresponding systemic exposure to ketoconazole. Furthermore, 
interindividual variability in clearance was increased upon concomitant ketoconazole 
administration compared to single agent treatment (33.7 % vs 53.2 %). With the aim to 
eliminate the observed variability in the extent to which docetaxel clearance is reduced, we 
subsequently treated patients with a higher ketoconazole dose, the dose currently under 
investigation for the treatment of androgen-independent prostate cancer patients in 
combination with docetaxel 22. We hypothesized that an increase in ketoconazole dose would 
result in sufficiently high exposure to ketoconazole in each patient and thus in maximum 
CYP3A inhibition overall, thereby eliminating or largely reducing the variability in (the 
reduction of) docetaxel clearance. Furthermore, we wished to assess if we could reduce the 
interindividual variability in docetaxel clearance and AUC by temporarily suppressing the 
source of variability, i.e. CYP3A catalytic activity, as such resulting in a uniform PK profile. 
Part of the variation in total CYP3A activity, which is reflected by significant 
interindividual variability in the PK of CYP3A substrates 23-25 is suggested to be related to 
genetic diversity in the genes encoding the CYP3A4 and CYP3A5 proteins 26. To date, most 
evidence infers that it is unlikely that CYP3A4 single nucleotide polymorphisms (SNPs) 
contribute substantially to the interindividual variability in CYP3A4 activity in vivo, due to 
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their limited functional significance and/or low allele frequency 27-30. Furthermore, more than 
80 % of Caucasian individuals is deficient in CYP3A5 metabolic activity due to the inactive 
CYP3A5*3C/*3C variant genotype 5,6. However, for individuals with at least one CYP3A5*1 
allele, CYP3A5 may account for at least 50 % of total CYP3A content, resulting in 
approximately 2- to 3-fold higher CYP3A activity in vitro 31. Moreover, CYP3A4 and 
CYP3A5 show distinct differences in susceptibility to inhibition by ketoconazole 32. 
Accordingly, part of the resulting interindividual variability in decrease of docetaxel 
clearance after ketoconazole treatment may be dependent on functional CYP3A4 and/or 
CYP3A5 genetic variants. We therefore included CYP3A4 and CYP3A5 genotyping in the 
study. 
We here report on the plasma PK of docetaxel in cancer patients, after i.v. 
administration of the drug with and without concomitant oral high-dose ketoconazole 
administration. 
 
Patients and methods 
Patient selection and study design 
Eligibility criteria, study design and sample calculation have been reported previously 
for the standard-dose ketoconazole study 12, and were the same for the current study. Briefly, 
cancer patients for whom no other treatment option was available were treated according to a 
randomized cross-over design (in order to exclude sequence bias) with two courses of 
docetaxel administered as a 1-hour i.v. infusion once every 3-weeks. One course was given at 
a dose of 100 mg/m2 and the other at a dose of 15 mg/m2 in combination with seven 400 mg 
doses of ketoconazole, orally administered once every 8 hours, starting 1 hour before 
docetaxel infusion, up to 47 hours after the start of docetaxel infusion. Concomitant use of 
CYP3A inducing or inhibiting medication, dietary supplements or other compounds was not 
allowed. Administration of medication known to inhibit gastric acid secretion (e.g. proton 
pump inhibitors, H2-receptor antagonists), thereby increasing stomach pH and interfering 
with the gastrointestinal absorption of ketoconazole 33, was also prohibited. The Erasmus MC 
Investigational Review Committee approved the study protocol and written informed consent 
for participation was obtained from all patients prior to study entry. 
 
Sample collection 
Blood samples were collected and processed as previously reported 12; samples were 
taken at the following time points: immediately before docetaxel infusion, at 30 and 55 
minutes after the start of docetaxel infusion, and at 10, 20 and 30 minutes and 1, 1.5, 2, 4, 5, 
8.5, 24, 32.5 and 48 hours after the end of docetaxel infusion. 
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Ketoconazole analysis 
Determination of ketoconazole concentrations in plasma was performed by reversed-
phase high performance liquid chromatography (HPLC) with ultraviolet detection (206 nm) 
according to previously published procedures 34. Briefly, prior to extraction and quantitation 
samples were diluted 5- or 10-fold (depending on the sampling time point) with phosphate 
buffered saline solution (Oxoid, Basingstoke, United Kingdom). Quantitative extraction was 
achieved by a single solvent extraction using a mixture of acteonitrile-n-butyl chloride (1 : 4 
v/v, 5 mL) after adding 100 µL methanol 0.05 M NaOH (2 : 3 v/v) and 100 µL internal 
standard solution (0.01 mg/mL clotrimazole in 50 % acetonitrile) to the prediluted samples 
(500 µL). Ketoconazole and clotrimazole were separated on a column packed with Inertsil 
ODS-80A (150 x 4.6 mm, 5 µm particle size, Alltech Applied Science, Breda, The 
Netherlands) and a mobile phase composed of water-acetonitrile-tetrahydrofuran-ammonium 
hydroxide-triethylamine (45 : 65 : 2.5 : 0.1 : 0.1, v/v/v/v/v). Ketoconazole plasma 
concentrations were quantitated over the range of 20.0 – 2000 ng/mL. Quality control (QC) 
samples at ketoconazole concentrations of 75 ng/mL, 750 ng/mL, 1500 ng/mL, and 15,000 
ng/mL, the latter QC diluted 10-fold prior to processing, were assayed in duplicate and 
distributed among the calibrators and patient samples in the analytical run. 
 
Docetaxel analysis  
Docetaxel was quantitated using HPLC with tandem mass-spectrometric detection 
(LC-MS/MS). Briefly, to 100 µL plasma aliquots, up to 20-fold diluted, 200 µL internal 
standard solution (5 ng/mL paclitaxel in acetonitrile) was added. Analyte and internal 
standard drug were extracted by liquid-liquid extraction with 1 mL n-butylchloride. Samples 
were vigorously mixed for 5 minutes, followed by centrifugation at 18,000 g also for 5 
minutes. Subsequently, 1 mL of the clear supernatant was evaporated under a stream of 
nitrogen at 60 °C and reconstituted with 150 µL of acetonitrile/water/formic acid (40 : 60 : 
0.1, v/v/v). Aliquots of 50 µL were injected into the LC-MS/MS (Model 2795 XC 
chromatograph, Waters Alliance, Mildford, MA, USA). Chromatographic separations were 
achieved on a Alltima HP C18 HL 3 µm column (50 x 2.1 mm internal diameter, Alltech 
Applied Science, Breda, The Netherlands). The mobile phase was composed of acetonitrile 
and water containing formic acid (0.1 % v/v) and delivered using a linear gradient setting at a 
flow rate of 0.2 mL/min where the composition changed from 50 % to 100 % acetonitrile in 1 
minute with an overall run-time of 5 minutes. Detection was performed with a MicroMass 
Quatro Micro triple-quadropole mass spectrometer (Cary, NC, USA) in the positive ion 
mode. The electrospray ionization operated at 3.2 kV and at a cone voltage of 25 V. The 
detector was programmed to allow the [MH]+ ions of docetaxel (m/z 808.40) and paclitaxel 
(m/z 854.40) to pass through the first quadropole and into the collision cell. The collision 
energy for collision-induced dissociation of docetaxel and paclitaxel was set at 12 eV and 20 
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eV, respectively, with argon used as collision gas at a pressure of 0.0023 mbar. The daughter 
ions of docetaxel (m/z 527.20) and paclitaxel (m/z 286.20) were monitored through the third 
quadropole. The dwell time per channel for data collection was 0.150 seconds. Docetaxel 
plasma concentrations were quantitated over the range of 5.00 ng/mL to 500 ng/mL. QC 
samples at docetaxel concentrations of 15.0 ng/mL, 225 ng/mL, 400 ng/mL and 6000 ng/mL, 
the latter QC diluted 20-fold prior to processing, were assayed in duplicate and distributed 
among the calibrators and patient samples in the analytical run. 
 
Pharmacokinetic data analysis - Ketoconazole 
For ketoconazole, a PK population model was fitted to the plasma-concentration time 
data from all patients simultaneously, using the NONMEM software program (double 
precision, version V; level 1.1) 35. For modelling purposes, we included the data from the 
patients previously treated with standard-dose ketoconazole. The PK population model did 
not include data from patients who were (erroneously) administered comedication known to 
limit ketoconazole gastrointestinal absorption. The NONMEM model accounts for both fixed 
and random effects, the latter corresponding to interpatient and residual variability. The first-
order conditional estimation (FOCE) method was used throughout the analysis, taking into 
account the interaction between interpatient and residual variability. Based on the derived 
population PK model and the observed individual plasma concentrations, individual PK 
parameter estimates were obtained by Bayesian (POSTHOC) analysis. Ketoconazole plasma 
concentration-time data were described by a one-compartment model with first order 
absorption and elimination (ADVAN 2 TRANS 2). The following PK parameters were 
estimated: Ka, first order rate absorption constant (h-1) describing absorption from the gut; 
V/F, central volume of distribution (L), CL/F, oral clearance (L/h) and lag time (h), the delay 
between drug administration and the beginning of absorption. Individual systemic exposure 
(AUC) was calculated by dividing total ketoconazole dose by apparent oral clearance (CL/F).  
Simultaneous analysis of the data from all patients requires statistical models for interpatient 
and residual variances. For interpatient variability, a log-normal parameter distribution was 
assumed. For instance, the variability in clearance was estimated using: 
 
CLi = CLpopη 
 
where CLi is the clearance of the “ith” individual, CLpop is the typical value in the population 
and η is the random interpatient variable with mean of zero and variance of ω2 36. For a non-
linear mixed effects model, the residual variance corresponds to the difference between the 
observed concentration (Cobs) and predicted concentration (Cpred). The latter is predicted 
based on the observed individual parameters (e.g. CLi). 
High-Dose Ketoconazole and Docetaxel 
 81
Residual variance was modelled with a proportional error (ε) as follows: 
 
Cobs = Cpred +  Cpred*ε 
 
where ε is an independent random variable with mean of zero and variance of σ2. At each 
step during the population model building, a specific assumption was tested and evaluated 
using the likelihood ratio test 37. 
 
Pharmacokinetic data analysis - Docetaxel  
Individual docetaxel PK parameters were estimated using model dependant methods 
implemented in WinNonLin 4.0 (Pharsight, CA, USA). Concentration-time data were fit with 
a three-compartment model with reciprocal squared prediction weighting. Model adequacy 
was guided by inspection of the coefficient of variation of the fitted PK parameters, and by 
the Akaike information criteria 38. Maximum plasma concentrations (Cmax) were obtained 
from the model-estimated plasma concentration at the end of docetaxel infusion. Calculated 
secondary parameters included half-life during the terminal phase of the disposition curve 
(t1/2,γ), AUC and total systemic clearance (CL, defined as docetaxel dose divided by AUC). 
 
CYP3A4 and CYP3A5 genotype analysis 
Polymerase chain reaction (PCR)-restriction fragment length polymorphism analysis 
for CYP3A5*3C, CYP3A5*6, CYP3A4*1B, CYP3A4*3, CYP3A4*17 and CYP3A4*18A 
variant alleles was performed as described previously 6,39,40. Based on allele frequencies in 
the Caucasian population, in which the CYP3A5*3C allele is the predominant allele, 
CYP3A5*6 genotyping was only performed for individuals with no, or only one 
CYP3A5*3C allele (i.e. with apparently at least one CYP3A5*1 allele). 
 
Study Objectives  
The primary objectives of this (pilot) study were to evaluate if concomitant oral high-
dose ketoconazole administration results in a uniform reduction of docetaxel clearance and 
can significantly reduce the interindividual variability, expressed as the coefficient of 
variation (CV, the result of expressing the standard deviation (SD) as percentage of the 
mean), in docetaxel clearance and AUC by 20 - 25 percentage points compared to single 
agent treatment. The aspired reduction in interindividual variability was based on our aim to 
achieve a clinically meaningful reduction of the typical interindividual variability values 
previously reported 11-16. 
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Statistical considerations  
PK parameter estimates for docetaxel and ketoconazole are reported as mean ± SD 
with range in parenthesis unless stated otherwise. The difference in docetaxel PK parameters 
between the two courses was evaluated statistically using a non-parametric two-tailed, 
Wilcoxon signed rank test for paired observations after testing for period effects. 
The difference in interindividual PK variability between the two courses was 
evaluated statistically after expressing the interindividual variability as the SD of the log-
transformed (ln) values for CL (SD lnCL) and AUC (SD lnAUC). The SD of lnCL and 
lnAUC is a one-parameter estimate that approximates the CV for CL and AUC. We tested 
whether the SD for lnCL or lnAUC would be significantly reduced upon concomitant 
ketoconazole administration. Statistical evaluation was performed using Pitman’s test which 
says that the null hypothesis of equal SDs of two paired measurements is equivalent to a zero 
Pearson correlation between sum and difference of the two paired measurements assuming a 
normal (Gaussian) distribution 41. In addition, as our sample size was limited, 95 % 
confidence intervals for the CV and the change in CV upon concomitant ketoconazole 
administration were estimated for the parameters CL and AUC using bootstrap methods. For 
this purpose, we drew 10,000 bootstrap samples of (seven) paired observations, with 
replacement, from our data-set of (seven) measurement pairs and calculated the CVs and 
change in CV in each bootstrap sample. The 2.5 and 97.5 percentiles of the obtained 
distribution of 10,000 CV- and CV-change-values are the estimated 95 % confidence limits 
of the CV and CV-change. 
For all tests the significance level was set at P < 0.05. Statistical calculations were 
performed with SPSS, version 11.5 (Chicago, IL, USA). 
 
Results 
Baseline patient, toxicity and genetic profiles 
A total of eight Caucasian patients were enrolled in the study. One patient was 
erroneously administered the proton pump inhibitor pantoprazole concomitant with 
ketoconazole. Thus, a total of seven patients were included in the final analysis. Table 1 lists 
the baseline patient characteristics. 
Only minimal docetaxel-related toxicity was observed in the course in combination 
with ketoconazole, and all patients tolerated the high-dose ketoconazole treatment well. In the 
single agent course three patients developed uncomplicated grade 4 neutropenia concomitant 
with grade 3 leucocytopenia, all other toxicities were not severe, and manageable. 
All patients were CYP3A5*3C variant allele homozygotes. The lack of CYP3A5*1 
allele carriers indicates that for all evaluated patients total CYP3A activity is solely 
attributable to CYP3A4. No patients were identified carrying variant alleles for CYP3A4*1B, 
CYP3A4*3, CYP3A4*17 or CYP3A4*18A. 
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Table 1. Baseline patient characteristics (N = 7) 
Characteristic   Value 
Age (years)  56 (44 – 69) 
Sex  
Male 6 
Female 1 
Body-surface area (m2) 1.88 (1.61 – 2.19) 
WHO performance status 1 (0 – 1) 
Tumour type  
Breast 1 
Prostate  1 
Head & Neck 3 
Other 2 
Haematology  
WBC (x 109/L) 9.1 (5.7 – 17.2) 
ANC (x 109/L) 6.8 (3.2 – 12.3) 
Platelets (x 109/L) 282 (156 – 480) 
Haemoglobin (mmol/L) 8.3 (5.8 – 9.2) 
Clinical chemistry  
ASAT (U/L) 25 (20 – 68) 
ALAT (U/L) 20 (9 – 28) 
Alk Phos (U/L) 100 (73 – 135) 
Total Bilirubin (µmol/L) 6 (5 –15) 
Total Protein (g/L) 74 (59 – 85) 
Serum Albumin (g/L) 40 (28 – 46) 
Serum AAG (g/L) 1.48 (0.86 – 2.62) 
 
Abbreviations: WHO, World Health Organization; WBC, white blood cell count; ANC, absolute 
neutrophil count; ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; Alk Phos, 
alkaline phosphatase; AAG, alpha-1 acid-glycoprotein. Values are given as median with range in 
parentheses (except for sex and tumour type). 
 
Ketoconazole analysis 
Ketoconazole PK was best described by a one-compartment model with first-order 
absorption and elimination. The population values for Ka, V/F, CL/F and lag time were 1.34 
h-1, 71.7 L, 7.76 L/h and 0.395 h, respectively. The corresponding values for interpatient 
variability were 122 %, 84 % and 67 %. Interpatient variability for lag time was not 
modelled. The residual variance error was 31.4 %. Based on the individual Bayesian PK 
parameter estimates (Table 2) the mean (± SD) AUC for ketoconazole was 542 mg·h/L (± 
185 mg·h/L; CV = 34 %) which is in line with previous data indicating substantial 
interindividual PK variability after the same oral dose (CV for Tmax, Cmax, AUC and T1/2 ≥ 50 
%) 42-44. In our patient group the observed wide interindividual variability in systemic 
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exposure was largely due to one patient for whom systemic exposure was extremely high 
(943 mg·h/L). Indeed, if we exclude this patient, mean systemic exposure is 476 mg·h/L 
(range, 378 – 536 mg·h/L) and interindividual variability is reduced to 12 %. 
 
Table 2. Individual Bayesian pharmacokinetic parameters of ketoconazole (N = 7) 
Parameter  Value  
Ka (h-1)  2.29 ± 2.93 (0.141 – 8.69)  
V/F (L)  109 ± 45.2 (33.1 – 162)  
CL/F (L/h)  5.54 ± 1.35 (2.97 – 7.40)  
AUC (mg.h/L)  542 ± 185 (378 –  943)  
 
Abbreviations: Ka, absorption rate constant; V/F, central volume of distribution; CL/F, oral clearance; 
AUC, area under the plasma concentration-time curve. Values are reported as mean ± SD with range 
between parentheses. 
 
Docetaxel analysis 
In the absence of ketoconazole all patients were administered docetaxel (100 mg/m2) 
according to protocol (median 190 mg, range, 160 - 220 mg); in the presence of ketoconazole 
median dose was 30 mg (range, 20 - 30 mg). Observed docetaxel plasma concentration-time 
curves for both treatments are shown in Figure 1. Table 3 lists a summary of the PK 
parameters of docetaxel with and without concomitant ketoconazole administration and 
includes the corresponding values for interindividual PK variability. As expected clearance 
was significantly reduced upon ketoconazole coadministration from 32.8 L/h ± 13.7 L/h to 
16.5 L/h ± 8.15 L/h (P = 0.018) and AUC, adjusted for difference in dose (thus enabling 
comparison) was increased from 34.5 ng.h.mL-1.mg-1 ± 12.2 ng.h.mL-1.mg-1 to 71.9 ng.h.mL-
1.mg-1 ± 27.2 ng.h.mL-1.mg-1 (P = 0.018). The mean fractional change in docetaxel clearance 
(ratio of clearance in the presence of ketoconazole to clearance in the absence of 
ketoconazole, CLketo=1 : CLketo=0) was 0.50 (median 0.53, range, 0.31 – 0.66), indicating that 
concomitant ketoconazole administration reduces docetaxel clearance on average by 50 % 
which is similar to our previous data 12 despite an almost five-fold increase in total 
ketoconazole dose. Furthermore, the range for the fractional change in docetaxel clearance 
(0.31 – 0.66) is only marginally narrower than we previously reported after standard-dose 
ketoconazole treatment (0.26 – 0.68). For both treatment courses, the degree of 
interindividual variability for clearance and (absolute) AUC is not reduced by ketoconazole 
administration (41.6 % vs 49.5 % and 28.0 % vs 35.1 %, respectively (P = 0.546 and P = 
0.513). The 95 % confidence intervals for the change in the CV-values for clearance (-4.85 to 
+19.8 percentage points) and (absolute) AUC (-6.40 to +18.6 percentage points), generated 
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using 10,000 bootstrap samples, rules out the possibility that the interindividual variability is 
reduced by 20 - 25 percentage points. 
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Figure 1. Observed plasma concentrations of docetaxel in the absence (solid line, closed symbols, 
dose 100 mg/m2) and presence (dashed line, open symbols, dose 15 mg/m2) of ketoconazole. Insert: 
observed docetaxel plasma concentrations up to 6 hours after start of docetaxel infusion. 
 
In contrast to our previous finding for the patients treated with standard-dose 
ketoconazole, where the fractional change in docetaxel clearance was weakly correlated (R2 = 
0.529, P = 0.064) with corresponding ketoconazole AUC (for the first dosing interval), we 
now observed no clear relationship between fractional change in docetaxel clearance and total 
ketoconazole AUC (Figure 2). Indeed, figure 2 suggests that upon achieving a sufficiently 
high systemic ketoconazole exposure (i.e. above a certain threshold ketoconazole exposure 
level), the observed variability in the fractional change in docetaxel clearance occurs 
independent of (increasing) ketoconazole AUC. 
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Figure 2. Relationship between ketoconazole area under the plasma concentration-time curve (AUC) 
and fractional change in docetaxel clearance (CL) defined as the ratio of CL in the presence and 
absence of ketoconazole.  
 
Discussion  
Previously we reported that docetaxel clearance is significantly reduced by 49 % after 
coadministration of standard-dose ketoconazole (total dose 600 mg) albeit with large 
interindividual variability (fractional change in clearance range, 0.26 - 0.68) 12. Furthermore, 
the interindividual variability for docetaxel clearance (expressed as CV) was increased from 
33.7 % to 53.2 % in the presence of ketoconazole. As the observed variability in clearance 
reduction was correlated to corresponding ketoconazole exposure, we hypothesized that an 
increase in ketoconazole dose would result in sufficiently high exposure to ketoconazole in 
each patient thereby achieving maximum CYP3A inhibition overall. However, the here 
reported study results show that, despite an almost five-fold increase in ketoconazole dose 
(total dose 2800 mg), variability in the fractional change in docetaxel clearance remains 
(range, 0.31 - 0.66) and is only marginally less than we previously reported. Furthermore, 
interindividual variability in docetaxel clearance and AUC after high-dose ketoconazole 
coadministration was not reduced (Table 3). 
Our findings are in line with preliminary observations where docetaxel clearance also 
showed increased variability upon ketoconazole coadministration both across and within 
different docetaxel dose levels (range, 10 mg/m2 to 30 mg/m2) 45. Furthermore, Van 
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Veldhuizen et al. 21 also reported inconsistent effects of concomitant ketoconazole on 
docetaxel systemic exposure. We therefore conclude that strong inhibition of CYP3A 
activity, through concomitant oral ketoconazole administration, does not reduce 
interindividual variability in docetaxel PK and is thus not suitable as a method to achieve a 
uniform PK profile. 
Several reasons may explain why our approach has not been successful. The choice 
for ketoconazole as CYP3A inhibitor, although highly potent, may, in retrospection, not be 
ideal. Ketoconazole is subject to large inter- and intraindividual variability in absorption 33,42, 
(largely) based on differences in intrinsic gastric acid secretion, which can be further 
increased through comedication. Indeed, the patient excluded due to erroneous pantoprazole 
use had the lowest exposure to ketoconazole (AUC 217 mg.h/L). Interestingly, despite the 
lowest ketoconazole exposure, docetaxel clearance was reduced from 45.4 L/h to 20.2 L/h, 
indicating that for this patient the fractional change in docetaxel clearance (0.45) is within the 
range reported for the other seven patients (0.31 – 0.66). In addition, if we include this patient 
in the PK analysis interindividual variability values for clearance in the absence and presence 
of ketoconazole are marginally affected and then correspond to 39.0 % and 45.3 %, 
respectively (95 % confidence interval for change in CV, -4.40 to +16.3 percentage points). 
In the here reported high-dose ketoconazole cohort no clear relationship was detected 
between ketoconazole exposure and decrease in docetaxel clearance (Figure 2). A possible 
explanation for this finding is that although sufficiently high systemic ketoconazole exposure 
was achieved, thus maximally inhibiting docetaxel metabolism and maximally reducing 
clearance in each individual patient, other factors also play a role in the (observed) variability 
in the fractional change in docetaxel clearance. Most importantly, we must conclude that a 
further increase in ketoconazole dose is pointless. Moreover, higher ketoconazole doses are 
not feasible due to the associated unacceptable (gastrointestinal) toxicity 46. 
All patients were CYP3A5*3C/*3C (variant allele) homozygotes, thus deficient in 
CYP3A5 catalytic activity. Accordingly, (part of) the interindividual variability in the 
decrease of docetaxel clearance cannot be explained for by interindividual variability in 
CYP3A5 activity (i.e. variable contribution of CYP3A5 to overall CYP3A activity) and/or by 
the differences in susceptibility to inhibition by ketoconazole for CYP3A4 and CYP3A5. In 
this study, the observed effects of ketoconazole are solely attributed to the effect on CYP3A4 
activity. No patient carried any of the, currently known and, based upon effect on activity 
and/or allele frequency, potentially clinically relevant CYP3A4 SNPs (CYP3A4*1B, 
CYP3A4*3, CYP3A4*17 or CYP3A4*18A). This indicates that it is highly unlikely that 
genetic differences contributed to the observed interindividual variability in the decrease of 
docetaxel clearance. Indeed, to date genetic variants in CYP3A4 and CYP3A5 have not been 
shown to significantly affect docetaxel clearance or the PK of frequently used CYP3A 
phenotyping probes such as midazolam, dexamethasone and erythromycin 18,19,47,48. 
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In vitro experiments have indicated that the quantitative contribution of CYP3A4/5 to 
the hepatic metabolism of docetaxel ranges from 64 % to 93 %, suggesting that less than 7 % 
to 36 % of the metabolism may be caused by other CYP-enzymes, not inhibited by 
ketoconazole 4. For instance, although reports are inconsistent, the predominantly extra-
hepatic (e.g. intestinal) expressed isozyme CYP1B1 has been associated with docetaxel 
metabolism 49,50. 
Although ketoconazole is also a (weak to modest) inhibitor of ABCB1 51, preclinical 
observations 52,53 and clinical observations 54-56 indicate that the influence of (inhibition of) 
ABCB1 function on the plasma PK of docetaxel is minimal to absent. Thus, we conclude that 
(variable) involvement of ABCB1 can be ruled out as explanation for the observed variability 
in reduction of docetaxel clearance. 
Despite the fact that this study is limited by small sample size, our current findings, 
lead us to conclude that purposely manipulating the PK profile of docetaxel through drug-
induced modulation (i.e. inhibition) of the major route of metabolism, in order to reduce 
interindividual PK variability, is not feasible with orally administered high-dose 
ketoconazole. It would seem that, given the large number of mechanisms contributing to the 
variable plasma disposition of docetaxel, attempting to control one factor, albeit the most 
important factor in the route of elimination, does not yield the anticipated effect, a uniform 
PK profile. 
 
Acknowledgements 
We wish to thank Dr. Paul G.H. Mulder for his assistance with the statistics. 
 
References 
1. Sparreboom A, Van Tellingen O, Scherrenburg EJ, et al. Isolation, purification and biological 
activity of major docetaxel metabolites from human faeces. Drug Metab Dispos 1996; 
24:655-8. 
2. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R. Hepatic 
biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in 
humans. Cancer Res 1996; 56:1296-302. 
3. Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T. Metabolism of docetaxel by human 
cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 
1996; 56:58-65. 
4. Shou M, Martinet M, Korzekwa KR, Krausz KW, Gonzalez FJ, Gelboin HV. Role of human 
cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme 
specificity, interindividual distribution and metabolic contribution in human liver. 
Pharmacogenetics 1998; 8:391-401. 
5. Garsa AA, McLeod HL, Marsh S. CYP3A4 and CYP3A5 genotyping by Pyrosequencing. 
BMC Med Genet 2005; 6:19. 
6. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele 
frequencies in Dutch Caucasians. Clin Chem 2002; 48:1668-71. 
Chapter 6 
 90
7. Lee SJ, Usmani KA, Chanas B, et al. Genetic findings and functional studies of human 
CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 
2003; 13:461-72. 
8. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere): a semi-synthetic analogue of taxol. J 
Natl Cancer Inst 1991; 83:288-91. 
9. Baker SD, Zhao M, Lee CK, et al. Comparative pharmacokinetics of weekly and every-three-
weeks docetaxel. Clin Cancer Res 2004; 10:1976-83. 
10. McLeod HL, Kearns CM, Kuhn JG, Bruno R. Evaluation of the linearity of docetaxel 
pharmacokinetics. Cancer Chemother Pharmacol 1998; 42:155-9. 
11. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an 
individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000; 
6:1255-8. 
12. Engels FK, Ten Tije AJ, Baker SD, et al. Effect of cytochrome P450 3A4 inhibition on the 
pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004; 75:448-54. 
13. Baker SD, Li J, ten Tije AJ, et al. Relationship of systemic exposure to unbound docetaxel 
and neutropenia. Clin Pharmacol Ther 2005; 77:43-53. 
14. Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of 
docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16:187-96. 
15. ten Tije AJ, Verweij J, Carducci MA, et al. Prospective evaluation of the pharmacokinetics 
and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005; 23:1070-7. 
16. Veyrat-Follet C, Bruno R, Olivares R, Rhodes GR, Chaikin P. Clinical trial simulation of 
docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 
2000; 68:677-87. 
17. Yamamoto N, Tamura T, Kamiya Y, Sekine I, Kunitoh H, Saijo N. Correlation between 
docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of 
exogenous cortisol. J Clin Oncol 2000; 18:2301-8. 
18. Puisset F, Chatelut E, Dalenc F, et al. Dexamethasone as a probe for docetaxel clearance. 
Cancer Chemother Pharmacol 2004; 54:265-72. 
19. Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel 
pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping 
strategies. J Clin Oncol 2002; 20:3683-90. 
20. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Human drug metabolism and the 
cytochromes P450: application and relevance of in vitro models. J Clin Pharmacol 2001; 
41:1149-79. 
21. Van Veldhuizen PJ, Reed G, Aggarwal A, Baranda J, Zulfiqar M, Williamson S. Docetaxel 
and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and 
pharmacokinetic study. Cancer 2003; 98:1855-62. 
22. Figg WD, Liu Y, Acharya MR, et al. A phase I trial of high dose ketoconazole plus weekly 
docetaxel in metastatic androgen-independent prostate cancer. Proc Am Soc Clin Oncol 2003; 
22:1731a. 
23. Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H. CYP3A5 genotype and 
midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 
2004; 75:529-38. 
24. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human 
CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54:1271-94. 
25. Mathijssen RH, van Schaik RH. Genotyping and phenotyping cytochrome P450: Perspectives 
for cancer treatment. Eur J Cancer 2006; 42:141-8. 
26. Ozdemir V, Kalowa W, Tang BK, et al. Evaluation of the genetic component of variability in 
CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10:373-
88. 
High-Dose Ketoconazole and Docetaxel 
 91
27. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and 
its possible consequences. Pharmacogenomics 2004; 5:243-72. 
28. Eiselt R, Domanski TL, Zibat A, et al. Identification and functional characterization of eight 
CYP3A4 protein variants. Pharmacogenetics 2001; 11:447-58. 
29. Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of 
their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001; 
299:825-31. 
30. Lee SJ, Bell DA, Coulter SJ, Ghanayem B, Goldstein JA. Recombinant CYP3A4*17 is 
defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may 
occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A 
haplotype. J Pharmacol Exp Ther 2005; 313:302-9. 
31. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization 
of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-91. 
32. Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P-450 3A 
(CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of 
CYP3A5 expression. Drug Metab Dispos 1999; 27:180-7. 
33. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin 
Pharmacokinet 1988; 14:13-34. 
34. de Bruijn P, Kehrer DF, Verweij J, Sparreboom A. Liquid chromatographic determination of 
ketoconazole, a potent inhibitor of CYP3A4-mediated metabolism. J Chromatogr B Biomed 
Sci Appl 2001; 753:395-400. 
35. Beal SL, Sheiner LB. NONMEM Users Guide. San Francisco: Division of Pharmacology, 
University of California, 1992. 
36. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in 
population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993; 21:735-50. 
37. White DB, Walawander CA, Liu DY, Grasela TH. Evaluation of hypothesis testing for 
comparing two populations using NONMEM analysis. J Pharmacokinet Biopharm 1992; 
20:295-313. 
38. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the 
evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6:165-75. 
39. van Schaik RH, de Wildt SN, van Iperen NM, Uitterlinden AG, van den Anker JN, 
Lindemans J. CYP3A4-V polymorphism detection by PCR-restriction fragment length 
polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem 
2000; 46:1834-6. 
40. van Schaik RH, de Wildt SN, Brosens R, van Fessem M, van den Anker JN, Lindemans J. 
The CYP3A4*3 allele: is it really rare? Clin Chem 2001; 47:1104-6. 
41. Bartko JJ. Measures of agreement: a single procedure. Stat Med 1994; 13:737-45. 
42. Jamis-Dow CA, Pearl ML, Watkins PB, Blake DS, Klecker RW, Collins JM. Predicting drug-
interactions in vivo from experiments in vitro. Human studies with paclitaxel and 
ketoconazole. Am J Clin Oncol 1997; 20:592-9. 
43. Huang YC, Colaizzi JL, Bierman RH, Woestenborghs R, Heykants J. Pharmacokinetics and 
dose proportionality of ketoconazole in normal volunteers. Antimicrob Agents Chemother 
1986; 30:206-10. 
44. Kehrer DF, Mathijssen RH, Verweij J, de Bruijn P, Sparreboom A. Modulation of irinotecan 
metabolism by ketoconazole. J Clin Oncol 2002; 20:3122-9. 
45. Yong WP, Goh BC, Zang LZ, et al. Docetaxel clearance is non linear and not predicted by 
CYP3A phenotyping when administered with ketoconazole [abstract]. Proc Amer Soc Clin 
Oncol, 2004;23:2058a. 
46. Sugar AM, Alsip SG, Galgiani JN, et al. Pharmacology and toxicity of high-dose 
ketoconazole. Antimicrob Agents Chemother 1987; 31:1874-8. 
Chapter 6 
 92
47. Baker SD, van Schaik RH, Rivory LP, et al. Factors affecting cytochrome P-450 3A activity 
in cancer patients. Clin Cancer Res 2004; 10:8341-50. 
48. Lepper ER, Baker SD, Permenter M, et al. Effect of common CYP3A4 and CYP3A5 variants 
on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer 
patients. Clin Cancer Res 2005; 11:7398-404. 
49. Bournique B, Lemarie A. Docetaxel (Taxotere) is not metabolized by recombinant human 
CYP1B1 in vitro, but acts as an effector of this isozyme. Drug Metab Dispos 2002; 30:1149-
52. 
50. Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL. Human CYP1B1 and anticancer 
agent metabolism: mechanism for tumour-specific drug inactivation? J Pharmacol Exp Ther 
2001; 296:537-41. 
51. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole 
antifungals with P glycoprotein. Antimicrob Agents Chemother 2002; 46:160-5. 
52. Kemper EM, Verheij M, Boogerd W, Beijnen JH, van Tellingen O. Improved penetration of 
docetaxel into the brain by coadministration of inhibitors of P-glycoprotein. Eur J Cancer 
2004; 40:1269-74. 
53. Bardelmeijer HA, Ouwehand M, Buckle T, et al. Low systemic exposure of oral docetaxel in 
mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res 2002; 
62:6158-64. 
54. van Zuylen L, Sparreboom A, van der Gaast A, et al. The orally administered P-glycoprotein 
inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin Cancer Res 
2000; 6:1365-71. 
55. Fracasso PM, Goldstein LJ, de Alwis DP, et al. Phase I study of docetaxel in combination 
with the p-glycoprotein inhibitor, zosuquidar, in resistant malignancies. Clin Cancer Res 
2004; 10:7220-8. 
56. van Zuylen L, Sparreboom A, van der Gaast A, et al. Disposition of docetaxel in the presence 
of P-glycoprotein inhibition by intravenous administration of R101933. Eur J Cancer 2002; 
38:1090-9. 
 
 
  
Chapter 7 
Quantification of [3H]-Docetaxel in Faeces and Urine: 
Development and Validation of a Novel Combustion 
Method 
F.K. Engels1, D. Buijs2, W.J. Loos1, J. Verweij1, W.H. Bakker2, E.P. Krenning2  
1Department of Medical Oncology and 2Department of Nuclear Medicine, 
Erasmus MC – Daniel den Hoed Cancer Center, Rotterdam, The Netherlands  
Anticancer Drugs 17(1): 63-67, 2006
Chapter 7 
 94
Abstract 
Most radiolabelled biological samples require extensive sample preparation to reduce 
quenching interference before quantification of radioactivity is possible. Clearly, a more 
rapid and simple method ensuring a constant count rate and optimal counting efficiency has 
important advantages. We report on the development and analytical method validation of a 
rapid and simple combustion method to quantify [3H]-docetaxel excreted in human faeces 
and urine. A 3-day validation procedure was performed; quality control (QC) samples, 
prepared in blank faeces and urine, were combusted 5 times and aliquots of the produced 
tritiated combustion water were counted in a liquid scintillation counter. The validation runs 
demonstrated adequate precision (< 7.6 %) across all QC levels. Sensitivity at the lowest QC 
level was excellent and recovery of radioactivity constant ranging from 85 % to 91.8 %. 
Clinical applicability of the method was tested in a cancer patient receiving docetaxel and a 
tracer amount of [3H]-docetaxel; during the first 72-hours after [3H]-docetaxel infusion, 60 % 
of total radioactivity was excreted in the collected faeces and urine, which is within the 
expected range. Combustion of tritiated faeces and urine samples is a simple, rapid, sensitive, 
precise and reproducible method with high recovery. It can be applied to quantify [3H]-
docetaxel excretion after intravenous administration. 
 
Introduction 
An important reason to administer a non-toxic tracer amount of radiolabelled drug to 
a patient is to quantify the drug in biological samples (e.g. faeces, urine, ascites) at detection 
levels below the lower limit of quantification for routinely used analytical techniques (e.g. 
high-performance liquid chromatography, HPLC). Radiochemicals used in (clinical) research 
include [3H]- or [14C]-radiolabelled compounds. Liquid scintillation counting (LSC) is the 
most efficient method to quantify these low energy beta-emitters. However, most 
radiolabelled biological samples cannot be directly subjected to LSC and first require a 
sample preparation procedure for example to reduce colour or chemical quenching 
interference. Indeed, with LSC the detection and quantification limit is affected by sample 
size, sample preparation method and counting efficiency. Ideally, the sample size is as large 
as possible, and pretreatment is simple, rapid and results in a clear, homogeneous and stable 
mixture of radioactive sample and appropriate liquid scintillation cocktail, thus allowing for a 
constant count rate and optimal counting efficiency. This ultimately gives the most accurate 
and reproducible counting results. Various sample preparation procedures to solubilize a 
biological matrix are applied and include acid or alkaline digestion. Indeed, in preclinical 
mass balance studies with [3H]-radiolabelled paclitaxel and docetaxel, faeces sample 
pretreatment involved initial homogenization with 4 % bovine serum albumin in water, 
followed by a 1.5-hour incubation with a (tissue) solubilizer (Soluene®) and a 2-hour 
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incubation with 2-propanol 1,2. Finally, 30 % hydrogen peroxide, necessary to bleach the 
samples, was added before mixing with a compatible liquid scintillation cocktail (Hionic-
Fluor). Combustion of biological samples is an alternative sample preparation method 3-6 and 
has several practical advantages. Combustion of a [3H]-radiolabelled sample produces a 
colourless amount of tritiated (combustion) water, which can be counted immediately after 
homogeneously mixing with liquid scintillation cocktail. It is a rapid method, quenching 
interference is avoided and sample size can be increased compared to acid or alkaline 
digestion, as such positively influencing the detection and quantification limit. 
The anticancer drug docetaxel (Taxotere®) is approved for the treatment of patients 
with locally advanced or metastatic breast cancer, non-small-cell lung cancer and androgen-
independent metastatic prostate cancer (http://www.taxotere.com). After intravenous (i.v.) 
administration the drug is extensively and predominantly metabolized by hepatic and 
intestinal cytochrome P450 (CYP) isozymes 3A 7,8. Indeed, the major metabolites of 
docetaxel and less than 10 % of the parent drug are excreted into the faeces, whereas total 
urinary excretion is less than 10 % 9,10. Preclinical metabolism and excretion studies with 
[14C]-radiolabelled docetaxel have demonstrated that the elimination of radioactivity in mice, 
dogs and rats was rapid and almost complete (range, 85 - 95%) within 7 days after 
administration 11,12. Clinical studies assessing excretion and metabolism of [14C]-
radiolabelled docetaxel are limited 13. In patients (N = 3) approximately 80 % of total 
administered radioactivity was excreted in the 7-day faeces, with the majority of excretion 
occurring during the first 48 hours and only 5 % of total radioactivity was retrieved in urine 
during the first 6 hours after administration. The catalytic activity of the isozyme CYP3A is 
readily modulated by inducing or inhibiting compounds such as drugs, dietary supplements 
and complementary and alternative medicines 14,15. Although docetaxel is subject to a host of 
CYP3A-mediated interactions that can affect treatment outcome, data on potential 
interactions are lacking. We therefore recently conducted a study to evaluate the effect of 
coadministration of the potent CYP3A inhibitor ketoconazole (Nizoral®) on the 
pharmacokinetics of docetaxel in cancer patients 14. A secondary objective of this project was 
to assess the influence of ketoconazole on the excretion profile and mass balance of docetaxel 
and its metabolites in faeces and urine samples using a radiolabelled tracer amount of [3H]-
docetaxel. In the context of this secondary objective we now report on the development and 
analytical method validation of a combustion method to quantify [3H]-docetaxel excreted in 
faeces and urine samples according to international guidelines for bioanalytical method 
validation 16. 
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Materials and Methods  
Chemicals and Solutions  
Tritiated docetaxel ([3H]-docetaxel; 1.0 mCi/mL in ethanol, specific activity 7.2 
Ci/mmol) was manufactured by Moravek Biochemicals Inc. (Brea, CA, USA) and 5 mL 
aliquots (working stock solution) of a 200-fold dilution in ethanol absolute (> 99.9 %; Merck, 
Darmstadt, Germany) were stored at –80 °C. Purity of the [3H]-docetaxel was analysed at two 
intervals (directly after purchase and prior to patient administration) by a reversed-phase 
HPLC method with ultraviolet detection at 230 nm 17. Briefly, to 10 µL docetaxel stock 
solution (1.0 mg/mL) prepared by dissolving the appropriate amount of drug (purity 99.3 %; 
Aventis Pharma, Hoevelaken, The Netherlands) in dimethylsulfoxide (purity 99.9 %; Sigma, 
St. Louis, MO, USA), 100 µL of [3H]-docetaxel working stock solution and 390 µL of 
purified water was added and mixed; a 100 µL aliquot of this solution was injected on the 
HPLC system and the eluted mobile phase collected in polyethylene vials every 30 seconds 
up to 15 minutes after injection; 150 µL of each fraction of collected eluted mobile phase was 
mixed with 2 mL liquid scintillation cocktail (Emulsifier Scintillator 299; Packard 
Bioscience, Groningen, The Netherlands). The collected fractions and a corresponding blank 
were counted in a liquid scintillator counter (Wallac 1409 Liquid Scintillation Counter; 
Perkin Elmer, Boston MA, USA). To assess purity of the [3H]-docetaxel lot, the time course 
(i.e. elution profile) of the recovered radioactivity was compared to the chromatographic 
profile of (unlabelled) docetaxel. Faeces and urine were obtained from healthy volunteers. 
Faeces was homogenized in 3 volumes (1 : 3 w/v) of phosphate buffered saline solution 
(PBS; Oxoid, Basingstoke, UK) using an Ultra-TurraxT25 homogenizer (Janke & Kunkel, 
IKA Labortechnik, Staufen, Germany) and stored at –20 °C. Pooled urine samples did not 
undergo any processing and were immediately stored at –20 °C. Water purified and deionized 
by the Milli-Q UF Plus system (Millipore®; Bedford, MA, USA) was used in all aqueous 
solutions. 
 
Quality control sample preparation 
Three levels of quality control (QC) samples (QC-low; QC-medium; QC-high) were 
prepared in homogenized blank faeces and two levels in pooled blank urine (QC-low; QC-
high). For this purpose a 1 : 10 and a 1 : 100 dilution (in PBS) of [3H]-docetaxel working 
stock solution were prepared. Weighted aliquots of 50 g of blank homogenized faeces were 
spiked with 800 µL or 300 µL of the 1 : 10 dilution to prepare the QC-high and QC-medium 
samples, respectively; 50 µL of the same dilution was used to spike 50 mL of blank urine 
(QC-high). Similarly, weighted aliquots of 50 g of homogenized blank faeces and 50 mL of 
blank urine were both spiked with 50 µL 1 : 100 dilution to produce QC-low samples. The 
chosen levels of radioactivity were based on preliminary data of measurements in patient 
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samples at time points when maximum and minimum excretion was expected. All QC-
samples were stored at –20 °C until analysis. For recovery calculation the nominal level of 
radioactivity in the amounts of [3H]-docetaxel used for spiking was measured in duplicate by 
LSC. 
 
Measurement of radioactivity levels 
The radionuclide fraction of [3H] was obtained after complete combustion of an 
aliquot of each QC-sample in a closed-type combustion flask (Parr; flask volume 300 mL), 
thus reducing the sample to ash and yielding tritiated (combustion) water, [3H2]O. Briefly, 
after accurately weighing the combustion flask a known amount (approximately 1.0 g to 1.5 
g) of sample was placed in the sample basket (1.5 cm high; 3 cm diameter) with a copper 
ignition wire connected to it. Additionally, for urine samples a piece of filter paper was added 
to absorb the sample and prevent it from spilling out of the basket. The combustion flask was 
then hermetically closed and filled with 25 atm oxygen using an oxygen cylinder with a 
pressure regulator. Combustion was started by applying an electric current (12 V) to the 
ignition wire. After combustion, the flask was cooled in an ice-water bath for approximately 
5 minutes. The combustion flask was then weighed again to determine the total produced 
amount of tritiated combustion water. Finally, to an exact (i.e. known) amount 
(approximately 2 mL) of tritiated combustion water 18 mL liquid scintillation cocktail 
(Emulsifier Scintillator 299) was added and the solution manually mixed in glass counting 
vials (Econo glass vial – 20 mL; Packard Bioscience) until homogeneous. Samples were 
counted in a liquid scintillator counter (Wallac 1409; Perkin Elmer). Counting time was set at 
1 hour per sample and in each run a corresponding combustion blank and a [3H]-standard 
were included to correct for background radioactivity and to check stability of the counting 
instrument, respectively. Using the known amounts of combusted sample and produced and 
counted tritiated combustion water, the total amount of radioactivity in the QC-samples could 
be calculated. 
 
Validation of precision and recovery 
The validation procedure was performed on three separate days (i.e. runs) and each 
faeces or urine QC sample was processed (i.e. combusted) 5- or 6 times, respectively. The 
precision of the assay was assessed by between-run precision (reproducibility) and within-run 
precision (repeatability). Estimates of the between-run precision and within-run precision 
were obtained for each (radioactivity) level by one-way analysis of variance (ANOVA) using 
the run day as classification variable. The between-groups mean square (MSbetw), the within-
groups mean square (MSwith), and the grand mean (GM) of the observed radioactivity levels 
across run days were calculated in SPSS for Windows, version 9.0 (SPSS; Chicago, IL, 
USA). 
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The between-run precision (BRP) was defined as: 
 
BRP (%) = {[(MSbetw - MSwith) / N] 0.5 / GM} x 100 
 
where N represents the number of replicate measurements within each validation run. The 
within-run precision (WRP) was calculated as: 
 
WRP (%) = {(MSwith) 0.5 / GM} x 100 
 
In cases where the MSwith is greater than the MSbetw, the resulting variance estimate is 
negative, implying that no additional variance was observed as a result of performing the 
assay in different runs. The average recovery (REC) for each QC sample was calculated as: 
 
REC (%) = (GM / nominal radioactivity level) x 100 
 
The bioanalytical method validation is accepted when the WRP and BRP at each level of QC 
samples are 15 % or less and at least 80 % of the QC samples at each level have an absolute 
deviation of 15 % or less of their nominal concentration 16. 
 
Lower Limit of Quantification 
In general, for a concentration (i.e. level of radioactivity) to be acceptable as the 
lowest level of quantification the percentage of deviation from the nominal value of at least 
80 % of the samples assayed should be 20 % or less, with a resulting WRP of 20 % or less 16. 
Although no samples were spiked with levels of radioactivity lower than the QC-low nominal 
values, calculation of the statistical error (standard deviation, SD and coefficient of variation, 
CV) for the accumulated counts for the QC-low samples gives an impression of the level of 
quantification (i.e. sensitivity), which can be achieved. The SD in the net count rate after 
correcting the gross count rate (Ra) for the blank (Rb), was calculated using the following 
error formula: 
SD = √(R a / ta + Rb / tb) 
 
where the counting time for both sample and blank (ta and tb) was 60 minutes. 
The CV (%) was calculated as: 
 
CV (%) = √{1 / (Ra*ta) + 1 / (Rb* tb)} x 100 
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Clinical applicability 
Complete 24-hour urine and faeces were collected up to 72 hours after a 1-hour i.v. 
infusion of 210 mg docetaxel (dose 100 mg/m2) and a tracer amount (approximately 50 µCi) 
of [3H]-docetaxel to a cancer patient participating in the previously mentioned study 14. 
Samples were stored, processed and analysed (in duplicate) as described for the QC-samples. 
The observed radioactivity levels in the samples were used to calculate the total amount of 
radioactivity recovered in each collected faeces and urine sample and the percentage of 
recovered radioactivity (i.e. relative to the amount which was added to the docetaxel 
infusion), was determined. 
Potential loss of added [3H]-docetaxel due to adhesion to the infusion bag (NaCl 0.9 
% wt/vol, 250 mL Viaflex; Baxter, Utrecht, The Netherlands), i.v. administration set (ref: 
591.078J; Graseby, Watford, UK) or connect set (ref. 76.4440; Codan, Lensahn, Germany) 
was assessed. For this purpose the clinical practice of infusion was simulated using two 
docetaxel infusions (dose 20 mg and 160 mg docetaxel), which both contained the same 
amount of [3H]-docetaxel used in the clinical trial 14. After the simulated infusion duplicate 
specimens of the infusion bags and lines were combusted, the combustion water distillated to 
produce a clear sample, mixed with liquid scintillation cocktail, and followed by LSC to 
determine the level of radioactivity. 
 
Results 
Method Validation  
No signs of degradation or decreased purity of the lot of [3H]-docetaxel, used for 
validation of the combustion method and throughout the clinical trial were observed, even 
after a period of prolonged storage at –80 °C; more than 90 % of the radioactivity recovered 
in the collected fractions of eluted mobile phase after chromatographic analysis of [3H]-
docetaxel was detected at the retention time of docetaxel (Figure 1). 
At each of the three or two, respectively, QC levels of [3H]-docetaxel in homogenized 
faeces and urine the within-run precision and between-run precision was less than 7.6 % 
(Table 1). The ratio of the volumes of [3H]-docetaxel 1 : 10 dilution used to spike the faeces 
QC samples (QC-medium 300 µL : QC-high 800 µL = 1.0 : 2.7) could also be calculated for 
the observed levels (grand mean) in the corresponding samples (QC-medium : QC-high = 1.0 
: 2.6), indicating linearity in the counting results. Similar results for linearity were seen in the 
urine samples. Furthermore, the ratio of the observed (grand mean) levels in the QC-low 
samples for the two matrices both spiked with 50 µL 1 : 100 dilution were as expected (QC-
low-urine : QC-low-faeces = 1.0 : 1.1). These results indicate that matrix interference can be 
excluded. Recovery of radioactivity in faeces and urine was constant and ranged from 85.0 % 
to 91.8 % (Table 1). At the lowest levels of radioactivity, calculation of the statistical error 
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demonstrated that the SD was less than 1 cpm and the CV was 5.2 % and 4.9 % for faeces 
and urine samples, respectively. 
 
 
Figure 1. Chromatographic tracing with ultraviolet detection (solid line), and off-line liquid 
scintillation counting (dashed line) after injection of docetaxel and an added tracer amount of [3H]-
docetaxel. 
 
Table 1. Within-run precision, between-run precision and recovery of [3H]-docetaxel in 
human faeces and urine 
QC sample Nominal 
(dpm / g) 
Observed
(dpm / g) 
WRP 
(%) 
BRP 
(%) 
N REC1 
(%) 
Faeces       
QC-low 190 170 5.2 # 5 89.2 (4.4) 
QC-medium 13722 12425 1.8 # 5 90.5 (1.5) 
QC-high 35344 32457 2.0 1.5 5 91.8 (2.2) 
Urine       
QC-low 186 158 7.6 # 6 85.0 (6.4) 
QC-high 2147 1967 2.2 # 6 91.6 (2.0) 
 
Abbreviations: QC, quality control; WRP, within-run precision; BRP, between-run precision; N 
number of replicate observations within each validation run; REC, recovery; #, no additional variation 
was observed by performing the assay in different runs. 1mean value for all observations with 
standard deviation between parentheses. 
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Clinical applicability 
The radioactivity excretion profiles in faeces and urine after docetaxel infusion (210 
mg) and an added tracer amount of [3H]-docetaxel are displayed in Figures 2A and 2B, 
respectively. During the first 72 hours after i.v. administration (i.e. the period during which 
the patient was admitted in the hospital) the total percentage of recovered radioactivity was 
60.41 % (55.79 % in faeces and 4.62 % in urine), which is within the expected range 
considering the time interval of sample collection. Loss of added [3H]-docetaxel due to 
adhesion to the infusion bag or administration set was neglectable for both high (100 mg/m2) 
and low (10 mg/m2) doses of docetaxel (≤ 0.3 %). 
 
Discussion 
We have here described the validation of a combustion method to quantify 
radioactivity levels in human faeces and urine collected after i.v. administration of a tracer 
amount of [3H]-docetaxel added to a docetaxel infusion. The described method is rapid, 
specific, precise, has a recovery of at least 85 % and allows sample aliquots of approximately 
1.5 g (1 : 3 w/v homogenized faeces or 2 mL urine) to be processed, which is more than 
previously described for analytical procedures using a non-combustion sample pretreatment 
method (i.e. 200 µL faeces homogenate 1 : 10; 20 mg dried faeces; 
http://www.packardbioscience.com) 2, as such lower levels of radioactivity can be detected. 
Indeed, when we analysed our QC samples according to the previously described non-
combustion method 2 the lowest QC level (for both matrices) could not be quantitated [data 
not shown]; recovery for the other two QC levels was in the same range as we found for the 
combustion method. Furthermore, these samples were clear, yet never completely colourless 
after sample preparation and chemiluminescence correction was required. 
The described combustion method was applied to samples collected from a cancer 
patient who received a docetaxel infusion with a tracer amount of [3H]-docetaxel added. 
Recovered radioactivity was within the expected range taking into account the period of 
sample collection (i.e. 72 hours). The method can therefore be applied to assess the influence 
of ketoconazole on the excretion profile and mass balance of docetaxel and its metabolites in 
faeces and urine samples. 
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Abstract 
Objective: The anticancer drug docetaxel is extensively metabolized by cytochrome 
P450 (CYP) 3A isozymes. Furthermore, docetaxel is also a substrate for the transmembrane 
ATP-binding cassette efflux transporter protein ABCB1. CYP3A-inhibition significantly 
reduces docetaxel total systemic clearance, on average by 50 %. However, data on the effect 
of CYP3A-inhibition on the faecal and urinary excretion of docetaxel are lacking. To further 
elucidate the role of CYP3A- and ABCB1-mediated elimination pathways for docetaxel we 
investigated the effect of the potent CYP3A-inhibitor, and also ABCB1-inhibitor, 
ketoconazole on the faecal and urinary disposition of docetaxel in cancer patients. 
Methods: Fifteen patients were treated with docetaxel (100 mg/m2), followed 3 weeks 
later by a reduced dose in combination with orally administered ketoconazole, or vice versa. 
Six patients were also administered [3H]-radiolabelled docetaxel. Faecal and urinary 
specimens, collected up to 72 hours post-infusion, were analysed for cumulative parent drug 
and radioactivity excretion. 
Results: Ketoconazole coadministration increased faecal parent drug excretion 2-fold 
from 2.6 % ± 2.8 % to 5.2 % ± 5.4% (mean ± SD, P = 0.03) but did not affect urinary parent 
drug excretion (P = 0.69). The sum of faecal and urinary parent drug excretion was 5.3 % ± 
3.0 % for docetaxel alone and 7.8 % ± 5.6 % in the presence of ketoconazole, respectively (P 
= 0.04). Total recovered radioactivity values were 45.8 % ± 19.1 % and 32.4 % ± 19.7 %, 
respectively (P = 0.23). 
Conclusion: CYP3A-inhibition by ketoconazole increases faecal parent drug excretion 
2-fold in cancer patients. A more pronounced increase was not achieved, most likely due to 
concomitant intestinal ABCB1-inhibition. 
 
Introduction 
In recent years, the clinical pharmacokinetics (PK) of the anticancer drug docetaxel 
have been subject of thorough investigation. After intravenous administration the drug is 
extensively metabolized by hepatic and intestinal cytochrome P450 (CYP) isozymes 3A 1,2, 
the catalytic activity of which is represented by two major isoforms, CYP3A4 and CYP3A5, 
albeit that CYP3A4 is the most active, possesses the highest affinity for docetaxel 3 and is 
predominant in Caucasians 4. Moreover, CYP3A activity is readily induced or inhibited by a 
broad range of compounds. Docetaxel is also a substrate for the ATP-binding cassette 
membrane-localized transporter, ABCB1 (P-glycoprotein; MDR-1) which acts as a 
(drug/xenobiotic-)efflux pump 5,6. ABCB1 is expressed in several tissues including the renal 
tubule, biliary tract and intestinal epithelium 7 and plays a prominent role in the faecal 
elimination of docetaxel 8,9. 
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Preclinical studies with [14C]-radiolabelled docetaxel have demonstrated that 
administered radioactivity is predominantly (range, 85 – 95 %) excreted in the faeces within 
7 days and that urinary excretion accounts for less than 5 % 10-12. Furthermore, the 
administered dose is primarily (≥ 75 %) excreted as four pharmacologically inactive 
metabolites 13 and less than 10 % is excreted unchanged 14. Clinical studies assessing 
excretion of [14C]-radiolabelled docetaxel are limited; in cancer patients (N = 3) 
approximately 80 % of total administered radioactivity was excreted in faeces collected up to 
7 days post-infusion and 5 % of total radioactivity was recovered in urine 15. 
The faecal disposition of docetaxel in the presence of ABCB1-inhibition has been 
studied previously 8, however, the effect of inhibition of CYP3A, the drug’s major route of 
inactivation, on docetaxel faecal and urinary excretion, has never yet been evaluated. We 
previously evaluated the effect of concomitant orally administered ketoconazole, a potent 
CYP3A-inhibitor 16 and also weak to modest ABCB1-inhibitor 7,17,18, on docetaxel plasma 
PK in cancer patients 19,20. Subsequently, the current study was undertaken to evaluate the 
effect of both CYP3A- and ABCB1-inhibition on docetaxel faecal and urinary excretion. The 
objectives of the current study were therefore to evaluate the influence of ketoconazole on (1) 
the faecal and urinary excretion of unchanged docetaxel (i.e. parent drug), on (2) the total 
faecal and urinary excretion of docetaxel using [3H]-radiolabelled docetaxel, and on (3) the 
mass balance of ([3H]-radiolabelled-)docetaxel. 
Wide variation in total CYP3A activity exists, as reflected by substantial 
interindividual PK variability for CYP3A substrates 21. Part of this variability has been 
related to genetic diversity in the genes encoding CYP3A4 and CYP3A5 proteins 22. 
However, currently, most evidence infers that it is unlikely that CYP3A4 single nucleotide 
polymorphisms (SNPs) contribute substantially to variability in CYP3A4 activity in vivo 23-25 
due to the low frequency of genetic polymorphisms. On the other hand, more than 80 % of 
Caucasians is deficient in CYP3A5 activity due to the CYP3A5*3C/*3C variant genotype 4. 
In individuals with at least one CYP3A5*1 allele, CYP3A5 may account for at least 50 % of 
total CYP3A content, resulting in 2- to 3-fold higher CYP3A activity in vitro 26. Moreover, 
CYP3A4 and CYP3A5 show distinct differences in susceptibility to inhibition by 
ketoconazole 27. ABCB1 polymorphisms have not been shown to affect docetaxel plasma PK 
28,29, yet their influence on faecal and urinary excretion is unknown. We included CYP3A5 
and ABCB1 genotyping in our study to gain insight in the effect of the various SNPs on 
docetaxel faecal and urinary excretion. Genotyping for CYP3A4 rare polymorphisms was 
performed to exclude genetic diversity in CYP3A4 activity. 
We here report on the disposition of docetaxel in the faeces and urine of cancer 
patients, after intravenous administration of the drug with and without concomitant oral 
administration of ketoconazole, a potent inhibitor of the drug’s major route of inactivation. 
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Methods 
Patient selection and study design 
Eligibility criteria and study design have been reported previously 19,20. Briefly, 
cancer patients for whom no other treatment was available were treated with two courses of 
docetaxel administered as a 1-hour intravenous infusion once every 3-weeks. Initially, one 
course was given at a dose of 100 mg/m2 and the other at a dose of 10 mg/m2 in combination 
with three 200 mg doses of ketoconazole, orally administered once every 24 hours up to 47 
hours after docetaxel infusion (standard-dose ketoconazole) 30. Seven patients were treated 
accordingly followed by plasma PK analysis. We observed wide variability in the reduction 
of docetaxel total clearance 19, which was attributed to variability in systemic ketoconazole 
exposure. We subsequently treated patients with a higher ketoconazole dose (seven 400 mg 
doses every 8 hours, up to 47 hours after docetaxel infusion; high-dose ketoconazole 31) in 
combination with docetaxel (15 mg/m2) 20. We hypothesized that an increase in ketoconazole 
dose would result in sufficiently high ketoconazole exposure in each patient and thus in 
maximum CYP3A-inhibition overall, thereby reducing the variability in the extent to which 
docetaxel clearance is reduced. In addition, we administered a tracer-dose of [3H]-
radiolabelled docetaxel to each patient for radioactivity measurements in faeces and urine, in 
the absence and presence of high-dose ketoconazole. The study protocol was approved by the 
Erasmus MC Investigational Review Committee and all patients gave written informed 
consent for participation. 
 
Chemicals  
Tritiated docetaxel ([3H]-docetaxel; 1.0 mCi/mL in ethanol, specific activity 7.2 
Ci/mmol; Moravek Biochemicals, Brea, CA, USA) and 5 mL aliquots of a 200-fold dilution 
in ethanol absolute (> 99.9 %; Merck, Darmstadt, Germany) were stored at –80 °C prior to 
adding to unlabelled docetaxel diluted in 250 mL 0.9 % (w/v) sodium chloride solution. 
Purity of [3H]-docetaxel was analysed by a reversed-phase high performance liquid 
chromatography (HPLC) method with ultraviolet detection at 230 nm 32. The elution profile 
of the recovered radioactivity was compared to the chromatographic profile of unlabelled 
docetaxel; the product showed no signs of degradation or decreased purity 33. 
 
Sample Collection  
During both courses, complete stool collections were obtained up to 72 hours post-
infusion and stored at –80 ºC until processing. Subsequently, weighted faeces samples were 
homogenized in 3 volumes (1 : 3 w/v) of phosphate buffered saline solution (PBS; Oxoid, 
Basingstoke, United Kingdom) using an Ultra-TurraxT25 homogenizer (Janke & Kunkel, 
IKA Labortechnik, Staufen, Germany) operating at 20,500 rpm and then stored at –80 °C 
prior to radioactivity measurements. Aliquots of faeces homogenates were further diluted (up 
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to 5-fold) with PBS and stored at –80 °C prior to chromatographic analysis. All voided urine 
was collected quantitatively during three intervals post-infusion (0-24 h, 24-48 h, 48-72 h) 
and two portions from each interval were stored at –80 °C prior to radioactivity 
measurements and chromatographic analysis. 
 
Docetaxel analysis  
Docetaxel was quantitated in faeces and urine samples using HPLC with tandem 
mass-spectrometric detection (LC-MS/MS). Prior to extraction all samples were diluted at 
volume ratios of at least 1 : 1 up to 1 : 50 with analyte-free lithium-heparinized human 
plasma. Hereafter, 100 µL aliquots of the diluted faeces or urine sample were processed and 
analysed as described previously 20. Docetaxel faeces and urine concentrations were 
quantitated over the range of 5.00 ng/mL to 500 ng/mL. For quantitation of docetaxel in the 
patient samples, quality control (QC) samples at docetaxel concentrations of 5.00 ng/mL, 
15.0 ng/mL, 225 ng/mL, 400 ng/mL and 6000 ng/mL, the latter QC diluted 20-fold prior to 
processing, were assayed in duplicate and distributed among the calibrators and samples in 
the analytical run. Finally, given the volume of collected urine and the weight of the collected 
faeces samples, the absolute amount of docetaxel excreted in each urine and faeces specimen 
was calculated assuming that 1 gram unhomogenized faeces equals 1 mL. 
 
Radioactivity measurements 
Details of the development and validation of the analytical method used to quantitate 
radioactivity levels in faeces and urine have been reported elsewhere 33. Briefly, the 
radionuclide fraction of [3H] was obtained after complete combustion of a known amount of 
sample aliquot (undiluted urine and 1 : 3 w/v diluted faeces) in a closed-type combustion 
flask of known weight, thus yielding a known amount of tritiated combustion water, [3H]2O. 
Subsequently, liquid scintillation (LS) cocktail was added to a quantitatively taken amount of 
[3H]2O, the solution then mixed until homogeneous and the samples counted in a LS-counter. 
Finally, based on the amount of radioactivity in the produced [3H]2O, the excreted 
radioactivity in the combusted samples was determined and thus the total amount of 
recovered radioactivity in the collected faeces and urine specimens. As [3H]-radiolabelled 
docetaxel is metabolized and eliminated identically to unlabelled drug, the recovered 
radioactivity reflects the sum of radioactivity from excreted parent drug and all excreted 
metabolites. 
 
Genotype analysis  
Polymerase chain reaction (PCR)-restriction fragment length polymorphism analysis 
for CYP3A5*3C, CYP3A5*6, CYP3A4*1B, CYP3A4*3, CYP3A4*17, CYP3A4*18A and 
ABCB1 3435C>T variant alleles was performed as described previously 4,34,35. Based on 
Chapter 8 
 110
allele frequencies in the Caucasian population, in which the CYP3A5*3C allele is the 
predominant allele, the rare CYP3A5*6 variant allele, which also results in completely or 
severely decreased CYP3A5 activity was only determined for individuals with no, or only 
one CYP3A5*3C allele (i.e. with apparently at least one CYP3A5*1 allele). 
 
Statistical considerations 
Excretion parameters are reported as mean values ± standard deviation (SD) unless 
stated otherwise. The difference in parameters between the two courses was evaluated 
statistically using a non-parametric two-tailed, Wilcoxon signed rank test for paired 
observations after testing for period effects. Comparison of the mean urinary and faecal 
parent drug excretion (in the presence of ketoconazole) between the high- and standard-dose 
ketoconazole patient-groups showed no significant differences (P = 0.17 and P = 0.95 
respectively, Mann-Whitney U test). Furthermore, the extent to which docetaxel total 
clearance was reduced was almost identical for high- and standard-dose ketoconazole 
treatment 19,20 suggesting that the increase in ketoconazole dose did not augment the extent of 
CYP3A-inhibition. Therefore, the excretion data of all patients were evaluated together, 
irrespective of ketoconazole dose. The significance level was set at P < 0.05. Statistical 
calculations were performed with SPSS version 11.5 (Chicago, IL, USA). 
 
Results  
Baseline patient profiles  
A total of fifteen Caucasian patients were included (standard-dose ketoconazole, N = 
7; high-dose ketoconazole, N = 8). For all patients urine samples were collected during both 
courses. For one patient (high-dose ketoconazole group) no faeces samples were collected, 
thus faeces samples were available for fourteen patients during both courses. None of the 
patients were administered CYP3A- inducing or inhibiting comedication, however two 
patients were administered medication known to reduce ketoconazole gastrointestinal 
absorption (pantoprazole and ranitidine), thus potentially decreasing systemic ketoconazole 
exposure 36. For the patient administered pantoprazole (and high-dose ketoconazole) 
ketoconazole exposure (area under the concentration-time curve, AUC) was approximately 4-
fold higher than median exposure (AUC = 60.1 mg.h/L; range,  19.6 – 81.3 mg.h/L) for 
patients treated with standard-dose ketoconazole (without interfering medication). As 
previously discussed, we did not observe a significant difference in docetaxel urinary and 
faecal excretion in the presence of ketoconazole between standard- or high-dose 
ketoconazole, therefore this patient was included in our analysis. Of note, this was also the 
patient for whom no faeces samples were available. For the patient administered ranitidine 
(and standard-dose ketoconazole), ketoconazole exposure was indeed the lowest (AUC = 
12.8 mg.h/L), yet differed only marginally from the exposure (AUC = 19.6 mg.h/L) for 
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another patient not administered interfering comedication. Furthermore, for this patient, 
faecal parent drug excretion in the presence of ketoconazole was increased by 44 % 
suggesting an inhibitory effect of ketoconazole. We therefore also included this patient in our 
analysis. Thus, fifteen patients were evaluable for cumulative urinary parent drug excretion-
analysis and fourteen for cumulative faecal parent drug excretion-analysis. Urine and faeces 
samples for radioactivity measurements were available for six and five patients, respectively, 
in the absence and presence of high-dose ketoconazole. Table 1 summarizes the baseline 
characteristics for the evaluable patients. 
 
Table 1. Baseline patient characteristics  
Characteristic Value  
Number   15   
Age (years) 50 (36 – 69) 
Sex (male / female) 11 / 4  
Body-surface area (m2) 1.89 (1.55 – 2.19) 
WHO performance status 1 (0 - 1) 
Tumour type  
Head & Neck  6 
Melanoma  2 
Breast   1 
Prostate  1 
Other  5 
Clinical Chemistry  
WBC (x 109/L) 8.2 (5.7 – 14.9) 
ANC (x 109/L) 6.8 (3.2 – 12.3) 
Platelets (x 109/L) 264 (156 – 930) 
Haemoglobin (mmol/L) 8.3 (5.8 – 9.2) 
ASAT (U/L) 25 (17 – 79) 
ALAT (U/L) 20 (6 – 30) 
Alk Phos (U/L) 77 (58 – 241) 
Total Bilirubin (µmol//L) 6 (4 – 15) 
Serum Albumin (g/L) 41 (28 – 46) 
Serum AAG (g/L) 1.03 (0.86 – 1.67) 
 
Abbreviations: WHO, World Health Organization; WBC, white blood cell count; ANC, absolute 
neutrophil count; ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; Alk Phos, 
alkaline phosphatase; AAG, alpha-1 acid glycoprotein. Values are given as median with range in 
parentheses (except for sex and tumour type). 
 
All patients were genotyped for CYP3A5*3C, CYP3A4*1B, CYP3A4*3, 
CYP3A4*17 and CYP3A4*18A variant alleles. Fourteen patients were homozygous for the 
CYP3A5*3C variant allele, and consequently deficient in CYP3A5 activity, indicating that 
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for these patients total hepatic and intestinal CYP3A activity is solely attributable to CYP3A4 
activity. Only CYP3A5 (not CYP3A4) is expressed to any significant degree in renal tubular 
epithelial cells 37. Thus for the CYP3A5*3C homozygous individuals, any effect of 
ketoconazole on urinary parent drug excretion cannot be attributed to CYP3A(5)-inhibition. 
One patient carried a single CYP3A5*1 allele, yet not the CYP3A5*6 variant allele, 
indicating that in this patient CYP3A5 is (most probably) active. This same patient was the 
only heterozygous carrier of the CYP3A4*1B variant allele (*1A/*1B). All other patients 
were homozygous CYP3A4*1A/*1A. No patients carried variant alleles for CYP3A4*3, 
CYP3A4*17 or CYP3A4*18A. ABCB1 3435C>T genotyping results were available for 
thirteen patients. The genotype distribution was one homozygous wild-type patient (C/C), 
eight heterozygous variant patients (C/T) and four homozygous variant patients (T/T). 
 
Faecal and urinary parent drug excretion  
A summary of the cumulative excretion of parent drug in faeces and urine collected 
up to 72 hours post-infusion during both courses is listed in Tables 2 and 3. Data are reported 
as total fraction (i.e. percentage) of the administered absolute docetaxel dose, which is 
excreted unchanged in the faeces (fef, %) or urine (feu, %). 
After single agent dosing a minor fraction of the administered docetaxel dose was 
recovered in the faeces unchanged (2.6 % ± 2.8 %). Total faecal parent drug excretion was 
approximately 2-fold higher in the presence of ketoconazole (5.2 % ± 5.4 %, P = 0.03). We 
observed a trend towards statistical significance when the faecal parent drug excretion in the 
absence and presence of ketoconazole was evaluated for each 24-hour interval (0 - 24 h, P = 
0.87, N = 7; 24 – 48 h, P = 0.52, N = 9; 48 – 72 h, P = 0.03, N = 6). Faecal specimens were 
not available for every patient in each 24-hour interval, explaining why the number of 
patients included in these sub-analyses is less than the fourteen evaluable patients. 
Furthermore, this also explains why the sum of the average fraction of parent drug excreted 
during each 24-hour period does not equal the total cumulative faecal parent drug excretion 
(0 – 72 h). 
Figure 1 shows the cumulative faecal parent drug excretion in the absence of 
ketoconazole as a function of CYP3A4*1B, CYP3A5*3C and ABCB1 3435C>T genotype. 
Mean faecal parent drug excretion for the CYP3A5*3C and CYP3A4*1A homozygous 
patients was 2.6 % and 2.4 % for the single CYP3A5*3C and CYP3A4*1B heterozygous 
patient. The genotype distribution (13 vs 1) does not allow statistical evaluation, however, 
these data do not suggest a substantial difference in faecal excretion for the evaluated 
genotypes. Mean faecal parent drug excretion for the C/T and T/T ABCB1 genotypes was 2.6 
% and 4.2 %, respectively (P = 0.85). Faecal excretion for the patient with C/C genotype was 
1.3 %. 
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Table 2. Cumulative faecal excretion of parent drug  
Parameter  Ketoconazole = 0 Ketoconazole = 1 P-value  
fef (%) 0 - 72 h, N = 14 2.6 ± 2.8 5.2 ± 5.4 < 0.05 
 (0.02 – 10.0) (0.04 – 14.3)  
fef (%) 0 - 24 h, N = 7 1.7  ± 3.1 1.7 ± 2.4 0.87 
 (0.03 – 8.7) (0.08 – 6.7)  
fef (%) 24 - 48 h, N = 9 1.8 ± 1.4 2.7 ± 2.2  0.52 
 (0.01 – 3.91)  (0.37 – 6.6)  
fef (%) 48 - 72 h, N = 6 0.74 ± 0.41 3.0 ± 1.9 < 0.05 
 (0.01 – 1.1) (1.1 – 5.5)  
 
Abbreviations: Ketoconazole = 0, ketoconazole absent; Ketoconazole = 1, ketoconazole present; fef, 
cumulative faecal parent drug excretion expressed as percentage of the absolute docetaxel dose 
administered; Values are given as mean ± SD with range in parentheses. 
 
The cumulative urinary parent drug excretion did not differ significantly between the 
two courses (P = 0.69) and renal parent drug excretion predominantly (> 80 %) took place 
during the first 24 hours post-infusion regardless of ketoconazole administration (Table 3). 
The ratio of the fraction of parent drug excreted during the first 24 hours to the total fraction 
of excreted parent drug (feu 0 – 24 h : feu 0 – 72 h) was significantly lower in the presence of 
ketoconazole (P = 0.02, N = 15). This was also the case when we evaluated this ratio for 
patients administered high-dose ketoconazole separately (P = 0.01), yet not for patients 
administered standard-dose ketoconazole (P = 0.93). 
 
Table 3. Cumulative urinary excretion of parent drug  
Parameter  Ketoconazole = 0 Ketoconazole = 1 P-value  
feu (%) 0-72 h, N = 15 2.6 ± 1.4 2.6 ± 1.1 0.69 
 (1.3 – 5.7) (1.1 – 5.0)  
feu0-24 h : feu0-72 h, N = 15 0.94 ± 0.03 0.88 ± 0.07 < 0.05 
 (0.86 – 0.97) (0.78 – 1.00)  
feu0-24 h : feu0-72 h, N = 71 0.93 ± 0.04 0.93 ± 0.07 0.93 
 (0.86 – 0.97) (0.84 – 1.00)  
feu0-24 h : feu0-72 h, N = 82 0.95 ± 0.02 0.83 ± 0.04 < 0.05 
 (0.91 – 0.97) (0.78 – 0.89)  
 
Abbreviations: Ketoconazole = 0, ketoconazole absent; Ketoconazole = 1, ketoconazole present; feu, 
cumulative urinary parent drug excretion expressed as percentage of the absolute docetaxel dose 
administered; ratio feu0-24 h : feu0-72 h, ratio of the urinary excretion of parent drug during the first 
24 hours to the total urinary excretion of parent drug up to 72 hours post-infusion. 1Standard-dose 
ketoconazole; 2High-dose ketoconazole. Values are given as mean ± SD with range in parentheses. 
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Figure 2 shows the cumulative urinary parent drug excretion in the absence of 
ketoconazole as a function of CYP3A4*1B, CYP3A5*3C and ABCB1 3435C>T genotype. 
Mean urinary parent drug excretion for the CYP3A5*3C and CYP3A4*1A homozygous 
patients was 2.6 % and 2.8 % for the CYP3A5*3C and CYP3A4*1B heterozygous 
individual, again not suggesting a substantial difference between the evaluated genotypes. 
Mean urinary parent drug excretion for the C/T and T/T ABCB1 genotypes was 2.8 % and 
1.7 %, respectively, (P = 0.04). Urinary excretion for the patient with C/C genotype was 5.2 
%. 
 
Radioactivity recovered in faeces and urine 
A summary of the cumulative radioactivity recovered in faeces (Raf, %) and urine 
(Rau, %) samples collected up to 72 hours post-infusion during both treatments is listed in 
Table 4. 
 
Table 4. Cumulative radioactivity recovered in faeces and urine 
Parameter  Ketoconazole = 0 Ketoconazole = 1 P-value  
Raf (%) 0-72 h, N = 5 40.4 ± 19.9 27.7 ± 20.3 0.23 
 (7.37 – 55.8) (1.17 – 45.5)  
fef : Raf, N = 5 0.10 ± 0.05 0.26 ± 0.09 < 0.05 
 (0.05 – 0.17) (0.12 – 0.35)  
Rau (%) 0-72 h, N = 6 5.13 ± 1.23 4.52 ± 1.38 0.17 
 (3.76 – 6.94) (3.48 – 7.14)  
Rau0-24 h : Rau0-72 h, N = 6 0.89 ± 0.04 0.78 ± 0.05 < 0.05 
 (0.82 – 0.93) (0.72 – 0.86)  
feu: Rau, N = 6 0.59 ± 0.22 0.66 ± 0.11 0.27 
 (0.28 – 0.83) (0.52 – 0.81)  
 
Abbreviations: Ketoconazole = 0, ketoconazole absent; Ketoconazole = 1, ketoconazole present; Raf, 
Rau, cumulative radioactivity recovered in faeces and urine, respectively, expressed as percentage of 
the absolute amount of added radioactivity; fef : Raf, ratio of total faecal excretion of parent drug to 
total faecal excretion of parent drug and all metabolites; feu : Rau, ratio of total urinary excretion of 
parent drug to total urinary excretion of parent drug and all metabolites; Rau0-24 h : Rau0-72 h, ratio 
of recovered urinary radioactivity during the first 24 hours to total recovered urinary radioactivity up 
to 72 hours post-infusion. Values are given as mean ± SD with range in parentheses. 
 
Mean cumulative faecal excretion of radioactivity was lower in the presence of 
ketoconazole (27.7 % vs 40.4 %), but this difference was not significant (P = 0.23). Mean 
faecal parent drug excretion in the presence and absence of ketoconazole was 6.7 % and 3.3 
% (for these five patients), respectively, suggesting that the fraction of excreted metabolites 
in the presence and absence of ketoconazole was 21.0 % and 37.1 %, respectively (P = 0.14). 
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We evaluated the influence of ketoconazole on the ratio of faecal parent drug excretion to 
faecal excretion of parent drug and all metabolites, the latter reflected by cumulative 
radioactivity excretion. This ratio (fef : Raf) was significantly higher (P = 0.04) in the 
presence of ketoconazole (0.26 ± 0.09) compared to single agent docetaxel (0.10 ± 0.05), 
confirming the observed increased parent drug excretion. 
The total fraction of radioactivity recovered in urine did not differ significantly 
between the two courses (P = 0.17). For both courses, the percentage of urinary recovered 
radioactivity is approximately 2 % higher than cumulative urinary parent drug excretion, 
suggesting that approximately 2 % of the administered docetaxel dose is eliminated renally as 
metabolite(s). The ratio of the cumulative fraction of radioactivity recovered in urine during 
the first 24 hours to the total fraction of urinary excreted radioactivity (ratio Rau 0 - 24 h : Rau 
0 – 72 h) was significantly lower in the course with ketoconazole (P = 0.03). In contrast to 
the faecal excretion data, ketoconazole did not influence the ratio of urinary parent drug 
excretion to urinary excretion of parent drug and all metabolites (feu : Rau; P = 0.27). 
 
Mass balance  
The mass balances of excreted parent drug and recovered radioactivity (determined by 
adding the cumulative faecal and urinary excretion data) for each course are summarized in 
Table 5. For parent drug total cumulative excretion is significantly higher in the presence of 
ketoconazole (P = 0.04). The mass balance of recovered radioactivity was lower in the course 
with ketoconazole, yet the difference was not significant (P = 0.23). 
 
Table 5. Mass balance parent drug excretion and Mass balance recovered radioactivity 
Parameter  Ketoconazole = 0 Ketoconazole = 1 P-value  
Mass balance (%) 0 – 72 h,  5.3 ± 3.0 7.8 ± 5.6 < 0.05 
N = 14 (fef + feu) (1.3 – 11.3) (1.1 – 18.0)  
Mass balance (%) 0 – 72 h, 45.8 ± 19.1 32.4 ± 19.7 0.23 
N = 5 (Raf + Rau) (13.7 – 60.4) (5.4 – 49.5)  
 
Abbreviations: Ketoconazole = 0, ketoconazole absent; Ketoconazole = 1, ketoconazole present; fef, 
feu, cumulative excretion of parent drug in faeces and urine, respectively, expressed as percentage of 
the absolute docetaxel dose administered; Raf, Rau cumulative radioactivity recovered in faeces and 
urine, respectively, expressed as percentage of the absolute amount of added radioactivity. Values are 
given as mean ± SD with range in parentheses. 
 
Mean cumulative total parent drug excretion for the CYP3A5*3C and CYP3A4*1A 
homozygous patients was 5.3 % and 5.2 % for the CYP3A5*3C and CYP3A4*1B 
heterozygous individual. Mean cumulative total parent drug excretion for the C/T and T/T 
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ABCB1 genotypes was 5.5 % and 5.8 %, respectively (P = 1.0). Cumulative total parent drug 
excretion for the patient with C/C genotype was 6.5 %. 
 
Discussion 
Although docetaxel plasma PK in cancer patients is well characterized, data on the 
faecal and urinary excretion of the drug are limited. In this study we evaluated the faecal and 
urinary excretion of docetaxel parent drug and [3H]-radiolabelled docetaxel in cancer 
patients, after intravenous docetaxel administration with and without concomitant orally 
administered ketoconazole, a potent inhibitor of CYP3A-mediated metabolism, the drug’s 
major route of inactivation, and also a (weak to modest) inhibitor of ABCB1, which plays an 
important role in the faecal disposition of docetaxel 8,9. Assessing purposeful modulation of 
docetaxel faecal and urinary disposition can contribute to a better overall understanding of 
the mechanistic aspects involved in docetaxel metabolism. Recently, hepatic CYP3A-
induction in vitro led to CYP2C8-mediated formation of a previously unidentified docetaxel 
metabolite 38. Furthermore, preliminary data indicate that renal function is the most 
significant predictor of docetaxel clearance in the presence of ketoconazole 39, which is in 
contrast with single agent treatment where hepatic function is a significant predictor of 
docetaxel clearance 40,41. 
In the absence of ketoconazole, faecal parent drug excretion was consistent with 
previous findings 9 and approximately 2-fold increased in the presence of ketoconazole. The 
relative contribution of ABCB1-inhibition is quantitatively less significant than the 
contribution of CYP3A-inhibition to the overall effect of ketoconazole-mediated drug-
interactions 7,17,18. Thus, the here observed drug-interaction should primarily be attributed to 
CYP3A-inhibition, however the influence of concomitant ABCB1-inhibition should not be 
overlooked. In the presence of a selective ABCB1-inhibitor re-absorption of docetaxel parent 
drug from the intestinal lumen (following biliary secretion) is a very efficient process and 
subsequent CYP3A-mediated metabolism in the liver and intestinal mucosa consequently 
leads to a marked reduction in faecal parent drug excretion 8,9. If theoretically, ketoconazole 
were to act only as a selective CYP3A-inhibitor, adequate ABCB1-mediated efflux of parent 
drug into the intestinal lumen would not be impaired. Consequently, due to ketoconazole-
mediated selective CYP3A-inhibition, one would expect the administered docetaxel dose to 
be excreted predominantly as parent drug. Concomitant ketoconazole-mediated ABCB1-
inhibition most likely explains why we did not observe a more marked increase in faecal 
parent drug excretion in the presence of ketoconazole (Figure 3: a schematic representation of 
the role of hepatic CYP3A and intestinal ABCB1 in docetaxel metabolism and excretion and 
the inhibitory effect of ketoconazole). Interestingly, we observed a trend towards a 
statistically significant difference in faecal parent drug excretion in the presence and absence 
of ketoconazole as the time interval post-infusion increased. The effect of ABCB1-inhibition 
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is expected to be most pronounced shortly after ketoconazole administration due to high local 
drug concentrations in the gut, and to decrease over time, such that in the 48 - 72 h interval, 
when no ketoconazole was administered, the (relative) contribution of ketoconazole-mediated 
CYP3A-inhibition is more pronounced than in the 0 – 24 h interval. 
 
 
 
Figure 3. Schematic representation of the role of hepatic CYP3A and intestinal ABCB1 in docetaxel 
metabolism and elimination in humans. 
A. Model of the hepatic-cellular plate showing the bile collecting system with (i) inhibition by 
ketoconazole of cytochrome P450 3A isozyme-mediated hepatic metabolism of docetaxel from the 
systemic circulation or the portal vein after re-absorption following biliary secretion and (ii) its 
subsequent secretion in the terminal bile duct. 
B. Model of the intestinal epithelium showing (i) re-uptake of docetaxel into the intestinal lumen, (ii) 
ABCB1-mediated efflux of docetaxel and its inhibition by ketoconazole and (iii) intestinal metabolism 
by the cytochrome P450 3A enzyme system and its inhibition by ketoconazole. Abbreviations: ABCB, 
ABCB1; doc, docetaxel; keto, ketoconazole; M, docetaxel metabolite M4; CYP3A, enzymes of the 
cytochrome P450 family, isoform 3A. 
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A second consequence of temporarily inhibiting CYP3A-mediated metabolism is a 
reduction in the fraction of formed metabolites. The difference between faecal recovered 
radioactivity (i.e. parent drug and all excreted metabolites) and faecal parent drug excretion 
reflects the faecal excretion of metabolites. We observed a lower fraction of excreted 
metabolites in the presence of ketoconazole (21.0 vs 37.1 %), although the difference was not 
statistically significant (P = 0.14). The lack of significance is possibly also a consequence of 
concomitant ABCB1-inhibition or because alternative routes of metabolism then prevail or 
due to our limited sample size (N = 5). 
The cumulative fraction of faecal recovered radioactivity was not significantly lower 
in the presence of ketoconazole (P = 0.23). This is in line with the concept of mass 
conservation, stating that (tritium-labelled) mass is neither created nor destroyed during a 
chemical reaction, i.e. metabolism. Thus, despite CYP3A-inhibition, the total fraction of 
excreted parent drug and all metabolites (i.e. recovered radioactivity) should not differ 
between the two courses. 
Urinary excretion plays a minor role in the elimination of docetaxel. We determined 
urinary parent drug excretion and urinary excretion of metabolites each to be approximately 2 
%. Interestingly, substantially increasing the ketoconazole dose significantly reduced parent 
drug excretion during the first 24 hours post-infusion relative to total parent drug excretion 
(ratio feu 0 – 24 h : feu 0 – 72 h). This effect is most likely attributable to ketoconazole-
mediated ABCB1-inhibition as, with the exception of one, all patients were deficient in renal 
CYP3A(5) activity. Ketoconazole-mediated inhibition of ABCB1 transport function is 
concentration dependant 42, therefore it is likely that the higher ketoconazole dose effectively 
inhibits ABCB1 localized on the apical surface of renal tubular epithelial cells 43 thereby 
limiting ABCB1-mediated renal parent drug secretion. Again, (the effect of) renal ABCB1-
inhibition seems most pronounced shortly after ketoconazole administration. However, 
ketoconazole-mediated ABCB1-inhibition was not marked enough to affect the cumulative 
urinary elimination of docetaxel. 
The mass balance for cumulative parent drug excretion was increased upon 
concomitant ketoconazole administration, yet not as marked as one may have expected, due 
to the discussed influence of concomitant intestinal ABCB1-inhibition. The mass balance for 
the fraction of recovered radioactivity, although lower in the presence of ketoconazole, did 
not differ significantly between the two courses, due to above-mentioned reasons. 
To our knowledge, the faecal and urinary excretion of docetaxel has not previously 
been evaluated as function of genotype. As our patient group was limited in size we only 
tentatively correlated parent drug excretion (in the absence of ketoconazole) to genotype. The 
mean cumulative faecal excretion for patients carrying the ABCB1 T/T genotype was more 
than 3-fold that observed for the (single) patient with the C/C genotype which is consistent 
with data suggesting higher expression of intestinal ABCB1 for the T/T genotype 44. 
Interestingly, the observed higher faecal excretion for homozygous variant allele carriers 
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(T/T) compared to the homozygous wild-type (C/C) patient is inversed for urinary excretion 
and could be a reflection of different ABCB1 3435C>T expression among tissues 44,45. 
We are aware of several limitations in our study; (1) the number of patients was 
limited, especially the sub-group administered [3H]-radiolabelled docetaxel, yet more than in 
previous excretion studies using radiolabelled docetaxel 15; (2) specimens were collected up 
to 72 hours post-infusion, the period of hospital admission; ideally specimens should be 
collected up to 7 days post-infusion yet this poses practical and logistical difficulties; (3) 
although patients consented to collection of all faecal and urinary specimens, it is possible 
that collection is not complete; (4) we did not analyse the faecal and urinary excretion of the 
major metabolites due to unavailability of reference compounds and (5) it is likely that by 
assuming that 1 gram unhomogenized faeces is equivalent to 1 mL, we have underestimated 
the cumulative faecal excretion. However, despite these limitations, this study has further 
elucidated the elimination pathways of docetaxel. Moreover, to the best of our knowledge, for 
the first time faecal and urinary excretion of docetaxel was evaluated after temporarily 
inhibiting the drug’s major route of inactivation. 
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Abstract 
Background: To date, data regarding the potential of cannabinoids to modulate 
cytochrome P450 (CYP) isozyme 3A activity are contradictory. Recently, a standardized 
medicinal cannabis product (variety Bedrocan®), was introduced in The Netherlands. We 
anticipated an increased use of medicinal cannabis concurrent with anticancer drugs, and 
undertook a drug-interaction study to evaluate the effect of concomitant medicinal cannabis 
on the pharmacokinetics of irinotecan and docetaxel, both subject to CYP3A-mediated 
biotransformation. 
Methods: Twenty-four cancer patients were treated intravenously with irinotecan (600 
mg, N = 12) or docetaxel (180 mg, N = 12), followed three weeks later by the same drugs 
concomitant with medicinal cannabis (200 mL herbal tea, 1 g/L) for 15 consecutive days, 
starting 12 days before the second treatment. Blood samples were obtained up to 55 hours 
after dosing and analysed for irinotecan and its metabolites (SN-38, SN-38G) and docetaxel. 
Pharmacokinetic analyses were performed during both treatments. Results are reported as the 
mean ratio (95 % confidence interval, CI) of the observed pharmacokinetic parameters with 
and without concomitant medicinal cannabis. 
Results: Medicinal cannabis administration did not significantly influence exposure 
to, and clearance of irinotecan (1.04; CI = 0.96 – 1.11 and 0.97; CI = 0.90 – 1.05, 
respectively) or docetaxel (1.11; CI = 0.94 – 1.28 and 0.95; CI = 0.82 – 1.08, respectively).  
Conclusion: Coadministration of medicinal cannabis, as herbal tea, in cancer patients 
treated with irinotecan or docetaxel does not significantly influence the plasma 
pharmacokinetics of these drugs. The evaluated variety of medicinal cannabis can be 
administered concomitantly with both anticancer agents without dose adjustments. 
 
Introduction 
For the past 4,000 years 1, patients and doctors of each era have resorted to cannabis 
when conventional treatments were ineffective or lacking 2,3. Indeed, in oncology beneficial 
effects have been reported for cancer-associated anorexia, (delayed) chemotherapy-induced 
nausea and vomiting, and palliation 4-8. However, largely due to the lack of well designed 
clinical trials, much controversy remains regarding the claimed benefits 9. 
The only FDA-approved medicinal cannabis products are an oral formulation 
containing dronabinol (Marinol®; Solvay Pharmaceuticals Inc, Marietta, GA, USA), the 
synthetic version of delta9-tetrahydrocannabinol (THC), the main pharmacologically active 
cannabinoid 10 and capsules containing nabilone, an analogue of dronabinol (Cesamet®, 
Valeant Pharmceuticals Int., Costa Mesa, CA, USA). In Canada, where seriously ill patients 
can apply for medicinal cannabis under the Canadian Marihuana Medical Access 
Regulations, the government licensed the prescription sale of an oromucosal spray called 
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Sativex® (GW Pharm Ltd, Salisbury, United Kingdom) containing both THC and cannabidiol 
(CBD) in April 2005. However, many patients claim (subjectively), that a whole or partially 
purified extract of Cannabis sativa L. offers advantages over a single isolated ingredient 10-12. 
In The Netherlands, the unavailability of a legal product forced patients to frequent 
‘coffeeshops’, which, although not prosecuted according to the Dutch soft-drugs policy, 
remain illegal. In September 2003, in order to stimulate the conduct of representative clinical 
trials evaluating the safety and efficacy of medicinal cannabis, while simultaneously offering 
patients access to a prescription product meeting pharmaceutical quality standards 
(standardized content; free of microbiological impurities) 13, a legal medicinal cannabis 
product was introduced in The Netherlands 14. However, as it is not an officially registered 
drug, pharmacokinetic drug-interactions have not been evaluated as recommended for new 
drug applications 15. Yet it has previously been shown that pharmacokinetic drug-
interactions, also with herbal products (increasingly used by cancer patients) 16,17, can result 
in under- or overdosing 18-20. 
Cannabinoids appear able to modulate the catalytic activity of several hepatic 
cytochrome P450 (CYP) isozymes, including isozyme 3A, responsible, in part, for the 
metabolism of 37 % of all currently FDA-approved anticancer drugs 21. The majority of in 
vitro and animal data suggest an inhibitory effect on CYP3A-mediated metabolism 22-25, yet 
induction of CYP3A has been observed after repeated administration 26,27. In vivo data are 
also contradictory; both CYP3A inhibition 28 and induction 29 have been reported. Moreover, 
clinical drug-interaction studies adequately assessing the effect of medicinal cannabis on the 
pharmacokinetics of concomitantly administered (anticancer) drugs are absent 30,31. 
We anticipated that the introduction of a legal cannabis product in The Netherlands 
would result in increased use of medicinal cannabis concomitant with cytotoxic drugs, many 
of which are highly toxic and characterized by narrow therapeutic windows. The postulated, 
albeit contradictory, effects of cannabinoids on CYP3A function and the absence of clinical 
drug-interaction studies, led us to initiate a drug-interaction study to assess the influence of 
medicinal cannabis on the pharmacokinetics of the anticancer drugs irinotecan and docetaxel, 
both CYP3A-substrates 32,33. We here report on the plasma pharmacokinetics of irinotecan 
and docetaxel after intravenous infusion to cancer patients, with and without concomitant oral 
medicinal cannabis administration. 
 
Patients and methods 
Patients and treatment 
Patients were eligible if they had a histologically or cytologically confirmed diagnosis 
of (metastatic) cancer for which irinotecan or docetaxel was considered an adequate option, 
which was refractory to conventional treatment or for which there was no standard regimen. 
Eligibility criteria were identical to those documented elsewhere 20,34. In addition, patients 
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with a history of, or current cannabis use were not eligible. The protocol was approved by the 
Institutional Review Board of the Erasmus MC and written informed consent was obtained 
from all patients prior to study entry. 
The primary study endpoint was a measurable effect of medicinal cannabis on the 
plasma pharmacokinetics of irinotecan and its metabolites SN-38 and SN-38-glucuronide 
(SN-38G) or on docetaxel plasma pharmacokinetics. Based on the assumption that the 
within-patient standard deviation of the response variable (i.e. irinotecan or docetaxel 
pharmacokinetic parameters) for two measurements is 0.2 (20 %), a power (1-β) of 0.9 (90 
%), a clinically relevant difference of 30 %, and a two-sided significance level of 0.05 (5 %), 
a sample size of (at least) twelve patients per treatment-arm (i.e. irinotecan or docetaxel) was 
required in a paired two-sided analysis 35. It was assumed that the interval between the two 
treatments was an adequate washout period, with no carryover effects. 
Patients meeting eligibility criteria received their first treatment of either irinotecan, 
as a 90-minute intravenous (i.v.) infusion or docetaxel, as a 1-hour i.v. infusion, at a fixed 
dose of 600 mg or 180 mg, respectively, followed three weeks later by a second treatment of 
the same drug in combination with medicinal cannabis. The decision to administer a fixed 
dose instead of a body surface area (BSA)-based dose, was based on analyses demonstrating 
that BSA-based dosing does not substantially decrease interindividual variability in drug 
clearance for these two drugs 36-39. For the second treatment, the first three patients were 
dosed irinotecan and docetaxel at 75 % (450 mg and 135 mg, respectively), after which a 
protocol-scheduled safety interim-analysis, including a pharmacokinetic analysis, was 
performed to determine if subsequent dose adjustments were necessary. If no clinically 
relevant 40,41 pharmacokinetic interaction or increased haematological toxicity was observed, 
the following nine patients were to be administered the same dose as in the first treatment. 
Dose reductions for the second treatment were allowed and based on the worst toxicity 
observed during the previous treatment. 
Irinotecan (Campto®, Pfizer, Capelle aan den IJssel, The Netherlands) and docetaxel 
(Taxotere®, Sanofi-Aventis, Gouda, The Netherlands) were diluted in 250 mL 0.9 % (wt/vol) 
sodium chloride prior to drug administration. Patients received oral and written instructions 
to prepare the medicinal cannabis (Cannabis Sativa L. Flos, variety Bedrocan®, Office for 
Medicinal Cannabis, The Hague, The Netherlands) containing 18 % THC and 0.8 % CBD, as 
200 mL herbal tea (1 g/L), and to administer it once daily in the evening 26 at home, for a 
total of 15 consecutive days as recommended 15, starting on day 10 of the first treatment. 
During both treatments, patients administered irinotecan received granisetron (1 mg i.v.) and 
dexamethasone (10 mg i.v.) 30 minutes prior to chemotherapy. Atropine (0.25 mg) was 
administered subcutaneously as treatment or prophylaxis for irinotecan-induced acute 
cholinergic syndrome. To prevent allergic reactions and oedema, for patients treated with 
docetaxel, premedication consisted of dexamethasone (8 mg, orally) given twice daily for 
three consecutive days, starting on the evening before docetaxel infusion. 
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During both treatments, physical examination, toxicity assessment 42, a complete 
blood count with differential and serum chemistry tests, including creatinine, alkaline 
phosphatase, aspartate aminotransferase, alanine aminotransferase, total bilirubin, and 
albumin were performed weekly. 
 
Pharmacokinetic analyses  
Irinotecan, its metabolites (SN-38, SN-38G) and docetaxel pharmacokinetic analyses 
were performed during both treatments. For irinotecan and docetaxel pharmacokinetics blood 
samples (approximately 7 mL in lithium-heparinized tubes) were collected up to 54 and 47 
hours after end of infusion, respectively, according to previously published sampling 
strategies 18,43. All samples were processed to plasma by centrifugation for 10 minutes at 
3,000 g (4 °C), and stored at –80 °C until analysis. Irinotecan and its metabolite 
concentrations were determined by validated assays based on reversed-phase high-
performance liquid chromatography (HPLC) with fluorescence detection 44,45. Docetaxel 
plasma concentrations were determined using HPLC with tandem mass-spectrometric 
detection 46. 
Based on a previously developed population model 47, and the observed individual 
plasma concentrations, individual pharmacokinetic parameter estimates for irinotecan and its 
metabolites were obtained by Bayesian (POSTHOC) analysis using non linear mixed-effect 
modelling implemented in the NONMEM software program (double precision, version V; 
level 1.1) 48. The area under the plasma concentration-time curve (AUC) was simulated for 
irinotecan and its metabolites from time 0 to 100 hours, to 500 hours, and to infinity after 
start of infusion for both treatments. (Metabolic) Clearance was defined as dose divided by 
AUC. Metabolic ratios, that is the relative extent of conversion (REC; AUC0-100 ratio of SN-
38 to irinotecan) and the relative extent of glucuronidation (REG; AUC0-100 ratio of SN-38G 
to SN-38) were calculated based on individual Bayesian predicted AUC values. 
For docetaxel, individual pharmacokinetic parameters were estimated using model 
dependent methods implemented in WinNonLin 4.0 (Pharsight, CA, USA). Concentration-
time data were fit with a three-compartment model with reciprocal squared prediction 
weighting. Model adequacy was guided by inspection of the coefficient of variation of the 
fitted pharmacokinetic parameters, and by the Akaike information criteria 49. Maximum 
plasma concentrations were obtained from the model-estimated plasma concentration at the 
end of infusion. Calculated secondary parameters included systemic exposure (AUC), total 
systemic clearance, half-life during the terminal phase of the disposition curve, and 
(apparent) volume of distribution. 
 
Cannabis screening 
A urine sample was collected just before start of the second treatment and stored at –
80 ºC until analysis. Samples were screened semi-quantitatively (i.e. results are reported as 
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‘positive’ that is above, or ‘negative’ that is below the threshold level of 50 µg/L) for 
presence of the primary urinary metabolite of orally ingested THC (11-nor-THC-9-carboxylic 
acid) using a validated cannabinoids assay (TDx/FLx® Cannabinoids assay, Abbott® 
Laboratories, IL, USA). The presence of cannabinoids and/or metabolite(s) in urine indicates 
previous cannabis exposure 50. 
 
Statistics 
All parameter estimates are reported as mean values with 95 % confidence intervals 
(CIs) in parenthesis unless stated otherwise. The difference in irinotecan and docetaxel 
pharmacokinetic parameters between the first and second treatment was evaluated by 
calculating 95 % CIs for the geometric mean ratios of the observed pharmacokinetic 
parameters in the presence and absence of medicinal cannabis (e.g. 95 % CI for ratio 
CLtreatment2 : CLtreatment1) 51. CIs for the geometric mean ratio provide an estimate of the 
distribution of the observed systemic exposure measure ratio of substrate and interacting drug 
vs substrate alone and convey a probability of the magnitude of the interaction. The 
difference in haematological toxicity for the two treatments was evaluated statistically using 
non-parametric two-tailed, Wilcoxon signed rank tests for paired observations, and the 
significance level was set at P < 0.05. Statistical calculations were performed with SPSS, 
version 11.5 (Chicago, IL, USA). 
 
Results 
Patient accrual  
For both the irinotecan- and docetaxel treatment-arm, twelve patients completed two 
treatments, did not use comedication and/or dietary supplements known to modulate CYP3A-
function, took their medicinal cannabis as prescribed (based on cannabis screening, patient 
oral declaration and patient treatment-diaries) and were evaluable for irinotecan and 
docetaxel pharmacokinetic analyses, respectively. Table 1 lists a summary of the baseline 
characteristics of the twelve patients in both treatment groups. 
 
Irinotecan treatment and pharmacokinetics  
All patients were administered 600 mg irinotecan during the first treatment. Two 
patients enrolled after the interim analysis, which did not demonstrate a substantial change in 
irinotecan pharmacokinetics or increased haematological toxicity, also received a reduced 
second irinotecan-dose due to toxicity, i.e. grade 3 diarrhoea (450 mg) and grade 3 liver 
function abnormalities (300 mg), respectively. All other patients (N = 7) were administered 
600 mg during the second treatment. 
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Table 1. Baseline patient characteristics (N = 12 per treatment arm) 
Characteristic Irinotecan Docetaxel 
Age (years) 58 (27 – 66) 55 (40 – 67) 
Sex   
Male 7 7 
Female 5 5 
Body-surface area (m2) 1.90 (1.56 – 2.20) 1.78 (1.50 – 2.16) 
WHO performance status 1 (0 – 1) 1 (0 – 1) 
Tumour type   
Pancreas 5 1 
Breast –  4 
Melanoma – 3 
Head & Neck – 2 
ACUP 2 – 
Lung 1 1 
Gastric 1 1 
Other  3 – 
Haematology   
WBC (x 109/L) 7.4 (4.4 – 13.5) 6.5 (4.3 – 15.6) 
ANC (x 109/L) 4.9 (2.1 – 11.2) 4.2 (2.8 – 14.5) 
Platelets (x 109/L) 233 (116 – 447) 293 (144 – 620) 
Haemoglobin (mmol/L) 8.2 (5.8 – 9.3) 8.2 (6.6 – 10.5) 
Clinical Chemistry   
ASAT (U/L) 16 (31 – 104) 30 (14 – 64) 
ALAT (U/L) 10 (35 – 133) 21 (12 – 65) 
Alk Phos (U/L) 66 (109 – 323) 96 (61 – 401) 
Total Bilirubin (µmol/L) 8 (4 – 21) 7 (3 – 25) 
Total Protein (g/L) 75 (66 – 88) 64 (48 – 80) 
Serum Albumin (g/L) 42 (29 – 45) 39 (32 – 48) 
Serum Creatinine (µmol/L) 63 (51 – 88) 64 (48 – 80) 
Serum AAG (g/L) 1.41 (0.74 – 2.84) 0.71 (0.47 – 2.16) 
 
Abbreviations: WHO, World Health Organization; ACUP, adeno carcinoma of unknown primary; 
WBC, white blood cell count; ANC, absolute neutrophil count; ASAT, aspartate aminotransferase; 
ALAT, alanine aminotransferase; Alk Phos, alkaline phosphatase; AAG, alpha-1 acid-glycoprotein. 
Values are given as median with range in parentheses (except for sex and tumour type). 
 
Upon concurrent medicinal cannabis use, irinotecan clearance and dose-normalized 
AUC were not significantly affected, as reflected by the geometric mean ratios and the 
corresponding 95 % CIs for both parameters being 0.97 (0.90 – 1.05) and 1.04 (0.96 – 1.11), 
respectively. Similarly, metabolic clearance and dose-normalized AUC of SN-38 and SN-
38G were not significantly changed. Table 2 summarizes the pharmacokinetic parameters for 
irinotecan with and without concomitant medicinal cannabis administration. The mean (N = 
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12) irinotecan, SN-38 and SN-38G plasma concentration-time curves for both treatments 
furthermore illustrate the similarity between the two treatments (Figure 1). 
 
Table 2. Irinotecan pharmacokinetic parameters (N = 12) in the absence (–) and presence (+) 
of medicinal cannabis 
Parameter1 Cannabis – Cannabis + Ratio2 
Absolute dose (mg) 600   525 (461 – 589)3 NA  
Irinotecan    
CL (L/h) 29.3 (23.8 – 34.7) 28.4 (22.7 – 34.0) 0.97 (0.90 – 1.05) 
AUC0-inf4 (ng.h/mL) 22,825 (17,141 –28,509) 23,644 (17,703 –29,932) 1.04 (0.96 – 1.11) 
SN-38    
CL (L/h) 400 (330 – 469)  341 (290 – 392) 0.90 (0.74 – 1.05) 
AUC0-1004 (ng.h/mL) 422 (325 – 519) 448 (364 – 532) 1.11 (0.98 – 1.23) 
SN-38G    
CL (L/h) 53.7 (36.6 – 70.9) 45.8 (30.4 – 61.2)  0.93 (0.74 – 1.12) 
AUC0-1004 (ng.h/mL) 3,837 (2,217 – 5,457) 4,101 (2,385 – 5,818) 1.10 (0.94 – 1.26) 
Relative AUCs    
REC (%) 1.95 (1.48 – 2.41) 2.04 (1.58 – 2.49) 1.07 (0.94 – 1.20) 
REG 7.39 (5.30 – 10.93) 6.90 (5.40 – 10.28) 0.98 (0.87 – 1.09) 
 
Abbreviations: Cannabis –, medicinal cannabis absent; Cannabis +, medicinal cannabis present; CL, 
clearance; AUC, area under the plasma concentration-time curve; 0-inf AUC extrapolated to infinity; 0-
100, AUC up to 100 hours; NA, not applicable; REC, relative extent of conversion (AUC0-100 SN-38 
over AUC0-100 irinotecan); REG, relative extent of glucuronidation (AUC0-100 SN-38G over AUC0-100 
SN-38). 1Values are reported as mean with 95 % confidence intervals in parentheses; 2Geometric 
mean ratios of the observed pharmacokinetic parameters with medicinal cannabis and without 
medicinal cannabis, a significant difference exists when the value 1.00 is not included within the 95 % 
confidence interval; 3Four patients received a reduced dose of 450 mg (75 %), and one of 300 mg (50 
%); 4Dose-normalized to 600 mg. 
 
Docetaxel treatment and pharmacokinetics  
In the absence of medicinal cannabis, all patients were administered 180 mg 
docetaxel. In the presence of medicinal cannabis, three patients, enrolled after the interim-
analysis, which did not demonstrate a substantial change in docetaxel pharmacokinetics or 
increased haematological toxicity, also received a reduced dose (135 mg) due to treatment-
related haematological toxicity (leukopenia and neutropenia grade 4). Table 3 summarizes the 
pharmacokinetic parameters for docetaxel with and without concomitant medicinal cannabis 
administration. 
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Table 3 Docetaxel pharmacokinetic parameters (N = 12) in the absence (–) and presence (+) 
of medicinal cannabis 
Parameter1 Cannabis – Cannabis + Ratio2 
Absolute dose (mg) 180   158 (143 – 172)3 NA 
CL (L/h) 40.4 (35.4 – 45.5) 37.9 (31.7 – 44.2) 0.95 (0.82 – 1.08) 
AUC4 (ng.h.mL-1.mg-1) 25.7 (22.2 – 29.2) 28.3 (22.9 – 33.7) 1.11 (0.94 – 1.28) 
Cmax4 (ng/mL.mg-1) 17.8 (15.7 – 20.0) 19.5 (15.8 – 23.2) 1.10 (0.94 – 1.27) 
Vss (L) 304 (250 – 358) 359 (264 – 454) 1.18 (0.94 – 1.43) 
T1/2, γ (h) 22.0 (17.9 – 26.1) 26.7 (21.3 – 32.2) 1.24 (1.00 – 1.48) 
 
Abbreviations: Cannabis –, medicinal cannabis absent; Cannabis +, medicinal cannabis present; CL, 
clearance; AUC, area under the plasma concentration-time curve; Cmax, peak plasma concentration; 
Vss, apparent volume of distribution; T1/2, γ, terminal elimination half-life; NA, not applicable. 1Values 
are reported as mean with 95 % confidence intervals in parentheses; 2Geometric mean ratios of the 
observed pharmacokinetic parameters with medicinal cannabis and without medicinal cannabis, a 
significant difference exists when the value 1.00 is not included within the 95 % confidence interval; 
3Six patients were administered a reduced dose of 135 mg (75 %); 4Dose-normalized, i.e. divided by 
dose. 
 
Upon concurrent medicinal cannabis use docetaxel clearance and dose-adjusted AUC 
were not significantly affected, as reflected by the geometric mean ratios and the 
corresponding 95 % CIs for both parameters being 0.95 (0.82 – 1.08) and 1.11 (0.94 – 1.28), 
respectively. Furthermore, for both parameters, interpatient variability, expressed as 
coefficient of variation, was only marginally increased in the presence of medicinal cannabis 
(from 20 % to 26 % and from 21 % to 30 %, respectively), yet within previously reported 
ranges 52,53. The mean (N = 12) docetaxel plasma concentration-time curves for both 
treatments illustrate the similarity between the two treatments (Figure 2). 
 
Cannabis screening 
All urine samples tested ‘positive’ for cannabinoids and/or metabolites. Although this 
is no definite confirmation of patient adherence, we have no reason to believe that patients 
did not take their medicinal cannabis as prescribed, which could explain the lack of a 
pharmacokinetic drug-interaction. 
 
Toxicity  
For both drug treatments, haematological toxicity was the predominant side-effect. 
Upon concurrent medicinal cannabis use, the relative haematological toxicity (expressed as 
percentage decrease in white blood cell count (WBC) and percentage decrease in absolute 
neutrophil count (ANC), at nadir compared to baseline) in those patients who received full 
dose docetaxel (180 mg) during both treatments (N = 6) was not significantly affected,
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Figure 1. Mean (95 % confidence interval, N = 12) plasma concentrations of irinotecan (dose 600 
mg) in the absence (solid line, closed symbols and error bars) and presence (dose-normalized to 600 
mg, dashed line, open symbols and error bars) of medicinal cannabis. Triangles, diamonds and 
circles represent concentrations of irinotecan, SN-38G, and SN-38, respectively. 
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Figure 2. Mean (95 % confidence interval, N = 12) plasma concentrations of docetaxel (dose 180 
mg) in the absence (solid line, closed symbols and error bars) and presence (dose-normalized to 180 
mg, dashed line, open symbols and error bars) of medicinal cannabis. 
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mean values (95 % confidence interval) for the first and second treatment being 82.6 % (75.2 
– 90.1 %) vs 80.6 % (73.2 – 88.0 %) and 91.3 % (85.7 – 96.8 %) vs 92.0 % (87.4 – 96.5 %), 
respectively (P = 0.75, Table 4). Patients treated with full-dosed irinotecan (600 mg) during 
both treatments (N = 7) showed a smaller percentage decrease in WBC, 38.8 % (20.2 – 57.4 
%) vs 23.5 % (11.1 – 35.8 %) and ANC, 44.4 % (22.0 – 66.7 %) vs 25.4 % (10.9 – 40.0 %) 
during the second treatment (P < 0.04, Table 4). However, the nadir values for WBC and 
ANC were identical for both treatments being 4.8 x 109/L (3.1 – 6.4 x 109/L) vs 4.6 x 109/L  
(3.6 – 6.0 x 109/L) and 3.0 x 109/L (1.91 – 4.0 x 109/L) vs 2.9 x 109/L (1.91 – 3.9 x 109/L), 
respectively, P > 0.60). 
For each treatment-arm the incidence and severity of non-haematological toxicities 
(irinotecan: fatigue, nausea, vomiting and diarrhoea; docetaxel: fatigue, increased hepatic 
transaminases and bilirubin) appeared similar between the first and second treatment, 
although the small number of patients and low incidence precluded statistical evaluation. 
Patients tolerated the medicinal cannabis tea well, the majority of patients indicated to sleep 
better and only a minority complained of minor headaches, mood disturbances or weird 
dreams. 
 
Discussion 
Our study shows that medicinal cannabis (variety Bedrocan®), ingested as herbal tea 
during 15 consecutive days, starting 12 days before intravenous administration of irinotecan 
or docetaxel, two anticancer drugs for which CYP3A is a major route of metabolism, does 
not influence the systemic pharmacokinetics, and does not negatively affect the 
haematological toxicity of these drugs. Furthermore, besides being inactivated by CYP3A, 
irinotecan is subject to carboxylesterase-mediated activation resulting in SN-38. SN-38 is 
subsequently detoxified in the liver to its glucuronide SN-38G by UDP 
glucuronosyltransferase 1A isoforms, in particular UGT1A1 54. Since both exposure to, and 
clearance of SN-38 and SN-38G, as well as the metabolic ratios for these two irinotecan 
metabolites were equal for the first and second treatment, it seems unlikely that the evaluated 
variety of medicinal cannabis affects these enzyme systems. We have no indications that 
patients were non-adherent, which could have explained the lack of a drug-interaction. 
Several aspects regarding the observed lack of a (statistically) significant and 
clinically relevant effect of medicinal cannabis on the pharmacokinetics of irinotecan and 
docetaxel require attention. Firstly, our conclusions apply specifically to the investigated 
medicinal cannabis variety. In The Netherlands, currently medicinal cannabis is available in 
two varieties (Bedrocan® and Bedrobinol®), both containing a standardized content of THC 
(18 % and 13 %, respectively) and CBD (0.8 % and 0.2 %, respectively). At present, there are 
plans to introduce a third variety with a significantly higher content of CBD, claimed to be 
beneficial for syndromes associated with spasticity. 
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To what extent a higher exposure to CBD, recently shown to inhibit the transporter protein 
ABCB1 (P-glycoprotein) in vitro 55 influences the pharmacokinetics of concomitantly 
prescribed drugs, remains to be investigated. Although it was anticipated that the availability 
of medicinal cannabis in Dutch pharmacies would decrease the need to resort to 
‘coffeeshops’ more than 80 % of the patients still frequent the illegal circuit 56. The high price 
in pharmacies, complaints of decreased effectiveness, and the hesitation of physicians to 
prescribe medicinal cannabis seem to be the major reasons underlying this finding. Since our 
conclusions do not apply to ‘illegal products’, oncologists should recommend patients who 
wish to use cannabis for medicinal purposes, to resort to prescription-based, legally produced 
cannabis instead of cannabis of unknown origin and quality. 
Secondly, the evaluated dose is the initial recommended dose, which may be 
increased according to an individual’s need. Again, it is possible that a higher cannabinoid 
exposure might yet result in an undesirable drug-interaction. Thirdly, we have evaluated 
orally administered medicinal cannabis. An alternative recommended route of administration 
is inhalation 15. Due to extensive first-pass metabolism and high lipid solubility only 10 % to 
20 % of orally administered THC reaches the systemic circulation unchanged 57. In contrast, 
up to 50 % of THC can be absorbed from the lungs, resulting in higher systemic exposure. 
From our data, we cannot draw justified conclusions regarding the potential effects of inhaled 
medicinal cannabis on the pharmacokinetics of concomitantly administered irinotecan and 
docetaxel or other (anticancer) drugs. 
The lower percentage decrease in WBC and ANC in patients administered irinotecan 
concomitant with medicinal cannabis, observed in our exploratory evaluation, is not on 
forehand attributable to a pharmacodynamic interaction given the fact that nadir values of 
WBC and ANC were almost identical for both treatments, yet is most likely to be of multi-
factorial origin or related to the limited sample size. Indeed, the study was not designed to 
detect statistically significant differences in pharmacodynamic parameters. Furthermore, the 
observed differences do not translate in different grades of neutropenia 42. 
Despite the low prescription rate of legal medicinal cannabis, there remains a need for 
clinical trials to evaluate the efficacy and safety of medicinal cannabis for specific indications 
and in combination with other drugs with a narrow therapeutic index, as well as research into 
adequate dosage forms. If, in the mean time, cancer patients wish to use medicinal cannabis 
(variety Bedrocan®, orally administered as recommended) concomitantly with irinotecan or 
docetaxel or other drugs primarily detoxified by CYP3A, we do not recommend any dose 
adjustments a priori. 
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Summary, Conclusions and Future Perspectives 
 
Summary and Conclusions 
Since clinical evaluations started in the early nineties, the anticancer drug docetaxel 
has obtained a prominent place in the treatment of various human malignancies. Marketing 
approval currently includes the treatment of patients with breast cancer, non-small-cell lung 
cancer, androgen-independent prostate cancer (AIPC) and patients with advanced gastric 
cancer. Following initial introduction much research has focused on docetaxel’s clinical 
pharmacological properties in an attempt to improve the risk-benefit ratio for docetaxel 
treatment. In particular, reducing the substantial degree of interindividual variability in 
docetaxel pharmacokinetics, which is associated with the observed variability in toxicity, is 
an aspect, which has received much attention. 
 
Chapter 2 provides an overview of research, which has focused on various 
pharmacological approaches, including reducing interindividual pharmacokinetic and 
pharmacodynamic variability, optimizing schedule and route of administration, reversing 
drug resistance and the development of structurally related second-generation taxanes, in an 
attempt to overcome current limitations associated with docetaxel treatment and to improve 
treatment outcome. 
 
Chapter 3 compares the efficacy and toxicity of the currently recommended 
treatment schedule based on intravenous docetaxel infusion once every 3 weeks (3-weekly) to 
the regimen involving weekly docetaxel administrations. Efficacy appears similar for the two 
schedules, while weekly docetaxel is significantly less myelotoxic. However, this benefit 
comes at the cost of more hyperlacrimation, cumulative skin- and nail toxicity and negatively 
affects quality of life. Currently, 3-weekly docetaxel remains the standard schedule whereas 
the weekly schedule offers a possibility of treatment individualization for those patients 
where the risk of severe myelosuppression is considered unacceptable. 
 
Chapter 4 documents research focused on the development of less toxic, solvent-free 
formulations for the delivery of docetaxel, while continuing to maximize the drug’s 
antitumour efficacy through preferential uptake of the drug at the tumour. This 
pharmaceutical strategy has lead to several alternative, solvent-free drug formulations 
including fibrinogen-coated olive oil droplets loaded with docetaxel, PEGylated docetaxel 
liposomes, docetaxel immunoliposomes, and docetaxel-encapsulated nanoparticle-aptamer 
bioconjugates, which are all currently in different preclinical stages of development, and with 
different advantages and disadvantages. Whether the observed advantages (improved 
pharmacokinetics, selective tumour uptake, increased survival) over the current docetaxel 
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formulation translate to clinical benefits remains to be seen. Clinical evaluations with a 
submicronic polysorbate-80 free dispersion formulation of docetaxel are limited to two phase 
I studies. However, based on toxicity considerations the development of this formulation was 
discontinued. 
 
In Chapter 5 the effect of the potent cytochrome P450 (CYP) 3A inhibitor 
ketoconazole on the pharmacokinetics of docetaxel was investigated. This drug combination 
is currently being evaluated for the treatment of patients with AIPC. Concomitant 
administration of a drug that inhibits the activity of CYP3A, responsible for the metabolism 
of docetaxel, has the potential to result in undesirable clinical consequences. Indeed, a 50 % 
decrease in docetaxel clearance has been shown to increase the odds of developing grade 4 
neutropenia and febrile neutropenia 4.3-fold and 3-fold, respectively. Concomitant 
ketoconazole reduced docetaxel clearance by 49 % (P = 0.018, N = 7). Mean (± SD) 
clearance values were 35.0 L/h (± 11.8 L/h) and 18.2 L/h (± 9.68 L/h) in the absence and 
presence of ketoconazole, respectively. The range for the degree to which docetaxel clearance 
was reduced was 32 – 74 % indicating substantial interindividual variability. Furthermore, the 
extent to which docetaxel clearance was reduced was weakly related to systemic 
ketoconazole exposure. Overall, this report shows that substantial dose reductions are 
required when docetaxel is administered with potent CYP3A inhibitors. 
 
Variable response (efficacy and toxicity) to docetaxel-based treatment is presumed to 
be largely related to interindividual variation in docetaxel pharmacokinetics, notably in the 
pharmacokinetic parameters systemic drug exposure and clearance. Moreover, phenotypic 
expression of CYP3A activity has been identified as a strong predictor of docetaxel clearance 
and observed variation in (intrinsic) CYP3A activity has been suggested to account to a large 
extent for the significant interindividual variability in docetaxel pharmacokinetics. The aim of 
the study presented in Chapter 6 was to reduce the interindividual variability in docetaxel 
systemic exposure and clearance in an attempt to improve the risk-benefit ratio for docetaxel 
therapy. It was hypothesized that by temporarily eliminating the cause of variability, i.e. 
variable CYP3A catalytic activity, using the potent CYP3A inhibitor ketoconazole, 
interindividual variability in docetaxel systemic exposure and clearance could be reduced. 
The results reported in Chapter 5 showed that there was wide variation in the extent to which 
docetaxel clearance was reduced, and that the degree to which clearance was decreased, was 
related to systemic ketoconazole exposure. Furthermore, interindividual variability in 
clearance (expressed as coefficient of variation) was increased upon concomitant 
ketoconazole administration compared to single agent treatment (34 % vs 53 %). It was 
hypothesized that an increase in ketoconazole dose (compared to Chapter 5) would result in 
sufficiently high ketoconazole exposure in each patient and thus in maximum CYP3A-
inhibition overall, thereby reducing the variability in the extent to which docetaxel clearance 
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is reduced. Docetaxel clearance (mean ± SD) was reduced by 50 % from 32.8 L/h ± 13.7 L/h 
to 16.5 L/h ± 8.15 L/h (P = 0.018, N = 7) upon ketoconazole coadministration, albeit with 
large interindividual variability (range, 34 – 69 % reduction). In the presence of 
ketoconazole, interindividual variability in docetaxel clearance and systemic exposure, 
expressed as coefficient of variation, was increased from 41.6 % to 49.5 % and from 28.0 % 
to 35.1 %, respectively, and not, as hypothesized, reduced. In addition, it was assessed if part 
of the resulting interindividual variability in decrease of docetaxel clearance after 
ketoconazole treatment could be dependent on functional CYP3A4 and/or CYP3A5 genetic 
variants. None of the patients carried the CYP3A5*1 allele indicating that for each evaluated 
patient total CYP3A activity is solely attributable to CYP3A4. No patient carried any of the 
currently known, potentially clinically relevant CYP3A4 single nucleotide polymorphisms 
(SNPs). Thus, it is highly unlikely that genetic differences contributed to the observed 
interindividual variability in the decrease of docetaxel clearance. It was concluded that the 
evaluated approach is unsuitable as method to achieve a uniform docetaxel pharmacokinetic 
profile. 
 
In Chapter 7 the development and analytical method validation of a rapid and simple 
combustion method to quantify [3H]-docetaxel excreted in human faeces and urine is 
described. An important reason to administer a non-toxic tracer amount of radiolabelled drug 
to a patient is to quantify the drug in biological samples (e.g. faeces, urine, ascites) at 
concentrations below the lower limit of quantification for routinely used analytical 
techniques, often with the purpose of assessing a mass balance. Radiochemicals used in 
clinical research include [3H]- or [14C]-radiolabelled compounds and liquid scintillation 
counting is the most efficient method to quantify these low energy beta-emitters. However, 
most radiolabelled biological samples require extensive sample preparation to reduce 
quenching interference before quantification of radioactivity is possible. Combustion of 
tritiated faeces and urine samples is a simple, rapid, sensitive, precise and reproducible 
method with high recovery. It can be applied to quantify [3H]-docetaxel excretion after 
intravenous administration. 
 
In Chapter 8 the influence of ketoconazole on the faecal and urinary disposition of 
docetaxel parent drug and [3H]-docetaxel was explored. Besides being a potent CYP3A 
inhibitor, ketoconazole is also a weak to modest inhibitor of the transmembrane ATP-binding 
cassette efflux transporter protein ABCB1, for which docetaxel is also a substrate. The 
influence of ABCB1 on the plasma pharmacokinetics of docetaxel is minimal to absent 
however, ABCB1 plays a prominent role in the faecal elimination of docetaxel. Concomitant 
ketoconazole increased faecal parent drug excretion (mean ± SD of the administered absolute 
docetaxel dose) 2-fold from 2.6 % ± 2.8 % to 5.2 % ± 5.4 % (P = 0.03, N = 14) but did not 
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affect urinary parent drug excretion, which was 2.6 % ± 1.4 % and 2.6 % ± 1.1 % in the 
absence and presence of ketoconazole, respectively (P = 0.69, N = 15). The sum of faecal and 
urinary parent drug excretion was 5.3 ± 3.0% for docetaxel alone and 7.8 % ± 5.6 % in the 
presence of ketoconazole (P = 0.04, N = 14). Total recovered radioactivity values in the 
absence and presence of ketoconazole were 45.8 % ± 19.1 % and 32.4 % ± 19.7 % of the 
administered [3H]-docetaxel dose, respectively (P = 0.23, N = 5) which is as expected given 
the 72 hour interval post-infusion during which faecal and urinary samples were collected. It 
was hypothesized that a more pronounced increase in faecal parent drug excretion upon 
concomitant ketoconazole administration was not achieved most likely due to concomitant 
intestinal ABCB1-inhibition. 
 
The fact that docetaxel is primarily metabolized by CYP3A makes the agent subject 
to a host of enzyme-mediated drug-interactions. In September 2003 a standardized medicinal 
cannabis product (variety Bedrocan®) was introduced in The Netherlands. Beneficial effects 
attributed to medicinal cannabis have been reported for cancer-associated anorexia, (delayed) 
chemotherapy-induced nausea and vomiting, and palliation. As in vitro- and in vivo data 
regarding the potential of cannabinoids to modulate CYP3A activity are contradictory, a 
drug-interaction study was conducted in cancer patients (N = 24) to evaluate the effect of 
concomitant medicinal cannabis on the pharmacokinetics of irinotecan and docetaxel, both 
dependent on CYP3A-mediated metabolism (Chapter 9). Coadministration of medicinal 
cannabis, as herbal tea, did not significantly influence the plasma pharmacokinetics of 
docetaxel or irinotecan (P > 0.31). Docetaxel systemic exposure and clearance, reported as 
the mean ratio in the presence and absence of medicinal cannabis (95 % confidence interval) 
was 1.11 (0.94 – 1.28) and 0.95 (0.82 – 1.08), respectively indicating the lack of a clinically 
relevant drug-interaction. The evaluated variety of medicinal cannabis can be administered 
concomitantly with both anticancer agents without dose adjustments. 
 
Future Perspectives  
The work presented in this thesis aimed to optimize docetaxel-based treatment 
through a reduction of the interpatient pharmacokinetic variability and to further elucidate the 
role of CYP3A- and ABCB1-mediated elimination pathways for docetaxel. Both aims were 
based on purposeful modulation of the drug’s pharmacokinetic profile using ketoconazole, a 
potent CYP3A inhibitor and, to a lesser degree, also inhibitor of ABCB1. Reducing 
interindividual variability in docetaxel pharmacokinetics by temporarily inhibiting the source 
of the observed variability (i.e. variable CYP3A catalytic activity) has however not proved 
feasible. Indeed, upon concomitant ketoconazole administration, a substantial degree of 
interpatient pharmacokinetic variation was still present, and could not be accounted for by 
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variable systemic exposure to ketoconazole or genetic diversity in the genes encoding the 
CYP3A4 and CYP3A5 proteins. 
These disappointing findings led us to initiate several currently ongoing studies, 
which evaluate alternative approaches to optimize docetaxel treatment. Monitoring plasma 
levels and pharmacokinetic-guided individualized dose adjustments is most often referred to 
as ‘therapeutic drug monitoring’ (TDM). Although widely practised in other areas of 
medicine routine TDM is limited in oncology. Application of limited sampling strategies 
(typically requiring 2 to 4 samples to be collected on an outpatient basis) in combination with 
a population pharmacokinetic model and Bayesian analysis allows individual 
pharmacokinetic parameters to be accurately estimated, and makes TDM a potential approach 
for anticancer drugs. Indeed, the performance and feasibility of pharmacokinetic-guided 
dosing of paclitaxel was recently successfully evaluated. In our centre we are currently in the 
final stages of conducting a study (N = 30) which applies a limited sampling strategy and a 
previously developed population pharmacokinetic model, incorporating albumin, alpha-1 
acid-glycoprotein, age, body surface area and elevated hepatic function, to evaluate the 
feasibility and performance of pharmacokinetic-guided individualized docetaxel dosing. In 
addition, the same limited sampling strategy and population pharmacokinetic model are being 
applied to evaluate the relationship between docetaxel pharmacokinetics and potentially 
clinically relevant CYP3A4, CYP3A5 and ABCB1 single nucleotide polymorphisms (SNPs) 
in a large population study (current inclusion N > 100). A similar population study is also 
being conducted to evaluate the relationship between paclitaxel pharmacokinetics and 
relevant polymorphisms in the drug’s metabolizing enzymes (current inclusion N > 100). At 
present pharmacokinetic-pharmacogenetic studies aimed at determining the clinical relevance 
of different CYP3A4, CYP3A5 and ABCB1 variant alleles in relation to docetaxel 
pharmacokinetic variability or the pharmacokinetic variability of other CYP3A or ABCB1 
substrates and/or probes, have yielded controversial results, in part due to underpowered 
studies given the allele frequency of the potentially clinically relevant SNPs. 
In clinical oncology it is generally accepted that the efficacy of anticancer drugs 
depends on the maintenance of adequate unbound (i.e. pharmacologically active) drug 
concentrations at the target tissue, the tumour site. However, very little is known about 
intratumoural pharmacokinetics due to the fact that up until now unbound drug 
concentrations could rarely be (easily) measured at the site of action. For this reason in 
clinical pharmacokinetics one typically measures total parent drug concentrations (and/or 
metabolite concentrations) in a more accessible, surrogate site of action, plasma (blood). 
Total plasma drug concentrations are then correlated to clinical parameters such as drug 
efficacy and/or toxicity. Yet, the pharmacokinetic behaviour of drugs in tumour tissue may be 
completely different from the kinetics in plasma due to tissue- or tumour specific 
metabolizing enzymes. Thus, interpatient variability in drug response may be explained for 
by (wide) interpatient pharmacokinetic variability at the target site. Microdialysis is a 
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relatively novel and minimally invasive sampling technique based on the diffusion of (endo- 
and exogenous) analytes from the interstitial compartment through a semi-permeable 
membrane. We are currently evaluating the feasibility of microdialysis sampling to gain 
insight in the tissue- and tumour pharmacokinetics of docetaxel, and in docetaxel-induced 
intratumoural pharmacodynamic changes in cancer patients intravenously administered 
docetaxel once every 3 weeks. 
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Samenvatting en Conclusies 
Sinds klinische evaluaties begin jaren 90 begonnen, heeft het antikanker middel 
docetaxel een prominente plaats veroverd bij de behandeling van diverse vormen van kanker. 
Op dit moment is docetaxel geregistreerd voor behandeling van patiënten met borstkanker, 
niet-kleincellig longkanker, hormoon-ongevoelig prostaatkanker en maagkanker. In 
aansluiting op de initiële introductie, heeft veel klinisch onderzoek zich gericht op de klinisch 
farmacologische eigenschappen van docetaxel met als doel de balans tussen effectiviteit en 
toxiciteit te verbeteren. In het bijzonder vormt het reduceren van de aanzienlijke 
interindividuele variatie in docetaxel farmacokinetiek, welke gerelateerd is aan de interpatient 
variabiliteit in bijwerkingen, een belangrijk aandachtspunt. 
 
Hoofdstuk 2 levert een overzicht van het onderzoek dat zich gericht heeft op 
verschillende farmacologische invalshoeken, waaronder het reduceren van de interindividuele 
variatie in farmacokinetiek en farmacodynamiek, optimalisatie van toedieningsschema en 
route, terugdringen van geneesmiddelresistentie en de ontwikkeling van structuur 
gerelateerde tweede-generatie taxanen, met als doel de huidige beperkingen gerelateerd aan 
de behandeling met docetaxel te overwinnen en de therapie-uitkomst te verbeteren. 
 
Hoofdstuk 3 vergelijkt de effectiviteit en de toxiciteit van het aanbevolen 
toedieningsschema gebaseerd op intraveneuze infusie van docetaxel eens per 3 weken (3-
wekelijks) met het schema van wekelijkse docetaxel infusies. Effectiviteit lijkt vergelijkbaar 
te zijn voor de twee schema’s, terwijl wekelijks docetaxel aanzienlijk minder myelotoxisch 
is. Echter, dit voordeel gaat ten koste van een toename in overmatige traanafscheiding, 
cumulatieve huid- en nagel toxiciteit en heeft een negatief effect op de kwaliteit van leven. 
Op dit moment blijft 3-wekelijks docetaxel derhalve het standaard toedieningsschema, terwijl 
het wekelijks schema een mogelijkheid biedt voor individualisatie van de behandeling bij die 
patiënten waarbij de kans op ernstige beenmergsuppressie onacceptabel wordt geacht. 
 
Hoofdstuk 4 levert een overzicht van het onderzoek dat gericht is op het ontwikkelen 
van minder toxische, oplosmiddel-vrije formuleringen voor de toediening van docetaxel, 
waarbij tegelijkertijd getracht wordt de antitumor effectiviteit te verbeteren door specifieke 
opname van docetaxel ter plekke van de tumor. Deze farmaceutische aanpak heeft geleid tot 
verschillende alternatieve, oplosmiddel-vrije formuleringen van docetaxel waaronder, 
olijfolie druppels geladen met docetaxel en gecoat met fibrinogeen, gePEGyleerde docetaxel 
liposomen, docetaxel immunoliposomen, en aptameer bioconjugaat nanopartikels geladen 
met docetaxel, allen op dit moment in verschillende stadia van preklinische ontwikkeling en 
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met verschillende voor- en nadelen. Of de waargenomen voordelen (verbeterd 
farmacokinetisch profiel, selectieve tumor opname, toegenomen overleving) ten opzichte van 
de huidige docetaxel formulering zich ook vertalen in klinische voordelen moet nog worden 
afgewacht. Klinische evaluaties met een polysorbate-80 vrije formulering van docetaxel zijn 
beperkt tot twee fase I studies. Echter, de ontwikkeling van deze formulering is op basis van 
toxiciteitsoverwegingen gestaakt. 
 
In Hoofdstuk 5 is het effect van de sterk werkzame cytochroom P450 (CYP) 3A 
remmer ketoconazol op de farmacokinetiek van docetaxel onderzocht. Deze 
geneesmiddelcombinatie wordt thans onderzocht voor de behandeling van hormoon-
ongevoelig prostaatkanker. Gelijktijdige toediening van een (genees)middel dat de activiteit 
van CYP3A, verantwoordelijk voor het metabolisme van docetaxel, remt, kan leiden tot 
ongewenste klinische consequenties. Zo is aangetoond dat een 50 % afname in docetaxel 
klaring de kans op het ontwikkelen van graad 4 neutropenie of  neutropene koorts met een 
factor 4.3 respectievelijk 3 doet toenemen. Bij gelijktijdige toediening van ketoconazol werd 
de klaring van docetaxel met 49 % gereduceerd (P = 0.018, N = 7). De gemiddelde (± SD) 
docetaxel klaring was 35.0 L/h (± 11.8 L/h) en 18.2 L/h (± 9.68 L/h) in de af- respectievelijk 
aanwezigheid van ketoconazol. De spreiding in de mate waarin de klaring van docetaxel werd 
gereduceerd liep van 32 – 74 %, hetgeen wijst op aanzienlijke interindividuele variabiliteit. 
Bovendien was de mate waarin de klaring van docetaxel afnam gerelateerd aan de 
systemische blootstelling aan ketoconazol. Dit onderzoek laat zien dat een aanzienlijke dosis 
reductie vereist is als docetaxel gelijktijdig wordt toegediend met sterk werkzame CYP3A 
remmers. 
 
Er wordt verondersteld dat de variabele respons (effectiviteit en toxiciteit) op 
behandeling met docetaxel grotendeels gerelateerd is aan de interindividuele variatie in 
docetaxel farmacokinetiek, met name in de farmacokinetische parameters blootstelling en 
klaring. Bovendien is de fenotypische activiteit van CYP3A geïdentificeerd als een sterke 
voorspeller van docetaxel klaring en heeft men gesuggereerd dat de geobserveerde 
(intrinsieke) variatie in CYP3A activiteit voor een groot deel de aanzienlijke interindividuele 
variatie in docetaxel farmacokinetiek kan verklaren. Het doel van het onderzoek 
gepresenteerd in Hoofdstuk 6 was het reduceren van de interindividuele variabiliteit in 
docetaxel blootstelling en klaring in een poging de balans tussen effectiviteit en toxiciteit 
voor de behandeling te verbeteren. Als werk hypothese gold dat door tijdelijk de oorzaak van 
de variabiliteit, d.w.z. variabele CYP3A activiteit, te onderdrukken, middels de sterk 
werkzame CYP3A remmer ketoconazol, de interindividuele variabiliteit in docetaxel 
blootstelling en klaring zou kunnen worden gereduceerd. De resultaten gepresenteerd in 
Hoofdstuk 5 lieten zien dat er een aanzienlijke variatie was in de mate waarin docetaxel 
klaring werd gereduceerd en dat deze mate van reductie gerelateerd was aan de systemische 
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ketoconazol blootstelling. Bovendien was de interindividuele variabiliteit in klaring 
(uitgedrukt als variatie coëfficiënt) toegenomen als gevolg van ketoconazol toediening 
vergeleken met docetaxel monotherapie (34 % vs 53 %). Verondersteld werd dat een toename 
in ketoconazol dosis (vergeleken met Hoofdstuk 5) zou leiden tot voldoende hoge 
blootstelling aan ketoconazol bij elke patiënt en dus in maximale CYP3A-remming, met als 
gevolg een afname van de variabiliteit in de mate waarin de klaring van docetaxel wordt 
gereduceerd. De klaring van docetaxel (gemiddelde ± SD) werd met 50 % gereduceerd van 
32.8 L/h ± 13.7 L/h naar 16.5 L/h ± 8.15 L/h (P = 0.018, N = 7) als gevolg van gelijktijdige 
ketoconazol toediening, echter met grote interindividuele variabiliteit (uitersten, 34 – 69 % 
afname). In aanwezigheid van ketoconazol, nam de interindividuele variabiliteit in docetaxel 
klaring en systemische blootstelling (uitgedrukt als variatie coëfficiënt) zelfs toe van 41.6 % 
naar 49.5 % en van 28.0 % naar 35.1 %, respectievelijk, en niet, zoals verondersteld, af. 
Aansluitend is geëvalueerd of een deel van de interindividuele variabiliteit in de afname van 
docetaxel klaring onder ketoconazol behandeling afhankelijk was van functionele CYP3A4 
en/of CYP3A5 genetische  varianten. Geen van de patiënten was drager van het CYP3A5*1 
allel, hetgeen aangeeft dat voor ieder geëvalueerde patiënt totale CYP3A activiteit uitsluitend 
toegeschreven kan worden aan CYP3A4. Geen enkele patiënt was drager van één van de, op 
dit moment bekende, potentieel klinisch relevante polymorfismen in het CYP3A4 gen. Het is 
derhalve zeer onwaarschijnlijk dat genetische verschillen bijgedragen hebben aan de 
waargenomen interindividuele variabiliteit in de afname van docetaxel klaring. 
Geconcludeerd is dat de geëvalueerde aanpak ongeschikt is als methode om een uniform 
farmacokinetisch profiel voor docetaxel te bereiken. 
 
In Hoofdstuk 7 wordt de ontwikkeling en analytische validatie van een snelle en 
eenvoudige verbrandingsmethode om [3H]-docetaxel, uitgescheiden in humaan feces en urine 
te kwantificeren, beschreven. Een belangrijke reden om een minimale en onschadelijke 
hoeveelheid van een radioactief-gelabelde verbinding aan een patiënt toe te dienen is om deze 
verbinding in een biologische matrix (bijv. feces, urine, ascites) te kwantificeren bij 
concentraties die onder de detectie limiet van de gebruikelijke analyse technieken liggen, 
veelal met als doel het bepalen van een massabalans. In klinisch onderzoek worden onder 
meer [3H]- of [14C]-radioactief-gelabelde verbindingen gebruikt; hierbij is vloeistof 
scintillatie telling de meest efficiënte methode om deze laag energetische beta-stralers te 
kwantificeren. Echter, de meeste radioactief-gelabelde biologische matrices vereisen een 
uitgebreide en bewerkelijke monstervoorbewerking procedure om verstoring door 'quenching' 
(uitdoving) te reduceren, alvorens tot kwantificering van de radioactiviteit kan worden 
overgegaan. Verbranding van getritieerde feces en urine monsters is een eenvoudige, snelle, 
gevoelige, precieze en reproduceerbare methode met hoge opbrengst. Deze methode kan 
worden gebruikt om de uitscheiding van [3H]-docetaxel, na intraveneuze toediening, te 
kwantificeren. 
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In Hoofdstuk 8 is de invloed van ketoconazol op de uitscheiding van docetaxel en 
[3H]-docetaxel in feces en urine onderzocht. Ketoconazol is naast een sterk werkzame 
CYP3A remmer, ook een zwakke tot matige remmer van de transmembraan gelokaliseerde 
‘ATP-binding cassette’ transporter-eiwit ABCB1, waar docetaxel ook substraat van is. De 
invloed van ABCB1 op de plasma farmacokinetiek van docetaxel is minimaal tot afwezig 
echter ABCB1 speelt een prominente rol in de fecale uitscheiding van docetaxel. Onder 
invloed van ketoconazol nam de fecale uitscheiding van docetaxel (gemiddelde ± SD van de 
toegediende absolute docetaxel dosis) met een factor 2 toe van 2.6 % ± 2.8 % tot 5.2 ± 5.4 % 
(P = 0.03, N = 14) maar had geen effect op de urine excretie welke 2.6 % ± 1.4 % en 2.6 % ± 
1.1 % bedroeg in de af- respectievelijk aanwezigheid van ketoconazol (P = 0.69, N = 15). De 
som van de uitscheiding in feces en urine bedroeg 5.3 % ± 3.0 % voor docetaxel 
monotherapie en 7.8 % ± 5.6 % in aanwezigheid van ketoconazol (P = 0.04, N = 14). De 
totale hoeveelheid gemeten radioactiviteit in af- respectievelijk aanwezigheid van 
ketoconazol bedroeg 45.8 % ± 19.1 % en 32.4 % ± 19.7 % van de toegediende dosis [3H]-
docetaxel (P = 0.23, N = 5) hetgeen overeenstemt met de verwachting gezien het 72-uurs 
interval na-infusie gedurende welk feces en urine monsters zijn verzameld. Verondersteld 
wordt dat een meer uitgesproken toename in de fecale excretie van docetaxel onder invloed 
van ketoconazol niet heeft plaatsgevonden als gevolg van gelijktijdige remming van 
intestinaal ABCB1. 
 
Het feit dat docetaxel grotendeels door CYP3A wordt gemetaboliseerd stelt deze 
verbinding bloot aan een scala van enzym-gemedieerde geneesmiddel interacties. In 
September 2003 is in Nederland een gestandaardiseerd medicinaal cannabis product (variëteit 
Bedrocan®) geïntroduceerd. Gunstige effecten toegeschreven aan medicinaal cannabis zijn 
gemeld voor kanker-geïnduceerde anorexie, (vertraagd)-chemotherapie geïnduceerde 
misselijkheid en braken en voor palliatie. Daar in vitro- en in vivo resultaten betreffende de 
mogelijkheid dat cannabinoïden de activiteit van CYP3A kunnen beïnvloeden tegenstrijdig 
zijn, is een geneesmiddelinteractie studie uitgevoerd bij kanker patiënten (N = 24) om het 
effect van gelijktijdige toediening van medicinaal cannabis op de farmacokinetiek van 
docetaxel en irinotecan, beiden afhankelijk van CYP3A-gemedieerd metabolisme, te 
onderzoeken (Hoofdstuk 9). Gelijktijdige toediening van medicinaal cannabis, als 
kruidenthee, had geen invloed op de plasma farmacokinetiek van docetaxel of irinotecan (P > 
0.31). Docetaxel systemische blootstelling en klaring, gerapporteerd als de gemiddelde ratio 
in de aan- en afwezigheid van medicinaal cannabis (95 % betrouwbaarheidsinterval) bedroeg 
1.11 (0.94 – 1.28) en 0.95 (0.82 – 1.08), respectievelijk, hetgeen niet wijst op een klinisch 
relevante geneesmiddelinteractie. De geëvalueerde variëteit van medicinaal cannabis kan 
zonder dosis aanpassing worden toegediend in combinatie met beide antikanker middelen. 
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Toekomstige ontwikkelingen  
Het beschreven werk in dit proefschrift had tot doel de behandeling met docetaxel te 
verbeteren door een reductie in de interpatient farmacokinetische variabiliteit en meer inzicht 
te verkrijgen in de rol van CYP3A- en ABCB1-gemedieerde eliminatie routes voor docetaxel. 
Beide doelen waren gestoeld op bewuste beïnvloeding van het farmacokinetisch profiel van 
docetaxel door gebruik te maken van ketoconazol, een sterk werkzame remmer van CYP3A 
en, in mindere mate, ook een remmer van ABCB1. Echter, reductie van de interindividuele 
variabiliteit in docetaxel farmacokinetiek door tijdelijk de bron van de geobserveerde 
variabiliteit (d.w.z. variabele CYP3A katalytische activiteit) te remmen, is niet haalbaar 
gebleken. Bij gelijktijdige toediening van ketoconazol was er nog steeds sprake van 
aanzienlijke interpatient farmacokinetische variatie welke niet kon worden verklaard door 
variabele systemische blootstelling aan ketoconazol of door genetische diversiteit in de genen 
die de CYP3A4 en CYP3A5 eiwitten coderen. 
Als reactie op deze tegenvallende resultaten hebben wij een aantal thans lopende 
nieuwe studies opgezet, die alternatieve uitgangspunten onderzoeken om de behandeling met 
docetaxel te optimaliseren. Het volgen van plasma concentraties in de tijd en 
farmacokinetisch-gestuurde individuele dosis aanpassingen wordt meestal gedefinieerd als 
‘therapeutic drug monitoring’ (TDM). Hoewel TDM in andere medische deelgebieden 
regelmatig wordt toegepast is het gebruik van TDM in de klinische oncologie beperkt. 
Toepassing van een ‘limited sampling’ aanpak (waarbij men slechts 2 tot 4 bloedmonsters, 
die poliklinisch kunnen worden afgenomen, nodig heeft) in combinatie met een populatie 
farmacokinetisch model en Bayesiaanse analyse maakt het mogelijk om individuele 
farmacokinetische parameters nauwkeurig te schatten en maakt TDM derhalve een potentiële 
aanpak voor antikanker geneesmiddelen. Reeds eerder is de uitvoerbaarheid en 
toepasbaarheid van farmacokinetisch gestuurd doseren van paclitaxel succesvol geëvalueerd. 
In onze kliniek loopt thans een onderzoek (N = 30) ten einde waarbij de ‘limited sampling’ 
aanpak en een reeds eerder ontwikkeld populatie farmacokinetisch model, welke albumine, 
alfa-1 zure glycoproteïne, leeftijd, lichaamsoppervlak en verhoogde leverfuncties 
incorporeert, wordt toegepast om de uitvoerbaarheid en toepasbaarheid van farmacokinetisch-
gestuurd geïndividualiseerd docetaxel doseren te evalueren. Daarnaast wordt dezelfde 
‘limited sampling’ aanpak en het populatie farmacokinetisch model toegepast om de relatie 
tussen docetaxel farmacokinetiek en potentieel klinisch relevante CYP3A4, CYP3A5 en 
ABCB1 polymorfismen in een groot populatie onderzoek te evalueren (huidige inclusie N > 
100). Eveneens wordt een vergelijkbare populatie studie uitgevoerd om de relatie tussen 
paclitaxel farmacokinetiek en relevante polymorphismen in de metaboliserende enzymen te 
evalueren (huidige inclusie N > 100). Tot op heden hebben farmacokinetisch-
farmacogenetisch georiënteerde studies, gericht op het vaststellen van de klinische relevantie 
van de verschillende CYP3A4, CYP3A5 en ABCB1 variant allelen in relatie tot docetaxel 
farmacokinetische variabiliteit, of de farmacokinetische variabiliteit van andere CYP3A en 
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ABCB1 substraten en/of ‘probes’, wisselende resultaten opgeleverd, deels als gevolg van te 
klein opgezette studies gezien de allel frequentie van de potentieel klinisch relevante 
polymorfismen. 
In de klinische oncologie is het over het algemeen geaccepteerd dat de effectiviteit 
van antikanker middelen afhankelijk is van het onderhouden van adequate, vrije, niet eiwit-
gebonden (d.w.z. farmacologisch actieve) geneesmiddelconcentraties bij het doelorgaan, de 
tumor. Echter, er is zeer weinig bekend over de intratumorale farmacokinetiek als gevolg van 
het feit dat tot op heden vrije geneesmiddel concentraties zelden (eenvoudig) bij de plaats van 
werking gemeten konden worden. Om deze reden is het gebruikelijk om bij klinisch 
farmacokinetische evaluaties de totale geneesmiddelconcentratie (en/of 
metabolietconcentraties) te meten in een beter toegankelijk, surrogaat doelorgaan, namelijk 
plasma (bloed). Totale plasma geneesmiddelconcentraties worden vervolgens gecorreleerd 
aan klinische parameters zoals effectiviteit en/of toxiciteit. Echter, het farmacokinetisch 
gedrag van geneesmiddelen in tumorweefsel is wellicht volledig anders dan het kinetisch 
gedrag in plasma als gevolg van weefsel- of tumor-specifieke metaboliserende enzymen. De 
interpatient variabiliteit in geneesmiddelrespons zou derhalve mogelijk verklaard kunnen 
worden door (grote) interpatient farmacokinetische variabiliteit bij het doelorgaan. 
Microdialyse is een relatief nieuwe en minimaal invasieve monster afnametechniek gebaseerd 
op diffusie van (endo- en exogene) verbindingen vanuit de extracellulaire ruimte door een 
semi-permeabel membraan. Wij evalueren thans bij kankerpatiënten die behandeld worden 
met 3-wekelijks intraveneus docetaxel de toepasbaarheid van microdialyse om inzicht te 
krijgen in de weefsel- en tumor farmacokinetiek van docetaxel en in docetaxel-geïnduceerde 
intratumorale farmacodynamische veranderingen. 
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Dankwoord 
Dit proefschrift is tot stand gekomen dankzij de inzet van velen, die ik graag allen 
persoonlijk zou willen bedanken, toch moet ik mij hier beperken tot enkelen. 
 
In de eerste plaats ben ik zeer veel dank verschuldigd aan alle patiënten die 
belangeloos hebben meegewerkt aan de onderzoeken beschreven in dit proefschrift en de nog 
lopende onderzoeken opgestart tijdens het werk aan dit proefschrift. Het contact met deze 
diverse groep van mensen vormde een enorme bron van inspiratie voor mij, en behoort voor 
mij zeker tot de leukste aspecten van het ‘promoveren’. 
 
Prof.dr. J. Verweij, promotor, beste Jaap, jou ben ik zeer veel dank verschuldigd voor 
de kans die je mij hebt geboden en het vertrouwen dat je in mij hebt gesteld. Als vreemde 
eend in de bijt haalde je mij de afdeling binnen, eerst voor de helft en toen, op mijn verzoek, 
helemaal. Dat laatste heeft ertoe geleid dat ik een completer beeld van de wereld van de 
medische wetenschap heb gekregen. Dat zie ik absoluut als een verrijking van mijn 
ontwikkeling en als een groot voorrecht. Het onderzoek is uiteraard met dit boekje nog niet 
klaar en ik kijk uit naar een prettige samenwerking bij de afronding van zowel het populatie 
docetaxel/paclitaxel farmacogenetica/farmacokinetiek onderzoek als het docetaxel TDM 
onderzoek. 
 
Dr. R.A.A. Mathôt, copromotor, beste Ron, het zal wellicht niet altijd makkelijk zijn 
geweest mij aan de andere kant van de Maas aan te sturen. Toch was je er als ik je nodig had, 
nam je de tijd voor me, en zorgde je ervoor dat ik altijd de Maas weer terug over fietste met 
het idee dat we op de goede weg waren. Dank hiervoor. Ook zal ik nooit vergeten hoe je mij 
hebt gesteund in mijn beslissing om de overstap naar de Interne Oncologie te maken, in die 
roerige tijd heeft dat veel geholpen. Verder dank ik je voor het feit dat je mij hebt ingewijd in 
de wereld van NONMEM en limited sampling farmacokinetiek en mij hebt aangemoedigd 
het docetaxel TDM onderzoek op te zetten. Ook al is dit onderzoek niet in het boekje 
gekomen, de analyses tot nog toe hebben mij definitief overtuigd van het nut van limited 
sampling. Ik durf nu al te zeggen dat er patiënten in de studie zitten die absoluut beter af zijn 
met hun PK-gestuurde dosis. 
 
Prof.dr. G. Stoter, beste Gerrit, ik dank jou hartelijk voor de geboden mogelijkheden 
tot het verrichten van wetenschappelijk onderzoek binnen de afdeling Interne Oncologie en 
voor de bereidheid de taak van secretaris van de promotiecommissie op je te nemen. 
 
Prof.dr. A.G. Vulto, beste Arnold, op deze plaats wil ik je bedanken voor het zitting 
nemen in mijn promotiecommissie maar vooral wil ik je mijn dank betuigen voor wat de 
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basis heeft gevormd voor dit proefschrift, namelijk de gedegen opleiding tot 
ziekenhuisapotheker. Jouw enthousiasme voor de ziekenhuisfarmacie en het doen van 
wetenschappelijk onderzoek zijn een bron van inspiratie, toen, nu, en in de toekomst. 
 
Prof.dr. H.J. Guchelaar dank ik eveneens voor de bereidheid om zitting te nemen in de 
promotiecommissie en voor de inhoudelijke beoordeling van dit proefschrift. 
 
Dr. A. Sparreboom, beste Alex, ook jou wil ik op deze plek bedanken voor het feit dat 
je aan het begin van dit proefschrift hebt gestaan. Tot mijn spijt – ik had maar wat graag 
onder jouw inspirerende leiding aan dit proefschrift gewerkt – kwam het groene licht voor de 
mogelijkheid om te promoveren op hetzelfde moment als het groene licht voor jou om bij het 
NCI te gaan werken. Which automatically brings me to Dr. Sharyn Baker, who I would like 
to thank for the docetaxel analyses for the first docetaxel/ketoconazole study, which were 
conducted under her supervision at the Analytical Pharmacology Core Laboratory at Johns 
Hopkins. 
 
Farmacologie collega’s, Dr. Kees Nooter, Dr. Erik Wiemer, Dr. Walter Loos, Peter de 
Bruin, Desirée van Zomeren, Mei Lam en Indra Ganesh, dank voor de plek die mij hier in het 
lab is geboden, de begeleiding die ik van jullie heb gekregen en de analyses die voor mij zijn 
verricht. 
 
Mede-promovendus Dr. Floris de Jong, wat was het knus zo in het begin in het ‘hok’ 
nietwaar! Maar jij koos, terecht, voor wat meer ruimte toen de gelegenheid zich aandiende en 
ik hoefde niet meer bang te zijn dat je door het toetsenbord heen zou slaan. 
 
Research verpleegkundigen en research assistenten, Conny, Monique, Diane, 
Suzanne, Monika, Annet en Hester en jullie voorgang(st)ers, zonder jullie zou geen enkel 
onderzoek kunnen lopen. Dank voor jullie flexibiliteit en onvermoeibare inzet en, niet te 
vergeten, dank ook voor de gezelligheid. Als ik het even zat was dan deed een loopje naar 
jullie altijd wonderen. 
 
Stafartsen en junioren (ook degenen die allang uit de Daniel zijn vertrokken!) van de 
afdeling Interne Oncologie en longartsen werkzaam in de Daniel, jullie ben ik veel dank 
verschuldigd voor het aandragen van patiënten voor mijn onderzoeken, voor de hulp die jullie 
mij bij mijn studies hebben geboden, voor de prettige samenwerking, en voor alles wat ik 
daardoor van jullie heb geleerd. Voor een ziekenhuisapotheker was dit, in meerdere 
opzichten, een heel leerzame tijd. 
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Verpleging, secretaresses en eigenlijk iedereen werkzaam op zowel de afdelingen B0, 
B0-Zuid als het Behandelcentrum, jullie dank ik voor de hartverwarmende inzet en zorg die 
jullie altijd aan de dag leggen voor alle patiënten en waar ik nog dagelijks veel bewondering 
en respect voor heb. Dank voor alle hulp die jullie hebben geboden bij het uitvoeren van mijn 
studies. Ik wil in het bijzonder de verpleging van het Behandelcentrum danken voor alle 
gezelligheid, jullie koffiekamer is een hele fijne plek om even binnen te vallen voor een 
kletspraatje! En ook Bimla wil ik graag apart bedanken voor haar altijd gulle lach en haar 
immer zonnige kijk op iedere nieuwe dag! 
 
Apothekers en apothekersassistenten van de Daniel, jullie wil ik allemaal bedanken 
voor alle ‘spoed’ infusen die bereid zijn door jullie voor mijn kinetiek patiënten en het feit dat 
ik altijd bij jullie terecht kon om chemoschema's te na te pluizen op zoek naar nieuwe 
patiënten. 
 
Dr. R.H.N van Schaik, beste Ron, jou en de genetica medewerkers van het AKC wil 
ik graag bedanken voor de genotyperingen, ook al ging het nu nog maar om kleine aantallen. 
Maar dat gaat veranderen bij de analyses voor het populatie docetaxel/paclitaxel 
farmacogenetica/farmacokinetiek onderzoek! 
 
Dr. W.H. Bakker, beste Willem, bedankt voor het meedenken met de radioactiviteits 
experimenten en voor de geboden gelegenheid om de feces en urine analyses bij de afdeling 
Nucleaire Geneeskunde zelfstandig te kunnen verrichten. Het gezelschap en de hulp van 
Dirk, Linda en Kees heb ik daarbij zeer gewaardeerd. 
 
De G-vleugel mag dan wel een eind verwijderd zijn van het farmacologie lab maar de 
medewerkers aldaar zijn ook broodnodig bij de tot standkoming van dit proefschrift. Dank 
Marijke en Kerstin van de bibliotheek voor het aanleveren van literatuur. Dank medewerkers 
van het trial bureau op G1 voor de patiënteninclusie en drie verdiepingen hoger, dank Linda, 
Aline en Ruth voor alle secretariële ondersteuning en bij tijd en wijle hulp bij MS-Word 
‘bugs’! 
 
Dr. P.G.H. Mulder, beste Paul, dank voor de hulp bij de statistische analyses van de 
high-dose ketoconazol data en voor de hulp bij de statistische opzet van de docetaxel TDM 
studie. 
 
Dan natuurlijk mijn trouwe vrienden, zonder jullie bij naam te noemen wil ik jullie 
allemaal bedanken voor alle steun en het immer luisterende oor dat jullie hebben getoond als 
ik weer eens liep te mopperen dat het toch echt niet meezat of als ik me, vooral in het begin, 
hardop afvroeg of ik wel de juiste keuze had gemaakt. De afgelopen jaren heb ik wel eens 
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vergeleken met de bijbelse ‘zeven magere jaren’. Niet terecht denk ik, want ondanks alles 
wist ik altijd dat, als het nodig was, ik een beroep op jullie kon doen en dat daarmee het leven 
er altijd weer rooskleuriger, gevarieerder en inspirerender uitzag. Die ‘wetenschap’ is, zeer, 
zeer veel waard. Twee mensen wil ik toch graag apart bedanken, Bieke en Linda, mijn 
paranimfen. Dank voor jullie steun tijdens de afgelopen promotiejaren, het glaasje wijn op de 
bank bij ‘van Dam’ deed veel goed, en Linda, de gedachten verzetten onder het motto van 
‘Kunst’ was altijd welkom! Dank ook voor alles wat jullie de afgelopen maanden voor me 
hebben betekend, promoveren, solliciteren, moeder worden, met al mijn vragen en zorgen 
kon ik bij jullie terecht. Dat was fijn. 
 
Lieve familie, en in het bijzonder lieve papa en mama, jullie wil ik allemaal danken 
voor de niet aflatende liefde en steun die jullie mij altijd hebben gegeven en de interesse die 
jullie altijd hebben getoond in deze obscure proefschrift materie. Lieve papa, wat had ik deze 
mijlpaal graag met je willen delen, wederom een gedeelde levenservaring. Vaak moet ik 
denken aan de laatste maanden, de bezoeken waarbij je steevast vroeg, ‘Fred, hoe is het met 
je onderzoek?’ alsof dat voor mij op die kostbare momenten belangrijk was. Maar het geeft 
toch maar aan dat je, ook al gleed je langzaam af, op een bepaalde manier nog erg bij de 
pinken was en dat je het belangrijk vond dat ik deze stap had gezet. Daarom weet ik zeker dat 
ook deze mijlpaal niet helemaal aan je voorbij gaat. Lieve mama, samen met papa heb jij mij 
gesteund in alle beslissingen die ik nam en die ertoe hebben geleid dat ik hier nu sta, zelfs als 
die beslissingen in moeilijke tijden moesten worden genomen, dank je wel daarvoor. 
 
And last but certainly not least, lieve Gneomar, ook blij dat het achter de rug is? Dit 
proefschrift is een mijlpaal die we samen hebben bereikt, vanaf het allermoeilijkste begin was 
je erbij en vanaf dag één heb je me gesteund en had je het volste vertrouwen in de goede 
afloop. Dank je wel daarvoor. Nu is het mijn beurt om je te steunen in je ontwikkeling tot top 
fotograaf, iets waar ik ook het volste vertrouwen in heb. Kortom, ik kijk al uit naar alle 
volgende mijlpalen en avonturen, samen! 
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Curriculum Vitae 
Frederike Engels werd op 1 mei 1970 geboren te Leiden. Na een Engelstalige 
basisopleiding behaalde zij in 1988 het VWO-gymnasiumdiploma aan het Rijnlands Lyceum 
te Wassenaar. Van september 1988 tot mei 1989 studeerde zij Frans aan de Ecole de Langue 
et de Civilisation Françaises van de Universiteit van Genève, en behaalde daar het Certificat 
d’Etudes Pratiques de Français. In 1989 is zij gestart met de studie Farmacie aan de 
Universiteit van Utrecht. In het vijfde jaar van de studie vervulde zij de functie van vice-
quaestrix in het Bestuur van de Utrechtsche Vrouwelijke Studenten Vereeniging / Nieuwe 
Vereniging van Vrouwelijke Studenten te Utrecht. Ter afsluiting van de doctoraal fase van de 
studie heeft zij gedurende zes maanden onderzoek gedaan naar hormonale invloeden op de 
expressie van Bcl-2, bij het Laboratoire d’Oncologie Moléculaire van de Universiteit van 
Parijs, waarna in september 1995 het doctoraal examen werd gehaald. De post-doctorale fase 
van de studie heeft zij vervolgens begin 1998 afgerond met het behalen van het 
apothekersdiploma. Aan het eind van de studie liep zij stage bij de Apotheek van het Erasmus 
MC. Na het behalen het apothekersdiploma is zij daar blijven werken en in juli 1999 aldaar 
begonnen met de opleiding tot ziekenhuisapotheker (opleider Prof.dr. A.G. Vulto). In juni 
2003 werd de opleiding voltooid. In de Apotheek van het Erasmus MC was zij vervolgens 
werkzaam als ziekenhuisapotheker met als aandachtsgebied de ondersteuning van klinische 
trials en had zij vanuit die hoedanigheid zitting in de Medisch Ethische Toetsings Commissie 
(METC) van het Erasmus MC (van 1 februari 2003 tot 1 juli 2004). In februari 2003 is zij 
gestart met de werkzaamheden voor dit proefschrift onder leiding van Prof.dr. J. Verweij in 
het Erasmus MC - locatie Daniel den Hoed kliniek. Medio 2004 kwam zij volledig in dienst 
van de afdeling Interne Oncologie, Erasmus MC - locatie Daniel den Hoed kliniek (Prof.dr. 
G. Stoter) om uitsluitend wetenschappelijk onderzoek te verrichten. 
Zij woont samen met Gneomar van Nispen en zij zijn in blijde verwachting van hun 
eerste kindje, dat zich medio januari aankondigt. 
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